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Background: Clinical trials show that antimicrobial-impregnated central venous catheters reduce
catheter-related bloodstream infection in adults and children receiving intensive care, but there is
insufficient evidence for use in newborn babies.
Objectives: The objectives were (1) to determine clinical effectiveness by conducting a randomised
controlled trial comparing antimicrobial-impregnated peripherally inserted central venous catheters
with standard peripherally inserted central venous catheters for reducing bloodstream or cerebrospinal
fluid infections (referred to as bloodstream infections); (2) to conduct an economic evaluation of the
costs, cost-effectiveness and value of conducting additional research; and (3) to conduct a
generalisability analysis of trial findings to neonatal care in the NHS.
Design: Three separate studies were undertaken, each addressing one of the three objectives. (1) This
was a multicentre, open-label, pragmatic randomised controlled trial; (2) an analysis was undertaken of
hospital care costs, lifetime cost-effectiveness and value of information from an NHS perspective; and
(3) this was a retrospective cohort study of bloodstream infection rates in neonatal units in England.
Setting: The randomised controlled trial was conducted in 18 neonatal intensive care units in England.
Participants: Participants were babies who required a peripherally inserted central venous catheter
(of 1 French gauge in size).
Interventions: The interventions were an antimicrobial-impregnated peripherally inserted central
venous catheter (coated with rifampicin–miconazole) or a standard peripherally inserted central venous
catheter, allocated randomly (1 : 1) using web randomisation.
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Main outcome measure: Study 1 – time to first bloodstream infection, sampled between 24 hours
after randomisation and 48 hours after peripherally inserted central venous catheter removal. Study 2
– cost-effectiveness of the antimicrobial-impregnated peripherally inserted central venous catheter
compared with the standard peripherally inserted central venous catheters. Study 3 – risk-adjusted
bloodstream rates in the trial compared with those in neonatal units in England. For study 3, the
data used were as follows: (1) case report forms and linked death registrations; (2) case report forms
and linked death registrations linked to administrative health records with 6-month follow-up; and
(3) neonatal health records linked to infection surveillance data.
Results: Study 1, clinical effectiveness – 861 babies were randomised (antimicrobial-impregnated
peripherally inserted central venous catheter, n = 430; standard peripherally inserted central venous
catheter, n = 431). Bloodstream infections occurred in 46 babies (10.7%) randomised to antimicrobial-
impregnated peripherally inserted central venous catheters and in 44 (10.2%) babies randomised
to standard peripherally inserted central venous catheters. No difference in time to bloodstream
infection was detected (hazard ratio 1.11, 95% confidence interval 0.73 to 1.67; p = 0.63). Secondary
outcomes of rifampicin resistance in positive blood/cerebrospinal fluid cultures, mortality, clinical
outcomes at neonatal unit discharge and time to peripherally inserted central venous catheter
removal were similar in both groups. Rifampicin resistance in positive peripherally inserted central
venous catheter tip cultures was higher in the antimicrobial-impregnated peripherally inserted central
venous catheter group (relative risk 3.51, 95% confidence interval 1.16 to 10.57; p = 0.02) than
in the standard peripherally inserted central venous catheter group. Adverse events were similar
in both groups. Study 2, economic evaluation – the mean cost of babies’ hospital care was £83,473.
Antimicrobial-impregnated peripherally inserted central venous catheters were not cost-effective.
Given the increased price, compared with standard peripherally inserted central venous catheters,
the minimum reduction in risk of bloodstream infection for antimicrobial-impregnated peripherally
inserted central venous catheters to be cost-effective was 3% and 15% for babies born at 23–27 and
28–32 weeks’ gestation, respectively. Study 3, generalisability analysis – risk-adjusted bloodstream
infection rates per 1000 peripherally inserted central venous catheter days were similar among babies
in the trial and in all neonatal units. Of all bloodstream infections in babies receiving intensive or
high-dependency care in neonatal units, 46% occurred during peripherally inserted central venous
catheter days.
Limitations: The trial was open label as antimicrobial-impregnated and standard peripherally inserted
central venous catheters are different colours. There was insufficient power to determine differences
in rifampicin resistance.
Conclusions: No evidence of benefit or harm was found of peripherally inserted central venous catheters
impregnated with rifampicin–miconazole during neonatal care. Interventions with small effects on
bloodstream infections could be cost-effective over a child’s life course. Findings were generalisable to
neonatal units in England. Future research should focus on other types of antimicrobial impregnation of
peripherally inserted central venous catheters and alternative approaches for preventing bloodstream
infections in neonatal care.
Trial registration: Current Controlled Trials ISRCTN81931394.
Funding: This project was funded by the National Institute for Health Research Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 24, No. 57.
See the NIHR Journals Library website for further project information.
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Bloodstream infection This refers to any positive bacterial or fungal cultures from blood or cerebrospinal
fluid samples. A clinically serious bloodstream infection refers to a bloodstream infection for which the
baby was treated for > 72 hours with intravenous antibiotics or died during treatment.
CATheter Infections in CHildren A randomised controlled trial and economic evaluation comparing
impregnated and standard central venous catheters in children.
Catheter-related bloodstream infection This refers to a bloodstream infection with isolation
of the same organism from the peripherally inserted central venous catheter tip and blood or
cerebrospinal fluid.
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Plain English summary
Babies who are born too early or who are very sick require intensive care after birth and duringearly life. Most will have a long, narrow, plastic tube, called a catheter, inserted into a vein. The
catheter is used to give babies fluids containing medicines and nutrition to keep them well and help
them grow.
The catheter can remain in place for several days or weeks. But the presence of plastic tubing in the
vein increases the risk of infection. This study aimed to find out whether or not catheters coated with
antimicrobial medicines, called rifampicin and miconazole, could reduce the risk of infection. These
medicines act by stopping germs from growing on the catheter, but do not harm the baby or interfere
with other treatments.
A randomised controlled trial was carried out in 18 neonatal units in England. Whenever a baby
needed a catheter, their parents were asked for consent to participate in the trial. The baby was then
randomised, similar to tossing a coin, to receive either the antimicrobial catheter or a standard one.
A total of 861 babies participated. We followed up all babies in the same way until after the catheter
was removed to compare how often babies in each group had an infection.
It was found that antimicrobial catheters were no better or worse at preventing infection than
standard catheters. Antimicrobial catheters cost more and we found no evidence of benefit; these
results suggest that their use in neonatal intensive care is not justified. It was calculated that further
research on ways to reduce infection may be good value for money, depending on the costs of this
research. The babies who took part in this study were typical of babies in England receiving catheters,
meaning that the results can be applied across the NHS. Future research should focus on catheters
that contain other types of antimicrobials and alternative ways of preventing infection.
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A bloodstream infection is a serious adverse outcome of using central venous catheters. Earlier
gestational age at birth is associated with increasing rates of bloodstream infection and in susceptibility
to serious and long-term adverse outcomes. Bloodstream infection increases the risks of death and
serious morbidity, especially adverse neurodevelopment in the long term.
Evidence from clinical trials shows that antimicrobial-impregnated central venous catheters reduce
catheter-related bloodstream infection in adults and children receiving intensive care. However,
there is insufficient evidence to guide use of antimicrobial-impregnated central venous catheters
for newborn babies receiving neonatal intensive care.
We conducted a large, pragmatic randomised controlled trial to address uncertainty about the
clinical effectiveness of antimicrobial-impregnated peripherally inserted central venous catheters for
reducing bloodstream infection in babies receiving neonatal care. The study had three objectives
addressed in three separate studies.
Study objectives
1. A clinical effectiveness randomised controlled trial of antimicrobial-impregnated versus standard
peripherally inserted central venous catheters for reducing the incidence of bloodstream or
cerebrospinal fluid infections (referred to as bloodstream infections).
2. An economic evaluation to determine the costs, cost-effectiveness and value of conducting
additional research.
3. A generalisability analysis of the trial findings to neonatal care in the NHS.
Clinical effectiveness randomised controlled trial
Methods
Design, trial population and intervention
We conducted a multicentre, open-label, two-arm, pragmatic randomised controlled trial. Trial
participants were newborn babies, admitted to one of 18 neonatal intensive care units in England,
who required the narrowest available peripherally inserted central venous catheter (1 French gauge).
Randomisation was 1 : 1 to receive an antimicrobial peripherally inserted central venous catheter,
impregnated with the antibiotic rifampicin and antifungal miconazole, or a standard peripherally
inserted central venous catheter, manufactured by Vygon (UK) Ltd (Swindon, UK).
Randomisation and masking
Random allocation used a web-based program controlled by Liverpool Clinical Trials Centre. Randomisation
sequences were computer-generated in random variable blocks of two and four, stratified by site. The
intervention was not masked for clinicians because rifampicin stained the antimicrobial-impregnated
peripherally inserted central venous catheter tubing brown, but all decisions about analyses were
prespecified in an analysis plan developed blind to treatment allocation.
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Main outcome measures
The primary outcome was the time from random allocation to the first microbiologically confirmed
bloodstream or cerebrospinal fluid infection between 24 hours after randomisation and 48 hours
after peripherally inserted central venous catheter removal or death. Secondary outcomes assessed
rifampicin resistance in any isolate from blood, cerebrospinal fluid or peripherally inserted central
venous catheter tip culture; potential biases in sampling or treatment; clinical outcomes at discharge
from neonatal care; and death up to 6 months after randomisation.
Sample size and statistical analyses
To detect a constant hazard ratio of 2.078 (i.e. a proportion of babies experiencing a bloodstream infection
in the standard peripherally inserted central venous catheter arm of 0.14 and in the antimicrobial-
impregnated peripherally inserted central venous catheter arm of 0.07) with 90% power and a significance
level of 0.05, using a two-sided log-rank test for equality of survival curves, required 816 babies and
79 events. To allow for a 5% loss to follow-up, the target was increased to 858 babies. Effectiveness
analyses included all randomised participants following the intention-to-treat principle. Safety analyses
excluded randomised babies who did not have a peripherally inserted central venous catheter inserted.
The primary outcome was analysed using the log-rank test and Cox regression to calculate the hazard ratio.
Results
We randomised 861 babies (antimicrobial-impregnated peripherally inserted central venous catheter
group, n = 430; standard peripherally inserted central venous catheter group, n = 431) over 17 months
from August 2015. Of these, 754 (87.6%) participants were born before 32 weeks of gestation. The
median time to peripherally inserted central venous catheter removal was 8.20 days (interquartile
range 4.77–12.13 days) in the antimicrobial-impregnated peripherally inserted central venous catheter
group and 7.86 days (interquartile range 5.00–12.53 days) in the standard peripherally inserted central
venous catheter group. Bloodstream infection occurred in 46 (10.7%) and 44 (10.2%) babies randomised
to the antimicrobial-impregnated peripherally inserted central venous catheter and standard peripherally
inserted central venous catheter groups, respectively. We did not find a difference in time to bloodstream
infection (hazard ratio 1.11, 95% confidence interval 0.73 to 1.67). Rifampicin resistance in positive blood or
cerebrospinal fluid cultures, mortality, clinical outcomes at neonatal unit discharge and time to peripherally
inserted central venous catheter removal did not differ significantly between groups, although rifampicin
resistance in positive cultures colonising peripherally inserted central venous catheter tips was higher in
the antibiotic group (relative risk 3.51, 95% confidence interval 1.16 to 10.57) than in the standard group.
Adverse events were similarly low in both groups.
Economic evaluation
We estimated the hospital costs and length of stay using routine health-care data. We developed a new
cost-effectiveness model to predict the PREVenting infection using Antimicrobial-Impregnated Long
lines (PREVAIL) trial participants’ long-term, quality-adjusted life expectancy, health-care costs and the
minimum reduction in the rate of bloodstream infections for antimicrobial-impregnated peripherally
inserted central venous catheters to be cost-effective, and we estimated the value of future research.
Methods
We estimated the costs of hospital care over 6 months from randomisation using routine health data,
costed on a 2016 price base. Data sources for PREVAIL trial participants were as follows:
l data from the PREVAIL trial
l data from the National Neonatal Research Database relating to each participant’s stay in neonatal
units (neonatal intensive care, local neonatal units or special care baby units)
l data from the Paediatric Intensive Care Audit Network on admissions to the paediatric intensive care unit
l Hospital Episode Statistics, containing information on all other hospital admissions, outpatient
appointments, accident and emergency attendances and deaths.
SCIENTIFIC SUMMARY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xxx
We developed a decision-analytic model to evaluate the cost-effectiveness of interventions to prevent
bloodstream infections from the perspective of the NHS. The model simulated the lifetime costs, life
expectancy and quality-adjusted life-years of babies requiring a peripherally inserted central venous
catheter during their neonatal unit stay. The model assumes that a bloodstream infection increases the
risk of death and the risk of developing neurodevelopmental impairment in early childhood, leading to
higher costs, worse quality of life and greater risk of death. The model was informed by the PREVAIL
trial and external literature. Model results were computed as mean costs and quality-adjusted life-years
over 10,000 Monte Carlo simulations. We used value-of-information methods to explore whether or not
uncertainty in the model evidence and assumptions warrants additional research.
Results
The length of hospital stay per infant was 68.43 days (standard deviation 36.64 days) for the
antimicrobial-impregnated peripherally inserted central venous catheter group and 70.60 days
(standard deviation 38.94 days) for the standard peripherally inserted central venous catheter
group. Most of this time was spent in the neonatal intensive care unit. The cost of hospital care per
baby was £82,752.99 (standard deviation £49,738.66) in the antimicrobial-impregnated peripherally
inserted central venous catheter group and £84,185.39 (standard deviation £50.602.54) in the standard
peripherally inserted central venous catheter group. The largest contribution to the total cost was the
neonatal intensive care unit stay and hospital care other than critical care. The type of peripherally
inserted central venous catheter did not have an impact on the length of hospital stay or cost.
The model predicted that greater levels of neurodevelopmental impairment are associated with a
reduction in life expectancy and quality-adjusted life-years and higher costs. For example, severe
neurodevelopmental impairment reduces life expectancy by 14.79 years (95% confidence interval
4.43 to 26.68 years), reduces quality-adjusted life expectancy by 10.63 quality-adjusted life-years
(95% confidence interval 7.74 to 14.02 quality-adjusted life-years) and costs of £19,060 (95%
confidence interval £14,197 to £24,697) to the NHS. The difference in lifetime costs between
the antimicrobial-impregnated and the standard peripherally inserted central venous catheter
was £54.85 (95% confidence interval £25.95 to £89.12); in health outcomes, the difference was
–0.01 quality-adjusted life-years (95% confidence interval –0.09 to 0.04 quality-adjusted life-years).
Therefore, antimicrobial-impregnated peripherally inserted central venous catheters were not
cost-effective. Results remained stable across a series of scenario-testing key assumptions. Given
the price difference between the antimicrobial-impregnated and the standard peripherally inserted
central venous catheter, the minimum reduction in the risk of bloodstream infection required for
the antimicrobial-impregnated peripherally inserted central venous catheter to be cost-effective
was 3% for babies born at 23–27 weeks’ gestational age, and 15% for babies born at 28–32 weeks’
gestational age. The value of additional research is £2M over a time horizon of 10 years, based largely
on the effectiveness of antimicrobial-impregnated peripherally inserted central venous catheters.
Generalisability analysis
We evaluated the generalisability of results from the PREVAIL trial to other babies who received
peripherally inserted central venous catheters in neonatal intensive care units. Peripherally inserted
central venous catheters are used in neonatal intensive care units and in local neonatal units; therefore,
we evaluated the applicability of the results of the PREVAIL trial to babies who receive peripherally
inserted central venous catheters in local neonatal units. We compared risk factors, bloodstream infection
rates and changes in bloodstream infection rates over time, adjusting for risk factors.We calculated what
proportion of bloodstream infections in neonatal units could be attributed to peripherally inserted central
venous catheters. These findings could help in targeting strategies to prevent bloodstream infections
occurring in neonatal units.
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Methods
We obtained clinical data from the National Neonatal Research Database for babies receiving intensive
and high-dependency care in 112 of 124 neonatal intensive care units and local neonatal units in England
from March 2010 to June 2017. We defined bloodstream infection as a link to a positive blood or
cerebrospinal fluid culture recorded in the national infection surveillance data set.
We determined the generalisability and applicability of results of the PREVAIL trial to babies who received
peripherally inserted central venous catheters in neonatal intensive care units and local neonatal units
during the PREVAIL trial period (August 2015 to January 2017).
First, we compared the prevalence of baby characteristics, all causative organisms of bloodstream
infection, and crude and risk-adjusted rates of bloodstream infection per 1000 peripherally inserted
central venous catheter days in babies who received the standard peripherally inserted central venous
catheter in the PREVAIL trial with those of other babies who received peripherally inserted central
venous catheters in neonatal intensive care units (those in the PREVAIL trial neonatal intensive
care units who were not enrolled in the PREVAIL trial, and those who received peripherally inserted
central venous catheters in non-PREVAIL trial neonatal intensive care units during the PREVAIL trial
recruitment period) and local neonatal units.
Second, we compared trends in bloodstream infection rates in PREVAIL trial neonatal intensive care
units, other neonatal intensive care units and local neonatal units, using multilevel Poisson regression,
restricted to clearly pathogenic organisms to avoid spurious trends caused by increased reporting of
skin commensals.
Third, to inform targeting of preventative strategies, we evaluated trends in rates of late-onset
bloodstream infection per 1000 days of intensive or high-dependency care and per 100 admissions.
Fourth, we determined the contribution of peripherally inserted central venous catheters to the
overall rate of bloodstream infection per admission by calculating the proportions of total bloodstream
infection that occur (1) as early onset without peripherally inserted central venous catheter before
2 days of age; (2) during peripherally inserted central venous catheter days at risk, defined as 1 day
after insertion to 2 days after PICC removal; and (3) as late onset without peripherally inserted central
venous catheter days (≥ 2 days after birth).
Results
We found no differences at the 5% level between PREVAIL trial babies and other babies receiving
peripherally inserted central venous catheters in neonatal intensive care units and local neonatal units
in the distribution of causative organisms isolated from bloodstream infection, or in crude and adjusted
rates of any bloodstream infection per 1000 peripherally inserted central venous catheter days.
We found stable rates over time in the bloodstream infection rate per 1000 peripherally inserted
central venous catheter days (for clearly pathogenic organisms) in PREVAIL trial neonatal intensive
care units from 2010 to 2017. The rate of late-onset bloodstream infection (i.e. bloodstream infection
in babies older than 2 days of age, with or without a peripherally inserted central venous catheter) per
1000 days of intensive and high-dependency care decreased in local neonatal units and the percentage
of admissions with at least one late-onset bloodstream infection declined in PREVAIL trial neonatal
intensive care units and local neonatal units from March 2010 to June 2017.
Of all bloodstream infections during neonatal intensive or high dependency care in neonatal units,
18% were early-onset bloodstream infections, 46% occurred on days when a peripherally inserted
central venous catheter was inserted, and 35% were late-onset bloodstream infections when there
was no peripherally inserted central venous catheter. For babies born before 32 weeks of gestation,
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the proportions were 8%, 55% and 37% for early-onset bloodstream infections, bloodstream infections
during peripherally inserted central venous catheter days and late-onset bloodstream infections when
there was no peripherally inserted central venous catheter, respectively, and 42%, 26% and 32%,
respectively, for babies born at ≥ 32 weeks of gestation.
Conclusions
Main findings
We found no evidence of benefit or harm of the use of the miconazole- and rifampicin-impregnated
peripherally inserted central venous catheter during neonatal care. Interventions with a small effect
on bloodstream infection could be cost-effective over the life course. Trial findings are generalisable
to neonatal care in England.
Implications for practice
l We found no evidence to support the use of antimicrobial-impregnated peripherally inserted central
venous catheters in neonatal intensive care. The antimicrobial-impregnated peripherally inserted
central venous catheter was not more effective than the standard peripherally inserted central
venous catheter, but was more costly; hence, it was not cost-effective.
l Rifampicin resistance in bloodstream infection or peripherally inserted central venous catheter tips
was not significantly increased in the antimicrobial-impregnated peripherally inserted central venous
catheter group compared with the standard peripherally inserted central venous catheter group,
but organisms isolated just from the peripherally inserted central venous catheter tip were more
likely to be rifampicin resistant. As rifampicin is not routinely used in UK neonatal care, this is likely
to be of limited clinical relevance in the UK setting.
l We found that preventing bloodstream infection in preterm babies can result in better health
outcomes over the babies’ lifetimes, with potential savings in terms of health service costs, by
avoiding serious outcomes of bloodstream infection, principally neurodevelopmental impairment
and death (as suggested by prior epidemiological studies).
l Findings from the PREVAIL trial are generalisable to neonatal intensive care in the NHS in England.
Rates of bloodstream infection per peripherally inserted central venous catheter days at risk in the
PREVAIL trial were similar to the rates across neonatal care in England, before and after adjusting
for birth characteristics and intensity of care. Similar organisms were cultured from babies in the
PREVAIL trial and babies not in the PREVAIL trial.
l Rates of bloodstream infection (excluding skin organisms) per 1000 peripherally inserted central
venous catheter days in neonatal intensive or high-dependency care remained stable in neonatal
intensive care units and local neonatal units from 2010 to 2017. The percentage of admissions with
at least one late-onset bloodstream infection (defined as during peripherally inserted central venous
catheter insertion or > 2 days after birth) declined in local neonatal units and neonatal intensive
care units that participated in the PREVAIL trial.
l A bloodstream infection that occurs while peripherally inserted central venous catheters are in situ
contributes to less than half of all bloodstream infection during neonatal intensive and high-dependency
care. Preventative strategies for reducing hospital-acquired bloodstream infections in neonatal care may
want to focus on other sources of infection in addition to central venous catheters.
Recommendations for research
l Low-cost interventions that reduce bloodstream infection in preterm babies by a small amount
would be likely to be cost-effective over the child’s life course, based on the assumption of reduced
risk of neurodevelopmental impairment and death. Investment in further research to develop other
types of antimicrobial peripherally inserted central venous catheter impregnation or alternative
approaches for preventing infection in neonatal care would, therefore, be worthwhile.
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l The finding of no evidence of benefit associated with the rifampicin- and miconazole-impregnated
peripherally inserted central venous catheter contrasts with substantial reductions in rates of
bloodstream infection or catheter-related bloodstream infection reported in previous trials in children
and adults randomised to rifampicin- and minocycline-impregnated central venous catheters, compared
with standard central venous catheters. We recommend further research to develop and evaluate
the rifampicin- and minocycline-impregnated peripherally inserted central venous catheter for use in
preterm babies.
l Further research is needed to strengthen the evidence on the causal link between bloodstream
infection and neurodevelopmental impairment and death, and on methods to reflect the uncertainty
in these causal links in cost-effectiveness modelling.
l Patient-level linked data combining electronic clinical records from neonatal care, Hospital Episode
Statistics and infection surveillance data should be made routinely available for research and
infection surveillance in England.
l Further research is required to understand which practices contribute to changes (or lack of change)
in rates of bloodstream infection over time in neonatal care.
Trial registration
The trial is registered as ISRCTN81931394.
Funding
This project was funded by the National Institute for Health Research Health Technology Assessment
programme and will be published in full in Health Technology Assessment; Vol. 24, No. 57. See the NIHR
Journals Library website for further project information.
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Chapter 1 Introduction
Parts of this chapter have been reproduced from Gilbert et al.1 © 2019 The Author(s). Published byElsevier Ltd. This is an open access article distributed under the terms of the CC-BY 4.0 license
(https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium.
Background
In the UK, approximately 8% of all babies are born preterm, defined as delivery before 37 weeks
of gestational age.2 Preterm birth is associated with high rates of neonatal and childhood mortality
and with high rates of long-term chronic conditions, manifesting as adverse neurodevelopment
and respiratory disease.3–6 Risks of these outcomes increase steeply with earlier gestational age at
birth. Risks are even higher in babies who develop a bloodstream infection (BSI).7–10 A BSI can be an
early-onset infection (i.e. before 2 days of age), which is thought to be predominantly due to organisms
transmitted from mother to baby.11,12 Thereafter, a BSI is commonly caused by organisms that enter
the bloodstream through skin or mucosal barriers in babies with immature immune defences, or
through contamination of internal devices, such as central venous catheters (CVCs).13–15 In the UK,
14% of all babies born are admitted to a neonatal unit (NNU), but this proportion is much higher
for babies born preterm: all of the 1.4% of babies born before 32 weeks of gestation spend time in
a NNU.16 On average, 5% of all babies admitted to a NNU experience a BSI, but this proportion rises
to 22% for babies born before 33 weeks of gestation and to 36% for babies born before 29 weeks of
gestation.17,18 Therefore, prevention of BSI, and its acute and long-term adverse outcomes, is a very
high priority for neonatal care.
Central venous catheters are a common source of BSI in babies receiving neonatal care. According to
two national surveillance studies,19,20 43–48% of BSIs occurring after the first 2 days of age are considered
to be related to CVCs. An estimated 21% of babies admitted born at ≥ 34 weeks of gestation and
admitted to a NNU receive a CVC, but this proportion rises to 70% for babies born before 32 weeks of
gestational age [based on unpublished analysis of the National Neonatal Research Database (NNRD)
(Katie Harron, University College London, 2014, personal communication)].21 Peripherally inserted
central venous catheters (PICCs) are frequently used in NNUs. The PICC is a very narrow tube placed
through the skin and into a central vein, using a needle, which is then removed. The PICC is used to
administer medicines, fluids or parenteral nutrition into a large vein near the heart. A PICC can stay
in place for several weeks, avoiding the need for repeated procedures, which can be harmful and
distressing for small babies.
The mechanism by which CVCs lead to BSI is through microbial colonisation. Bacteria or fungi stick to the
catheter tubing inside the vein and secrete a protective biofilm protecting themselves from host defences
and any circulating antimicrobial agents, and enabling sustained colonisation.22,23 The organisms multiply
and, in babies with immature immunity, infection spreads via the bloodstream, causing sepsis and infecting
other organs, with damaging effects, particularly on the brain and lungs. The organism causing the BSI is
important. Gram-positive organisms, such as Group B streptococci, and Gram-negative organisms, including
Escherichia coli, Klebsiella and Pseudomonas, are associated with high rates of mortality and morbidity.7 BSIs
due to skin commensals, predominantly coagulase-negative staphylococci (CoNS), can also cause death
and adverse neurodevelopmental outcomes, but the risk is lower than for clearly pathogenic organisms.17
Lower risks of adverse consequences for BSIs due to skin organisms may reflect two factors. First, skin
organisms are less virulent than non-skin organisms, evidenced by their status as normal commensal
bacteria that colonise the skin and gut of newborn babies. Second, skin organisms frequently contaminate
blood culture samples. A positive culture from blood does not, therefore, always reflect the presence of
organisms circulating in the bloodstream, and rates of infection with skin organisms may be overestimated.
DOI: 10.3310/hta24570 Health Technology Assessment 2020 Vol. 24 No. 57
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Gilbert et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
1
Bloodstream infections related to PICCs can be treated with intravenous antibiotics, and sometimes
require removal of the PICC.24 Systemic antibiotic treatment alters the microbial ecology of the gut,
which increases the risk of necrotising enterocolitis (NEC), an inflammatory condition of gut mucosa,
which affects babies born before 32 weeks of gestation.25,26 Prevention of BSIs in babies who receive
a PICC is, therefore, important to avoid these serious and costly consequences.
Antimicrobial impregnation of the tubing of CVCs is widely used to prevent BSIs in adult and paediatric
intensive care. Use of antimicrobial-impregnated CVCs is recommended in UK27 and US28 national
guidelines for patients at high risk of infection. No such recommendations exist, however, for newborn
babies, because of the lack of antimicrobial-impregnated catheters suitable for preterm babies and
the lack of evidence from adequately powered randomised trials.29,30 Various forms of antimicrobial
impregnation have been evaluated in 54 randomised controlled trials (RCTs) and numerous systematic
reviews, including two systematic reviews combined with network meta-analyses that reported direct and
indirect comparisons between types of CVCs.31,32 The network meta-analyses report the most effective
form of antimicrobial impregnation to be a combination of minocycline and rifampicin antimicrobials.
However, the only form of impregnated PICC licensed in Europe for newborn babies, and small enough
for use in preterm babies, is the Premistar™ catheter, manufactured by Vygon (UK) Ltd (Swindon, UK).
The Premistar PICC is impregnated with the antifungal miconazole, in combination with the antibacterial
agent rifampicin. In the next section, we summarise findings from an overview of systematic reviews
of RCTs that evaluated CVCs impregnated with miconazole and rifampicin, or with minocycline and
rifampicin, in any setting or age group.
Evidence review
We searched the Cochrane Central Register of Controlled Trials, EMBASE and MEDLINE on 29 March 2018,
and ClinicalTrials.gov and the World Health Organization International Clinical Trials Registry Platform
on 3 April 2018, for studies evaluating the effectiveness of antimicrobial-impregnated CVCs compared
with any other type of CVC for reducing the rate of BSIs in newborn infants, children and adults.
We included systematic reviews or meta-analyses of RCTs of miconazole- and rifampicin-impregnated
or minocycline- and rifampicin-impregnated CVCs published since 2008, and RCTs in children or
newborn infants published since the searches conducted in the systematic reviews. We used search
terms related to CVCs, antimicrobial impregnation and infection. We identified 11 RCTs of CVCs
impregnated with rifampicin combined with another antimicrobial agent (two with miconazole and nine
with minocycline) (Table 1).
Further details of studies and search terms are reported in the appendix to the recent trial report.1
Of the two trials that compared miconazole- and rifampicin-impregnated CVCs with standard CVCs,
one involved newborn infants, but was published as an abstract only.30 The other was conducted in
adult surgical patients.36 Neither trial reported a significant difference in the rate of catheter-related
BSIs. This widely used outcome may give biased catheter-related BSI results because of inhibition of
laboratory culture of organisms from the CVC tip due to leaching of the antimicrobial agent from the
impregnated CVC tubing onto the culture media.34 Use of any BSI as an outcome, meaning any positive
culture, whether catheter related or otherwise, avoids this problem.
There were nine RCTs34,37–44 of minocycline- and rifampicin-impregnated CVCs. In eight of the RCTs,
the comparator was standard CVCs, in the other RCT the comparator was CVCs impregnated with
chlorhexidine and silver sulfadiazine. Two RCTs were conducted with children and seven with adults.
All nine RCTs reported large reductions in the rates of catheter-related BSIs. The systematic review
and network meta-analysis of trials in adults by Chong et al.32 reported an estimated risk ratio for
minocycline and rifampicin impregnation, compared with no impregnation, of 0.29 [95% confidence
interval (CI) 0.16, 0.52]. Only one RCT, the CATheter Infections in CHildren (CATCH) trial,34 reported
results for BSI from any cause: the rate of BSI was reduced by 57% (see Table 1).
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TABLE 1 Overview of evidence on the effectiveness of miconazole- and rifampicin-impregnated or minocycline- and rifampicin-impregnated CVCs for reducing the rate of BSIs








Children Balain 201529 Review No RCTs
Wu 201733 Review No RCTs
Flemmer 201630 Study 1 RCT 86 PICC colonisation and
signs of sepsis
OR 0.22 (0.02 to 2.27)




Children Wu 201733 Review 2 RCTs 1773 Catheter-related BSI OR 0.40 (0.15 to 1.04)
Gilbert 201634 Study 1 RCT 1485 BSI HR 0.43 (0.20 to 0.96)
Adults Lai 201635 Review 4 RCTs 1335 Catheter-related BSI RR 0.26 (0.13 to 0.49)
Chong 201732 Review and network
meta-analysis
7 RCTs 2724a Catheter-related BSI RR 0.29 (0.16 to 0.52)
CI, confidence interval; HR, hazard ratio; OR, odds ratio; RR, relative risk.






































































































































































































































































































































































Citing the paucity of evidence for newborn babies, a systematic review published in The Cochrane Library
in 2015 recommended that a large, simple and pragmatic RCT of antimicrobial-impregnated CVCs be
undertaken to guide policy and practice.29 The only type of antimicrobial-impregnated CVC developed
and licensed to date for use in newborn babies in the UK is the Premistar, which is impregnated with
miconazole and rifampicin. Although two RCTs found no evidence of reduced catheter-related BSIs
with rifampicin–miconazole impregnation, an in vitro experimental study reported reduced bacterial
colonisation of CVCs with rifampicin–miconazole impregnation, compared with no impregnation.30,36,45
When planning the PREVenting infection using Antimicrobial-Impregnated Long lines (PREVAIL)
trial, we sought support for the proposed trial from the Neonatology Clinical Studies Group of the
Medicines for Children Research Network. The group emphasised the need for RCT evidence of
reduced rates of BSIs in preterm babies, and of safety in relation to antibiotic resistance. Extrapolation
of findings from children and adults was not sufficient for clinicians to change practice. Concerns were
expressed about the additional costs of impregnated CVCs, and the fact that rates of hospital-acquired
infection were declining following implementation of ‘bundles’ of practice designed to improve sterile
procedures during catheter insertion and maintenance of the line.46–48
Combining the overview of published evidence and clinical opinion, it was concluded that:
l The frequency and serious long-term consequences of BSI in preterm babies could result in
significant health gains and reduced health-care costs if impregnated CVCs were found to reduce
rates of BSI in babies receiving neonatal intensive care.
l Evidence would be needed from a large RCT specifically in preterm newborns of the benefits, safety
and cost-effectiveness of miconazole- and rifampicin-impregnated PICCs before neonatologists
would be willing or able to change purchasing decisions to adopt this type of PICC in NNUs.
l Reductions over time in BSI rates due to improved infection control practices in neonatal care
would need to be taken into account when applying the findings of a large RCT to practice.
Aims and objectives
Aims
The overall aim of the study was to determine whether or not antimicrobial-impregnated PICCs
(AM-PICCs) should be adopted across the NHS for babies receiving neonatal care. We undertook
three inter-related analyses to address this aim (see Figure 1):
1. a clinical effectiveness RCT – to determine the clinical effectiveness of AM-PICCs, compared with
standard PICCs (S-PICCs), for babies receiving neonatal care
2. an economic analysis – to determine the cost-effectiveness of AM-PICCs, compared with S-PICCs,
from an NHS perspective
3. a generalisability analysis – to generalise the trial results to neonatal care in the NHS in England.
Objectives
Clinical effectiveness randomised controlled trial
The objectives of the RCT were to determine the clinical effectiveness of AM-PICCs compared with
S-PICCs in terms of:
l time to BSI (primary outcome), and other measures of BSI (e.g. rate)
l safety, including measures of rifampicin resistance in blood, cerebrospinal fluid (CSF) and PICC cultures
l clinical outcomes, for example death before discharge, NEC, time to full enteral feeds and time to
PICC removal.
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The data sources were case report forms (CRFs) completed by research nurses from routine clinical
records, and mortality within 6 months of randomisation based on linked death registration data.
Economic analysis
The economic analysis was conducted to determine:
l the hospital costs of using AM-PICCs compared with S-PICCs over the 6-month follow-up of
the trial
l the cost-effectiveness of AM-PICCs versus S-PICC in terms of NHS costs and quality-adjusted
life-years (QALYs), combined to assess incremental net health benefit over the babies’
expected lifetimes
l the value of further information from research.
The original study objectives included determining the cost to the NHS of a BSI in preterm babies and
the value of implementing the cost-effective PICC type. These objectives were not addressed because
we found no evidence of a reduction in BSI rates in babies randomised to AM-PICCs, compared with
babies randomised to S-PICCs.
The data sources were as follows: national data from Hospital Episodes Statistics (HES) [all admissions,
accident and emergency (A&E), outpatients], paediatric intensive care unit (PICU) admissions [from the
Paediatric Intensive Care Audit Network (PICANet)]; and the NNRD for all care in NNUs.
Generalisability analysis
The objectives of the generalisability analysis were as follows:
l to determine generalisability and applicability by comparing BSI risk factors, causative organisms
and rates of BSI among babies in the PREVAIL trial with other babies receiving PICCs
l to determine the applicability of BSI rates in the PREVAIL trial to rates of BSI in the NHS in
England by comparing trends in BSI in babies receiving PICCs in the PREVAIL trial neonatal
intensive care units (NICUs), non-PREVAIL trial NICUs and local neonatal units (LNUs)
l to provide context through understanding of changes in BSI over time by evaluating trends in rates
of late-onset BSI per 1000 days of intensive or high-dependency care and per 100 admissions for all
babies receiving intensive or high-dependency care in NICUs and LNUs
l to determine the contribution of PICCs to the overall rate of BSI per admission.
The data source was the NNRD linked to national laboratory infection surveillance data for England.
The three components of the study are illustrated in Figure 1. We also considered further uses of
these linked data. First, for ongoing monitoring of BSI rates following implementation of an effective
intervention. Second, to link trial and linked administrative health data to school achievement data to
assess long-term effects of PICC impregnation on cognitive ability measured in school achievement
assessments. These uses have not been pursued, because the infection outcome in the randomised
groups did not differ.
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(1) Clinical effectiveness RCT:
BSI outcomes up to 48 hours
after PICC removal, clinical
outcomes at NNU discharge
(2) Economic analyses: cost-effectiveness
and value-of-information analysis
(follow-up 6 months after randomisation)
(3) Generalisability analyses
Administrative data:









FIGURE 1 Flow diagram to show inter-relationship between the three components of the PREVAIL study.
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Chapter 2 Clinical effectiveness
randomised controlled trial methods
Parts of this chapter have been reproduced from Gilbert et al.1 © 2019 The Author(s). Published byElsevier Ltd. This is an open access article distributed under the terms of the CC-BY 4.0 license
(https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium.
Trial design
We conducted an open-label, two-arm parallel-group RCT in 18 NICUs in England. The trial was a
pragmatic trial designed to determine the clinical effectiveness of AM-PICCs in the context of local
practice in NICUs. Recruitment was planned over a 24-month period, starting in June 2015. An internal
pilot was used to assess recruitment. The threshold for determining that recruitment was feasible
was set at 130 participants being randomised after 8 months (to allow the initial sites 6 months of
recruiting at full capacity). An interim analysis of the primary outcome took place half-way through
the trial (when approximately half of the participants had been randomised), using Haybittle–Peto
stopping rule.49
Ethics approval and research governance
The protocol was approved by the Yorkshire and the Humber Health Research Authority (reference
number 14-YH-1202). The trial was funded by the National Institute for Health Research (NIHR)
Health Technology Assessment programme and included in the International Standard Randomised
Controlled Trial Number registry [https://doi.org/10.1186/ISRCTN81931394 (accessed 22 July 2020)].
Centre-specific approval was obtained at all recruiting centres.
Full details of the amended trial protocol (version 5.0, 26 April 2017), the research ethics approval and
the statistical analysis plan are available online [http://prevailtrial.org.uk/ (accessed 22 July 2020)].
A summary of substantial protocol amendments is provided in Appendix 1, Table 26.
Selection of trial sites
Recruitment took place in 18 out of 43 NICUs in England. Overall, there are 154 NNUs in England
(Table 2), of which 43 are NICUs that provide intensive care for babies, such as invasive ventilation
and organ system support (Table 3). Days of intensive care are supported by nurse staffing ratios of
one nurse to one baby, with step-down care for high-dependency (one nurse to two babies) and special
care (one nurse to four babies).51 Of the 154 NNUs, 76 LNUs provide short-term intensive care and
high-dependency and special care, and 35 NNUs provide special care only [i.e. special care baby units
(SCBUs)]. One in 10 babies admitted to a NNU is transferred to another unit for higher or lower levels
of care. Step-up transfers between NNUs within neonatal networks are used to provide centralised
intensive care when needed, including neonatal surgery for a small proportion of babies. Step-down
transfers are frequently used to allow babies to be cared for near to parents and to reduce pressure
for beds in NICUs. Low-intensity neonatal care is also provided in transitional care wards, which are
not considered here.
We invited expressions of interest from NNUs in 2015. We prioritised NICUs with the largest number
of babies born before 32 weeks of gestation, using NNRD data, and those sites invited to participate
through the Children’s Clinical Research Network.
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Participants
Eligible participants were all babies who required the narrowest (1 French gauge) PICC. Only babies
who had previously participated in the trial or who were known to have an allergy or hypersensitivity
to rifampicin or miconazole were excluded.
The reason for insertion was not requested, but PICCs are primarily used for parenteral nutrition,
particularly in preterm babies. As this was a pragmatic trial, designed to reflect routine practice, we
did not restrict eligible participants to preterm babies. However, in practice, the 1-French gauge PICC
is predominantly used in preterm babies born before 32 weeks of gestation, as more mature and larger
babies normally require a wider-gauge PICC to infuse sufficient volumes of fluid. Preliminary, unpublished
analyses using the NNRD revealed that 70% of babies in neonatal units born before 32 weeks of gestation
had a PICC inserted (unpublished data, NNRD, England).
TABLE 3 Definitions of level of neonatal care
Level of care Care received
Level 3: intensive care Any day on which a baby receives/undergoes at least one of the following:
l Mechanical respiratory support via a tracheal tube
l Both non-invasive ventilation AND parenteral nutrition
l Surgery
Or the day of death
Level 2: high-dependency care Any day on which a baby who does not meet the criteria for intensive care receives at
least one of the following:
l Non-invasive respiratory support
l Parenteral nutrition
Level 1: special care Any day on which a baby who does not meet the criteria for intensive or
high-dependency care receives or has at least one of the following:
l Oxygen via low-flow nasal cannula
l Feeding by nasogastric tube, jejunal tube or gastrostomy
l Continuous physiological monitoring
l Care of stoma
l Presence of an intravenous cannula
l Phototherapy
l Special observation of physiological variables at least every 4 hours
TABLE 2 Number of NICUs, LNUs and SCBUs in the NHS in England in 2017, based on data from the NNAP16









NICU [provide intensive care, high-dependency
care and special care (levels 1–3)]
43 (27.9) 22,717 (42.9) 509 (200–1150) 3.4%
LNU [provide short-term intensive care,
high-dependency care and special care
(levels 1–2)]
76 (49.4) 24,211 (45.8) 307 (83–749) 3.6%
SCBU [provide special care only (level 1)] 35 (22.7) 5972 (11.3) 154 (46–362) 0.9%
Total 154 52,900 319 (46–1150) 7.8%
NNAP, National Neonatal Audit Programme.
a Babies are counted if admitted for at least 12 hours to receive special care, high-dependency care or intensive care.
Only the first admission for each baby is counted.
b The number of live births in England was obtained from the Office for National Statistics.50
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The principal investigator (PI) or research nurse (RN) maintained a screening log of babies whose
parents were approached about the trial, detailing reasons for declining consent or reasons for no
randomisation occurring for those who did consent. They also kept a log of all babies who received a
PICC [a 1-French Premicath®; Vygon (UK) Ltd], but whose parents were not approached for the trial,
and why they were not approached.
Enrolment
When a baby was likely to require a PICC (Premicath, 1 French), the clinician or RN provided written
information and met with the parents to discuss participation in the trial.52 Written consent was
required, along with confirmation of eligibility from the PI or designated other before randomisation
could occur. Twins were treated as separate individuals for consent and randomisation, if both babies
required a PICC. Babies could be simultaneously enrolled in multiple studies, as agreed between
chief investigators.
Randomisation, concealment and blinding
Participants were randomised to either an AM-PICC or a S-PICC using a secure web-based randomisation
programme by the PI or delegated other at each of the 18 recruitment sites. PICC insertion was scheduled
to occur within 48 hours of randomisation by a designated staff member. Randomisation sequences were
computer-generated by an independent statistician in random, variable blocks of two and four, stratified
by site. Randomisation was controlled centrally by the Liverpool Clinical Trials Centre (LCTC), at the
University of Liverpool (UoL), to ensure allocation concealment. It was impractical to mask clinicians
to PICC allocation because rifampicin caused brown staining of the AM-PICC. Participant inclusion in
analyses and occurrence of outcome events were determined by following an analysis plan that was
specified before individuals saw unblinded data.
Treatments
Trial participants were allocated in a ratio of 1 : 1 to receive either:
l a miconazole- and rifampicin-impregnated PICC (AM-PICC; Premistar)
l a standard (non-impregnated) PICC (S-PICC; Premicath).
Miconazole is an antifungal agent that is effective against systemic fungal infection. Rifampicin is an
antibacterial agent, previously evaluated as rifampicin–minocycline CVC impregnation in adults and
children. The manufacturer, Vygon (UK) Ltd, reported continuing elution from the CVC of rifampicin
and miconazole over 21 days.53 The AM-PICC was marketed after certification under the Conformité
Européenne (CE) process in December 2012 (certificate number Z/12/02895).
The method for PICC insertion was according to clinician preference. Either a needle or a 24-gauge
intravenous cannula was inserted into a peripheral vein and the PICC tubing was threaded through the
stylet until the tip reached a large central vein, such as the inferior or superior vena cava. The position
of the PICC was checked by a radiograph. In the case of malposition, for example in a spinal vein or
the PICC tip lying within the heart, the catheter was adjusted or withdrawn. For the purposes of the
trial, a PICC was deemed to have been successfully inserted if the site of line insertion was dressed in
preparation for a radiograph to confirm PICC tip position, even if the result of the radiograph led to
the PICC being withdrawn. If PICC insertion was unsuccessful, the clinical team attempted further
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insertions using the same type of PICC as randomised until 48 hours after randomisation, at which
point subsequent PICC insertion attempts were of the S-PICC regardless of the randomised allocation.
Babies could not be randomised more than once.
Follow-up
Infection outcomes (including the primary outcome) were captured for all babies until 48 hours after
PICC removal, or following the last unsuccessful PICC insertion or randomisation (if insertion was
not attempted) (Figure 2). During this time, the RN assessed babies daily to record whether or not
any blood or CSF samples were taken for clinical indications of infection (or results received), any
concomitant antimicrobials or parenteral nutrition were given, the PICC was removed (and tip
cultured) or any adverse events (AEs) were observed.
Follow-up for secondary clinical outcomes continued until discharge from the neonatal unit, death or
6 months after randomisation, whichever occurred first (see Figure 2). As babies matured and required
less intensive care, some were transferred to a NNU nearer home that was not one of the recruitment
centres. We counted date of discharge from the final NNU after all transfers. Information was captured
on all deaths within 6 months of randomisation.
Data were collected on paper-based CRFs completed by centre staff authorised to do so and returned
to the LCTC. Information on deaths was recorded on the CRF, if death occurred in the NNU, and/or
through linked death registration records.
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FIGURE 2 Schematic representation of the trial procedures.
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We recorded the following demographic and relevant clinical characteristics at randomisation.
l demographics – sex, birthweight, gestational age at birth and age at randomisation
l delivery characteristics – born in the trial hospital or transferred to the trial hospital after birth,
vaginal or caesarean delivery, ruptured membranes > 24 hours before birth, maternal antenatal
steroids received or not, and maternal antibiotics received within 12 hours pre delivery
l characteristics of neonatal care before randomisation – surgery in the previous 14 days, samples
taken, antimicrobial medication received and the highest level of respiratory support required,
all within the previous 72 hours
l other clinical characteristics – major congenital anomaly; appearance, pulse, grimace, activity,
respiration (Apgar) score at 5 minutes of age; number of invasive devices in situ; and the site where
the randomised PICC was successfully inserted.
Adherence to treatment and the protocol
To measure adherence to the intervention, we recorded whether or not a PICC was inserted, and,
if so, whether or not it was the allocated PICC, the reasons for removal, the length of time that the
PICC was in situ, and whether or not positive samples were tested for resistance.
Protocol deviations were monitored centrally via evaluation of inclusion/exclusion criteria at trial entry
and throughout the course of the trial. Some of the secondary outcomes (see the following sections)
were also designed to detect potential biases in adherence to the trial protocol that might be influenced
by knowledge of the type of PICC.
Primary outcome
The primary outcome was time from randomisation to first bloodstream or CSF infection, defined
as a microbiological culture of a bacteria or fungus from blood or CSF sampled for clinical reasons.
We use the term BSI to refer to a positive culture from blood or CSF. We defined the primary outcome
time window as the period when any positive blood or CSF cultures could be counted in the primary
outcome. The time window was from 24 hours post randomisation until 48 hours after PICC removal
or death (or 48 hours after randomisation if the PICC was not inserted; see Figure 2). We imposed
a priori decision rules to avoid counting pre-existing BSI. We excluded microbial cultures that were
within the time window if the same organism was isolated from blood or CSF and samples were taken
< 14 days apart, or if a different organism was isolated and samples were < 24 hours apart. When
there were multiple positive cultures within the primary outcome time window, each positive culture
was assessed and the first one that met the definition was counted.
Secondary outcomes
Secondary outcomes related to infection
These outcomes were measured during the primary outcome time window (see Figure 2):
l rifampicin resistance in any isolate from blood or CSF culture
l rifampicin resistance in any isolate from the PICC tip
l rifampicin resistance in any isolate from blood or CSF culture or from the PICC tip [this was added
as an additional analysis in version 2.0 of the statistical analysis plan, which was approved on
7 March 2018, before database lock (study closure)]
l occurrence of one or more BSI
l rate of BSIs (including recurrent BSIs) per 1000 PICC days
l rate of catheter-related BSIs (defined as isolation of the same organism from the PICC tip and blood
or CSF) per 1000 PICC days
l type of organism isolated from BSI meeting primary outcome criteria.
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Multiple infection episodes within the time window were considered as distinct infection episodes if
positive samples for each episode involved the same organism in samples taken > 14 days apart or
involved different organisms in samples taken > 24 hours apart.
Rifampicin resistance was detected using ETEST® (bioMérieux, Marcy-l'Étoile, France) strips.54
Other clinical secondary outcomes
These outcomes were captured up until neonatal discharge home, death or 6 months after
randomisation, whichever occurred first (see Figure 2):
l chronic lung disease – respiratory support (mechanical ventilation or continuous positive pressure
via endotracheal tube or nasal tube) or supplemental oxygen at 36 weeks’ postmenstrual age
l NEC – Bell’s stage II or III
l abnormalities on cranial ultrasound (periventricular leukomalacia or intracranial haemorrhage;
worst grade of one to four used in analyses)
l treatment for retinopathy of prematurity (medical or surgical)
l time from randomisation to full milk feeds (150 ml/kg/day)
l total duration of parenteral nutrition from randomisation until discharge from neonatal care
l death –
¢ before discharge home from neonatal care
¢ within 6 months (26 weeks) of randomisation.
Secondary outcomes to detect potential biases in sampling or treatment on the
basis of knowledge of peripherally inserted central venous catheter allocation
l Rate of blood/CSF culture sampling per 1000 PICC days.
l Duration of antimicrobial exposure from randomisation up to 48 hours after PICC removal.
l Time from randomisation to PICC removal.
Safety outcomes
All AEs (expected and unexpected) considered to be related to the PICC were reported until 48 hours
after PICC removal.
Sample size
The sample size calculation for the primary outcome was based on the log-rank test for equality of
survival curves. We hypothesised a similar effect of rifampicin–miconazole impregnation to that of
minocycline–rifampicin. We considered a 50% reduction to be conservative, given results of a network
meta-analysis by Wang et al.31 for catheter-related BSI [mean odds ratio (OR) 0.18 and upper 95% CI
0.34], and the results of the CATCH trial.34 Using a two-sided significance level of 0.05, to detect a
reduction in the proportion of babies experiencing a BSI from 14% in the standard arm, which was
expected based on audit data from three participating NNUs, to 7% in the antimicrobial-impregnated
arm, 79 events were required from 816 babies (408 in each arm) for 90% power. To allow for a 5%
loss to follow-up, the target was inflated to 858 babies.
Statistical methods
General statistical considerations
The analysis and reporting of the trial were undertaken in accordance with the Consolidated Standards
of Reporting Trials (CONSORT)55,56 and the International Conference on Harmonisation E9 Guidelines.57
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The main features of the statistical analysis plan are included in this section, with a full and detailed
statistical analysis plan provided as a supplementary file58 on the PREVAIL trial website.
Outcome data were analysed according to the intention-to-treat principle, which is including all
randomised participants in the group to which they were allocated (regardless of whether or not the
allocated PICC was inserted) and for whom the outcome was measured/observed. All statistical tests
were two-sided and performed using a 5% significance level. We used 95% CIs throughout. There were
no adjustments for multiple testing; rather, all secondary analyses were treated as hypothesis-generating.
All analyses were conducted with SAS® version 9.4 (SAS Institute Inc., Cary, NC, USA). Results from the
primary outcome and safety analyses were validated by independent programming by another statistician
from the point of raw data.
Baseline characteristics
Demographics and other clinical baseline characteristics were summarised for each treatment group
and overall, using descriptive statistics. No formal statistical testing was performed on these data.
Descriptive statistics, including the number of observations, mean and standard deviation (SD) for
continuous variables, and counts and percentages for discrete variables, were presented as appropriate.
Adherence to treatment and the protocol
All protocol deviations were agreed with the co-chief investigators prior to them seeing any unblinded
results. These data were summarised for each treatment group and overall, using descriptive statistics,
as for the baseline data. No formal statistical testing was performed on these data.
Primary outcome
The primary outcome, time to first BSI, was measured from randomisation to the first sample that met
the definition of an independent episode of BSI. Participants not experiencing the primary outcome
were censored at death, 48 hours after PICC removal or 48 hours after randomisation (for those with
no PICC inserted). The difference between the groups was tested using the log-rank test, and the
hazard ratios (HR) and associated 95% CIs obtained from the Cox proportional hazards model were
presented. Kaplan–Meier curves were used to present the number of babies at risk. The number of
samples taken, the number of babies with samples taken and the number of babies with a BSI within
the primary outcome time window were also presented for each treatment group, overall and split by
sample type.
Four sensitivity analyses of the primary outcome were prespecified to determine the robustness of the
results of the primary analysis:
1. time from randomisation to first clinically serious BSI, defined as treatment with antimicrobials for
≥ 72 hours or death during treatment
2. time from PICC insertion to first BSI
3. time from randomisation to first BSI excluding samples obtained via arterial cannulas or CVCs
4. time from randomisation to first BSI including only clearly pathogenic organisms, as defined in
Appendix 1, Table 27.
After seeing the results, we specified an additional analysis of the primary outcome to investigate
whether or not the treatment effect varied by gestational age at birth (< 28 weeks or ≥ 28 weeks of
gestation at birth) using a Cox proportional hazards model, including an interaction between treatment
and gestational age.
DOI: 10.3310/hta24570 Health Technology Assessment 2020 Vol. 24 No. 57
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Gilbert et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
13
Secondary outcomes
Secondary outcomes relating to infection
The analysis of the rifampicin resistance outcomes and occurrence of one or more BSI used Fisher’s
exact test to compare the proportions of participants in each group for whom these outcomes (rifampicin
resistance and BSI) were observed. Relative risks (RRs) were presented, along with 95% CIs. Frequency
tables are also presented for the resistance outcomes, split by treatment and whether samples were
Gram positive or negative, along with line listings of the resistant isolates showing the type of PICC and
the organism cultured (see Appendix 2, Table 38).
The differences in the rate of BSI (including recurrent BSI) and rate of catheter-related BSI per 1000
PICC days during the primary outcome time window were analysed using Poisson regression. The rate
ratios and associated 95% CIs were presented. For comparability with published studies, rates per 1000
PICC days between randomisation and PICC removal were also reported.
The number and proportion of BSIs by type of organism isolated were presented, but no formal
statistical analysis of this outcome was performed.
Other clinical secondary outcomes
The proportion of participants in each treatment group experiencing chronic lung disease, NEC,
abnormalities on cranial ultrasound and treatment for retinopathy of prematurity were compared using
Fisher’s exact test. RRs were presented, along with 95% CIs. We described the type of treatment given
for retinopathy of prematurity without formal statistical analysis by treatment allocation.
The time to full milk feeds was compared across the two treatment groups using the log-rank test
and Cox proportional hazards models. The HRs and associated 95% CIs were presented, along with
a Kaplan–Meier curve stratified by treatment. Survival times were measured from randomisation.
The duration of parenteral nutrition was compared across the two treatment groups using the
Mann–Whitney U-test. The medians and interquartile ranges (IQRs) were presented for each group.
Death was analysed in two ways. Fisher’s exact test was used to compare the proportion of deaths
in each group before discharge home from neonatal care and within 6 months from randomisation
(updated to include data from NHS digital). RRs were presented, along with associated 95% CIs.
Time to death was analysed using the log-rank test and Cox proportional hazard models. The HR
and associated 95% CIs were presented, along with a Kaplan–Meier curve stratified by treatment.
Survival times were measured from randomisation.
Secondary outcomes to detect potential biases in sampling or treatment on the
basis of knowledge of peripherally inserted central venous catheter allocation
The difference in rate of blood/CSF culture sampling per 1000 PICC days (during the primary outcome
time window) was analysed using Poisson regression. The rate ratio and associated 95% CIs were
presented. As with the other rate outcomes, for comparability with published studies, the rate per
1000 PICC days between randomisation and PICC removal was also reported.
Time to PICC removal was compared across the two treatment groups using the log-rank test and
Cox proportional hazard models. The HR and associated 95% CIs were presented, along with a
Kaplan–Meier curve stratified by treatment. Survival times were measured from randomisation.
The difference between groups in the duration of antimicrobial exposure was analysed using the
Mann–Whitney U-test. The medians and IQRs were presented for each group.
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Safety analyses
The statistical analysis plan specified that all babies who had a PICC inserted or who had an attempted
insertion would be included in the safety analysis population. The plan specified that babies who had
a PICC inserted would be analysed according to the treatment they received, and that babies for
whom PICC insertion was attempted but unsuccessful would be analysed according to the allocated
treatment group, as information was not recorded on the type of PICC that was used for attempted
insertion. However, after seeing the trial results, it was deemed more appropriate to exclude babies in
whom insertion was unsuccessful from the safety analysis population.
All AEs and serious adverse events (SAEs) reported by the clinical investigator and classified as ‘possibly’,
‘probably’ or ‘almost certainly’ related to the trial treatment were presented. The number (and percentage)
of occurrences of each AE/SAE and of babies experiencing each AE/SAE were presented for each treatment
arm. The same information was also presented split by severity. For each baby, only the maximum severity
that they experienced for each type of AE was displayed. No formal statistical testing was undertaken.
Patient and public involvement
We worked closely with Bliss (registered charity number 1002973) to develop the trial, provide advice
to the trial team, identify suitable parent and public representatives and disseminate updates and
results. Bliss was involved in the development of the study at an early stage, as one of their members
was a co-applicant to the grant. A Bliss representative was a member of the Trial Management Group
(TMG) and was involved in the development and review of trial documentation.
A parent of a prematurely born infant who had spent substantial time in a NICU sat on the Trial
Steering Committee (TSC) and assisted with decision-making about the trial. The parent representative
also aided with the review of trial documentation.
Trial oversight and role of funders
Trial Management Group
The TMG comprised the co-chief investigators, specific co-investigators (clinical and non-clinical),
members of the LCTC and members of the chief investigator’s team at University College London
(UCL). The TMG was responsible for the month-to-month management of the trial. The TMG proposed
the membership of the oversight committees [the TSC and the Independent Data and Safety Monitoring
Committee (IDSMC)] to the trial funders, who then made appointments according to their constitutional
requirements. Members are listed in the Acknowledgements.
Trial Steering Committee
The TSC consisted of an independent chairperson, an independent expert in the field of neonatology,
an independent statistician and a parent representative. One of the co-chief investigators was a non-
independent member of the TSC. The TSC was the executive decision-making committee considering
the recommendations of the IDSMC. Monitoring reports viewed by the TSC did not present data split
by treatment group. Members are listed in the Acknowledgements.
Independent Data and Safety Monitoring Committee
The IDSMC included an independent chairperson, an expert in the field of microbiology and an
independent statistician. The IDSMC was responsible for reviewing and assessing recruitment and
for interim monitoring of safety and effectiveness, trial conduct and external data. The IDSMC
provided recommendations to the TSC concerning the continuation of the trial. Members are listed
in the Acknowledgements.
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Role of the funding source
The funder appointed independent members to the TSC and the IDSMC, approved all protocol
amendments and monitored study progress against agreed milestones. The funder had no involvement
in data interpretation or writing of the report. The corresponding author had full access to all outputs
from the data in the study.
Dual publication
Chapters 1 and 2 contain information published in the 2019 report of the PREVAIL trial findings,
with further details and results.1 Chapter 2 includes details reported in the PREVAIL trial protocol
and statistical analysis plan, which have already been published on the PREVAIL website.58,59
CLINICAL EFFECTIVENESS RANDOMISED CONTROLLED TRIAL METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
16
Chapter 3 Clinical effectiveness randomised
controlled trial results
Recruitment
The first participant was randomised on 12 August 2015. The internal pilot at 8 months found that
actual recruitment (n = 229) exceeded the target number (n = 179) (see Appendix 2, Figure 15) and
the threshold of 130 participants, which was set to demonstrate feasibility. The last participant was
randomised on 11 January 2017, 4 months earlier than planned, as the recruitment target had been
met (see Appendix 2, Table 28, for additional randomisation information for each site). Clinical follow-up
of enrolled participants continued until 30 May 2017.
The CONSORT flow diagram (Figure 3) illustrates the pathway of participants through the trial. Parents
or legal guardians of 1404 babies were approached about the trial; consent was provided for 937 (66.7%)
babies, and 861 (61.3%) went on to be randomised (see Appendix 2, Table 29, for screening and recruitment
details for all sites). The most frequently recorded reason for declining consent was that the parents did not
want their baby to participate in research [195/467 (41.8%); see Appendix 2, Table 31]. The most frequently
recorded reason for babies not being randomised despite parents providing consent was that the baby
no longer required a PICC [49/76 (64.5%); see Appendix 2, Table 32]. There were an additional 487 babies
who received a PICC (1 French gauge) at one of the participating sites during the recruitment period, but
who were not approached for the trial. The most frequent reasons recorded were parents not available
[163/487 (33.5%)] or missed by the clinical team [134/487 (27.5%); see Appendix 2, Table 30].
A total of 191 babies (22.2%) were co-enrolled in the PREVAIL trial and at least one other RCT.
Appendix 2, Table 33, provides details on the number of babies who were co-enrolled in other trials
at each of the recruiting sites.
Interim analysis
An interim analysis was undertaken using a data snapshot taken on 22 June 2016. At this point,
523 participants were randomised. A total of 412 participants were included in the intention-to-treat
analysis set (i.e. randomised and consented with sufficient data to analyse), and 411 participants were
included in the safety analysis set (i.e. insertion successful or attempted).
In the AM-PICC group, 27 of the 208 participants had experienced at least one BSI (13.0%) and in the
S-PICC group, 21 of the 204 participants had experienced at least one BSI (10.3%). The median time to
BSI could not be calculated as the event had not been experienced by enough participants. There was
no difference between the two groups (HR 1.24, 95% CI 0.70 to 2.19; p-value 0.46).
In the AM-PICC group, 24 related AEs occurred in 22 of the 206 participants (10.7%); in the S-PICC
group, 22 related AEs occurred in 20 of the 205 participants (9.8%). One of the related AEs in the
AM-PICC group was classified as an unexpected SAE.
The IDSMC did not raise any significant issues of trial conduct, governance or safety and was happy to
recommend that the trial continue as planned.
Details of all oversight committee meetings along with recommendations are shown in Appendix 2, Table 34.
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The two treatment groups were comparable in terms of baseline characteristics (Tables 4–7). Of the
861 babies who were randomised, 715 (83%) were randomised before 7 days of age and 754 (88%)








• Excluded from analysis, n = 0
• Withdrew from follow-up after completing trial
    treatment, n = 0
• Discontinued intervention, n = 0
• Lost to follow-up after primary outcome time
    window complete, n = 3
• Lost to follow-up during primary outcome time
    window, n = 0
Analysis
• Declined consent, n = 467
• Consented but not randomised,
    n = 76
Excluded
(n = 543)
Note: these reasons are not
mutually exclusive
• Parents not available to
    consent, n = 163
• Parents’ lack of understanding,
    n = 8
• Parents do not understand
    English/Urdu, n = 18
• Consultant preference, n = 22
• Missed by clinical team, n = 134
• Baby previously entered into
    PREVAIL, n = 10
• No reason given, n = 5
• Not approached for other
    reason, n = 148
Not approached
(n = 487)
• Received allocated PICC, n = 373
• Received non-allocated 1-French PICC, n = 23
• Received 2-French PICC, n = 5
• Did not receive any PICC, n = 29
    • Attempted insertion, n = 17
    • Did not attempt insertion, n = 12
Allocated to AM-PICC
(n = 430)
• Received allocated PICC, n = 407
• Received non-allocated 1-French PICC, n = 1
• Received 2-French PICC, n = 7
• Did not receive any PICC, n = 16
    • Attempted insertion, n = 9
    • Did not attempt insertion, n = 7
Allocated to S-PICC
(n = 431)
• Withdrew from follow-up after completing trial
    treatment, n = 0
• Discontinued intervention, n = 0
• Lost to follow-up after primary outcome time
    window complete, n = 4
• Lost to follow-up during primary outcome time







• Excluded from analysis, n = 0
Analysed
(n = 431)
FIGURE 3 The CONSORT flow diagram for all trial participants.
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TABLE 4 Baseline characteristics: demographics
Baseline characteristic
Trial group
AM-PICC (N= 430) S-PICC (N= 431)
Sex, n (%)
Male 214 (49.8) 225 (52.2)
Female 216 (50.2) 206 (47.8)
Birthweight (g)
Median (IQR) 962.5 (729–1220) 960 (770–1250)
< 750, n (%) 119 (27.7) 92 (21.3)
750–999, n (%) 110 (25.6) 140 (32.5)
1000–1249, n (%) 102 (23.7) 91 (21.2)
1250–1499, n (%) 52 (12.1) 62 (14.4)
1500–1749, n (%) 27 (6.3) 27 (6.3)
1750–1999, n (%) 8 (1.9) 7 (1.6)
≥ 2000, n (%) 12 (2.8) 12 (2.8)
Gestational age at birth (weeks)
Median (IQR) 27.90 (25.78–29.94) 28.06 (26.23–30.14)
< 26, n (%) 115 (26.7) 93 (21.6)
26 or 27, n (%) 101 (23.5) 110 (25.5)
28 or 29, n (%) 103 (24.0) 102 (23.7)
30 or 31, n (%) 54 (12.6) 76 (17.6)
32 or 33, n (%) 28 (6.5) 15 (3.5)
34 or 35, n (%) 7 (1.6) 9 (2.1)
36 or 37, n (%) 5 (1.2) 3 (0.7)
≥ 38, n (%) 7 (1.6) 11 (2.6)
Missing, n (%) 10 (2.3) 12 (2.8)
< 32, n (%) 373 (86.7) 381 (88.4)
Age at randomisation (days)
Median (IQR) 4.12 (2.04–5.93) 3.90 (1.90–6.12)
< 2, n (%) 106 (24.7) 113 (26.2)
2–6, n (%) 256 (59.5) 240 (55.7)
7–13, n (%) 39 (9.1) 52 (12.1)
14–20, n (%) 6 (1.4) 11 (2.6)
21–27, n (%) 3 (0.7) 5 (1.2)
≥ 28, n (%) 20 (4.7) 10 (2.3)
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TABLE 5 Baseline characteristics: delivery characteristics
Baseline characteristic
Trial group, n (%)
AM-PICC (N= 430) S-PICC (N= 431)
Location of birth
Born in study hospital 340 (79.1) 367 (85.2)
Transferred after birth 90 (20.9) 64 (14.8)
Mode of delivery
Vaginal 196 (45.6) 198 (45.9)
Caesarean 234 (54.4) 233 (54.1)
Membrane rupture > 24 hours before delivery
Yes 111 (25.8) 104 (24.1)
No 299 (69.5) 310 (71.9)
Missing 20 (4.7) 17 (3.9)
Maternal antenatal corticosteroids
Yes 375 (87.2) 381 (88.4)
No 53 (12.3) 50 (11.6)
Missing 2 (0.5) 0 (0)
Maternal antibiotics ≤ 12 hours before delivery
Yes 135 (31.4) 102 (23.7)
No 275 (64.0) 310 (71.9)
Missing 20 (4.7) 19 (4.4)
TABLE 6 Baseline characteristics: neonatal care
Baseline characteristic
Trial group, n (%)
AM-PICC (N= 430) S-PICC (N= 431)
Surgery before randomisation
> 6 days 2 (0.5) 3 (0.7)
≤ 6 days 15 (3.5) 10 (2.3)
No surgery 413 (96.0) 418 (97.0)
Positive blood culture < 72 hours prior to randomisation
Yes 29 (6.7) 19 (4.4)
No 401 (93.3) 412 (95.6)
Antibiotics/antifungals < 72 hours prior to randomisationa
Yes 367 (85.3) 363 (84.2)
No 63 (14.7) 68 (15.8)
Respiratory support < 72 hours prior to randomisation
Invasive ventilation 262 (60.9) 257 (59.6)
Non-invasive ventilation 122 (28.4) 133 (30.9)
Oxygen only 9 (2.1) 7 (1.6)
None 37 (8.6) 34 (7.9)
a Excluding prophylaxis.
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Adherence to treatment and the protocol
Fewer babies randomised to the AM-PICC had the randomly allocated PICC inserted [373 participants
(86.7%)] than those randomised to the S-PICC group [407 participants (94.4%)] (Table 8). Approximately
half of the babies who did not receive the allocated AM-PICC had no PICC inserted, and half received a
different PICC.
The intention-to-treat analysis population included all 861 participants (100%) who were randomised,
regardless of whether or not they received the allocated PICC. The safety population as defined in
the statistical analysis plan (all participants in whom insertion was successful or attempted) included
842 of the 861 randomised participants (97.8%). The modified safety analysis (all participants in whom
insertion was successful) included 816 of the 861 randomised participants (94.8%) (see Table 8 for
further details on which participants were included in the safety analysis populations).
The time points for end of follow-up were similar in both groups (see Table 8). The majority of participants
completed follow-up for infection outcomes (outcomes for which samples were required to be taken)
48 hours after removal of the PICC [785/861 (91.2%)] and follow-up for other outcomes at discharge
home from neonatal care [768/861 (89.2%)].
The type and frequency of sampling for microbiological cultures were similar in both groups (see
Appendix 2, Table 35); blood/CSF samples were taken from 198 babies in the AM-PICC group (46.0%)
and from 190 babies in the S-PICC group (44.1%). The frequency of testing for rifampicin resistance
TABLE 7 Baseline characteristics: other clinical characteristics
Baseline characteristic
Trial group, n (%)
AM-PICC (N= 430) S-PICC (N= 431)
Major congenital anomaly
Yes 21 (4.9) 27 (6.3)
No 408 (94.9) 404 (93.7)
Missing 1 (0.2) 0 (0.0)
Apgar score at 5 minutes
0–3 23 (5.3) 19 (4.4)
4–7 138 (32.1) 140 (32.5)
8–10 247 (57.4) 249 (57.8)
Missing 22 (5.1) 23 (5.3)
Devices in situ at randomisation
< 4 370 (86.0) 390 (90.5)
≥ 4 60 (14.0) 41 (9.5)
PICC insertion site
No PICC inserted 29 (6.7) 16 (3.7)
Lower limb 207 (48.1) 220 (51.0)
Upper limb 191 (44.4) 190 (44.1)
Scalp 3 (0.7) 3 (0.7)
Other 0 (0.0) 1 (0.2)
Missing 0 (0.0) 1 (0.2)
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in blood or CSF positive cultures was slightly lower in the AM-PICC group than in the S-PICC group,
but similar for PICC tips, although there were half as many positive cultures from PICC tips in the
AM-PICC group [47 participants (10.9%)] as in the S-PICC group [90 participants (20.9%)].
Protocol deviations were generally similar across the two treatment groups (see Appendix 2, Table 36).
A total of 86 participants (10.0%) had at least one major protocol deviation. The most common major
deviation was not receiving the allocated PICC [81 participants (9.4%)], and the most common minor
deviations were the PICC tip culture not being taken at removal [167 participants (19.4%)] and
resistance testing not being done on positive cultures [135 participants (15.7%)].
Primary outcome
A total of 46 participants in the AM-PICC group (10.7%) and 44 participants in the S-PICC group
(10.2%) experienced a BSI in the primary outcome time window. The median time to BSI could not
be calculated as not enough participants experienced an event. The time from randomisation until
first BSI did not differ between the groups (HR 1.11, 95% CI 0.73 to 1.67) (Table 9 and Figure 4).
The Kaplan–Meier curves crossed when the numbers at risk were low. A time-varying coefficient was
added to the model to check the assumption of proportional hazards; this was not significant (p = 0.62).
TABLE 8 The PICC insertion status and end point of follow-up
Trial group, n (%)
AM-PICC (N= 430) S-PICC (N= 431)
PICC status
Allocated PICC inserted 373 (86.7)a,b 407 (94.4)c,d
Non-allocated PICC inserted 28 (6.5)c 8 (1.9)a
1 French PICC 23 (5.3)d 1 (0.2)b
2 French PICC 5 (1.2) 7 (1.6)
No PICC inserted 29 (6.7) 16 (3.7)
PICC insertion attempted 17 (4.0)a 9 (2.1)c
PICC insertion not attempted 12 (2.8) 7 (1.6)
End of follow-up for infection outcomes
48 hours after PICC removal 387 (90.0) 398 (92.3)
Death with PICC in situ 13 (3.0) 18 (4.2)
48 hours after randomisation 29 (6.7) 15 (3.5)
Lost to follow-up 1 (0.2) 0 (0.0)
End of follow-up for other outcomes
Discharge home from neonatal care 383 (89.1) 385 (89.3)
Transfer to non-participating site 4 (0.9) 3 (0.7)
Death before discharge 36 (8.4) 33 (7.7)
6 months after randomisation 6 (1.4) 10 (2.3)
a Included in AM-PICC group in safety analysis set defined in the statistical analysis plan.
b Included in AM-PICC group in modified safety analysis set.
c Included in S-PICC group in safety analysis set defined in the statistical analysis plan.
d Included in S-PICC group in modified safety analysis set.
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The results from all four sensitivity analyses are consistent with the results from the primary analysis,
indicating that the original results are robust regarding the assumptions that were made (see Table 9).
The post hoc analysis that was performed to determine if there was evidence of a difference in treatment
effect for babies with a gestational age of < 28 weeks compared with babies with a gestational age of
≥ 28 weeks found that this was not the case (p = 0.28). Appendix 2, Figures 16 and 17 show further results
from the post hoc analysis.
Secondary outcomes
Secondary outcomes relating to infection
The proportion of babies experiencing rifampicin resistance from PICC tip cultures was significantly
higher in the AM-PICC group than in the S-PICC group, but this was not observed in blood or CSF
cultures or in the combined outcome of blood or CSF or PICC tip cultures (Table 10). Resistant
organisms are categorised and shown by intervention group in Appendix 2, Table 38.
TABLE 9 Results: primary outcome
Primary outcome
Trial group, n (%)





Time to first BSI 46 (10.7) 44 (10.2) 1.11 (0.73 to 1.67) 0.63
Sensitivity analyses
Time to first clinically serious BSI 42 (9.8) 40 (9.3) 1.11 (0.72 to 1.71) 0.65
Time to first BSI (from insertion)a 45 (11.2) 44 (10.6) 1.08 (0.71 to 1.64) 0.72
Time to first BSI excluding arterial or PICC samples 45 (10.5) 43 (10.0) 1.11 (0.73 to 1.68) 0.64
Time to first BSI excluding skin organisms 16 (3.7) 9 (2.1) 1.90 (0.84 to 4.31) 0.12
a Only includes participants for whom a PICC was successfully inserted (AM-PICC: 401 babies; S-PICC: 415 babies).
Notes
Events were considered only on samples taken between 24 hours after randomisation until 48 hours after removal.
































































FIGURE 4 Kaplan–Meier plot: time to first BSI (primary outcome). The table under the graph presents the numbers of
study participants at risk (i.e. not censored) at each time point.
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The number of participants experiencing one or more BSI during the primary outcome time window
was not significantly different between the two groups (see Table 10). Details on the number of BSIs
that each participant experienced are provided in Appendix 2, Table 39.
There were no significant differences in the rates of BSI or catheter-related BSI (see Table 10). Results
from sensitivity analyses of the rates during the time that the PICC was in situ were consistent with
the main results.
The types of organisms isolated from BSIs are shown in Table 11.
Other clinical secondary outcomes
There were no significant differences in the proportions of participants experiencing chronic lung
disease, NEC, abnormality on cranial ultrasound or treatment for retinopathy of prematurity (Table 12).
Further information on the type of treatment for retinopathy of prematurity is shown in Appendix 2,
Table 40.
There was no detectable difference in time to full milk feeds (the median number of days was
approximately 9 in each group) or in the duration of parenteral nutrition (the median number of days
was 11 in the AM-PICC group and 10 in the S-PICC group) (see Table 12).
There was no difference between the treatment groups in terms of the proportion of deaths before
discharge home from neonatal care or within 6 months of randomisation, or in terms of the time to
death within 6 months of randomisation (see Table 12).









Rifampicin resistance n (%) n (%) RR (95% CI)
Rifampicin resistance from blood/CSF culture 4 (0.9) 7 (1.6) 0.57 (0.17 to 1.94) 0.55
Rifampicin resistance from PICC tip culture 14 (3.3) 4 (0.9) 3.51 (1.16 to 10.57) 0.02
Rifampicin resistance from blood/CSF or
PICC tip culturea
18 (4.2) 10 (2.3) 1.80 (0.84 to 3.86) 0.13
Occurrence of ≥ 1 BSI 46 (10.7) 44 (10.2) 1.05 (0.71 to 1.55) 0.82
Rate of BSI per 1000 PICC days Rate ratio (95% CI)
Rate of BSI 13.15 10.87 1.21 (0.78 to 1.88) 0.40
Rate of BSI (when line is in situ)b 12.57 11.21 1.12 (0.73 to 1.12) 0.60
Rate of catheter-related BSI 1.84 2.35 0.78 (0.27 to 2.25) 0.65
Rate of catheter-related BSI (when line is in situ)b 1.71 2.46 0.70 (0.25 to 1.96) 0.49
a Outcome not prespecified in protocol, but requested by investigators and included in the statistical analysis plan
before any unmasked data were seen.
b Sensitivity analysis – includes only babies for whom a PICC was successfully inserted (AM-PICC: 401 babies;
S-PICC: 415 babies).
Note
Events were considered only on samples taken between 24 hours after randomisation and 48 hours after removal.
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Five deaths were captured in the CRFs that were not reported in the data provided by NHS Digital,
and two deaths were reported in the data provided by NHS Digital that were not captured in the
CRFs. There was also a discrepancy in the date of death for one baby; the date reported by NHS
Digital was 1 day later than the date captured in the CRF.
TABLE 11 Results: secondary outcome – type of organism isolated from BSI
Category Organism
Trial group, n (%)
AM-PICC (N= 49) S-PICC (N= 45)
Gram-positive CoNS 31 (63.3)a 35 (77.8)a
Enterococcus spp. 3 (6.1) 1 (2.2)
Staphylococcus aureus 2 (4.1) 2 (4.4)
Haemolytic streptococcus 1 (2.0) 0 (0.0)
Gram-negative E. coli 4 (8.2)a 2 (4.4)
Klebsiella spp. 4 (8.2)a 1 (2.2)
Enterobacter spp. 2 (4.1) 1 (2.2)
Acinetobacter spp. 0 (0.0) 1 (2.2)
Moraxella osloensis 0 (0.0) 1 (2.2)
Fungi Candida spp. 2 (4.1)a 1 (2.2)
Total (n) 49 45
a Indicates cases in which a single baby grew multiple organisms.
Note
Data are n (%) of participants experiencing a BSI.








n (%) n (%) RR (95% CI)
Chronic lung disease 190 (44.2) 178 (41.3) 1.07 (0.92 to 1.25) 0.41
NEC: Bell’s stage II or III 41 (9.5) 46 (10.7) 0.89 (0.59 to 1.32) 0.57
Abnormality on cranial ultrasound 166 (38.6) 150 (34.8) 1.11 (0.93 to 1.33) 0.26
Treatment for retinopathy of prematurity 40 (9.3) 30 (7.0) 1.34 (0.85 to 2.11) 0.21
Death before discharge 36 (8.4) 33 (7.7) 1.09 (0.70 to 1.72) 0.71
Death within 6 months of randomisation 36 (8.4) 35 (8.1) 1.03 (0.66 to 1.61) 0.90
Median (IQR) Median (IQR) HR (95% CI)
Time to death within 6 months of
randomisationa
– – 1.06 (0.67 to 1.70) 0.79
Time to full milk feeds (days) 9.51 (6.37–17.26) 9.40 (6.32–16.37) 0.99 (0.86 to 1.14) 0.85
Days of parenteral nutrition 11.00 (7.00–19.00) 10.00 (7.00–18.00) – 0.83
a Median time to event not reported as not enough participants experienced an event.
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Secondary outcomes to detect potential biases in sampling or treatment on the
basis of knowledge of peripherally inserted central venous catheter allocation
The rate of blood sampling for signs of infection was significantly higher in the AM-PICC arm than
in the S-PICC arm (98/1000 PICC days vs. 80/1000 PICC days, respectively; rate ratio 1.23, 95% CI
1.05 to 1.45; p-value 0.01) (Table 13). There were no differences in the median time to PICC removal
(8 days in both groups) or in the median duration of antimicrobial treatment (3 days in both groups)
(see Table 13).
Safety analysis
All related AEs in participants who had a 1 French PICC successfully inserted are listed in Table 14.
A total of 60 events were reported from 49 participants in the AM-PICC group (13.1%), and 50 events
were reported from 45 participants in the S-PICC group (10.5%).
One SAE involving supraventricular tachycardia following PICC placement was reported in the AM-PICC
arm. This event met the seriousness criterion of ‘medically significant’, and the local investigator felt
that it was ‘possibly’ related to the recent insertion of the PICC. The event resolved and the PICC was
not removed. This event was assessed as ‘unlikely’ to be related to the trial intervention by the chief
investigator, but was reported to the Medicines and Healthcare products Regulatory Agency Adverse
Incident Centre in line with the local investigator’s assessment.




difference p-valueAM-PICC (n= 430) S-PICC (n= 431)
Rate per 1000 PICC days Rate per 1000 PICC days Rate ratio (95% CI)
Rate of blood/CSF culture
sampling
97.90 79.64 1.23 (1.05 to 1.45) 0.01
Rate of blood/CSF sampling
(line in situ)a
93.72 82.01 1.14 (0.98 to 1.34) 0.09
Median (IQR) Median (IQR) HR (95% CI)
Time to PICC removal (days) 8.20 (4.77–12.13) 7.86 (5.00–12.53) 1.03 (0.89 to 1.18) 0.73
Days of antimicrobial
treatment
3.00 (2.00–6.00) 3.00 (2.00–6.00) – 0.25
a Sensitivity analysis – includes only babies for whom a PICC was successfully inserted (AM-PICC: 401 babies;
S-PICC: 415 babies).
TABLE 14 Related AEs
AE
AM-PICC group (N= 374 participants) S-PICC group (N= 430 participants)
Events (n) Participants, n (%) Events (n) Participants, n (%)
Any AE 60 49 (13.1) 50 45 (10.5)
Evidence of catheter blockage 15 15 (4.0) 15 15 (3.5)
Extravasation 11 11 (2.9) 11 11 (2.6)
Swelling/haematoma at line site 10 10 (2.7) 7 7 (1.6)
Clinically evident thrombophlebitis 4 4 (1.1) 7 7 (1.6)
Difficulty removing stylet 8 8 (2.1) 1 1 (0.2)
Catheter damage 3 3 (0.8) 4 4 (0.9)
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Chapter 4 Economic evaluation
Introduction
The aim of the economic evaluation was to examine the costs and health benefits of using AM-PICCs
rather than S-PICCs in PREVAIL trial babies. In doing so, the economic analysis can inform decisions
regarding which type of PICC should be purchased for neonatal care in the NHS, identify the areas
where more research is needed and inform future research by providing estimates on the costs of
having babies in the NICU.
The economic evaluation planned to include the following elements, as defined in the PREVAIL trial
protocol,59 section 2.3.2:
1. the hospital costs of using AM-PICCs compared with using S-PICCs over the time horizon of the trial
2. the cost-effectiveness of AM-PICCs compared with that of S-PICCs over a patient’s expected lifetime,
including the minimum clinical effectiveness required for AM-PICCs to be considered cost-effective
3. the value of information (VoI) to assess the benefits of potential additional research
4. the value of implementing the cost-effective PICC type
5. the hospital costs to the NHS of a BSI.
As reported in Chapter 3, the PREVAIL trial found that there was no difference in the risk of BSI or of
clinically serious BSI between the AM-PICC and the S-PICC groups. The implication is that AM-PICCs
are unlikely to be cost-effective, compared with S-PICCs, given the additional purchasing cost and that
the prevention of BSI was expected to be their key benefit. Consequently, the economic analysis plan
was revised to include elements 1, 2 and 3 in the preceding list, but not 4 or 5.
The objective of 1, to estimate the hospital costs of using AM-PICCs compared with using S-PICCs,
was to understand whether or not the type of PICC had any impact on the costs of hospitalisations.
This is henceforth referred to as the ‘cost of hospital care’. Estimates of the cost of hospital care are
useful to understand the resources required to improve the health of preterm babies and to inform
research on the cost-effectiveness of interventions to reduce hospital length of stay or other hospital use.
Objective 2, to examine the cost-effectiveness of AM-PICCs compared with S-PICCs over a patient’s
expected lifetime, required the development of a cost-effectiveness model informed by population-
specific inputs to evaluate interventions to prevent BSI. As far as was possible and relevant, the
cost-effectiveness model was informed by data collected in the PREVAIL trial. The cost-effectiveness
model was used to estimate the cost-effectiveness of AM-PICCs compared with S-PICCs, given the
results of the trial, and to determine the minimum effect that would be required so that AM-PICCs
were cost-effective given their greater acquisition cost.
The objective of 3, calculating the VoI, was to estimate the impact of parameter uncertainty on the
likelihood of not choosing the most cost-effective option and the consequences in terms of health
losses and additional costs. These estimates are used to calculate the expected value of further
information and the magnitude of the benefits of investing in future research.60
The economic analysis planned to include objective 4, the value of implementing the cost-effective
PICC type.61 This analysis was not conducted because, as it is unlikely that the AM-PICC is the
cost-effective technology and the type of PICC currently implemented is the S-PICC, there is
no value in implementation activities.
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The estimation of the hospital costs to the NHS of a BSI (objective 5) was not conducted for two reasons.
First, this analysis required the use of the random allocation to one of the two PICC types as an instrument
to estimate the causal effect of BSI on the costs. As the PREVAIL trial found that there was no difference
in the risk of BSI between the two PICC types, the instrumental variable analysis was not feasible.
Second, the process for the health economics team to receive the data suffered a considerable delay
(see Appendix 3), which did not allow sufficient time to explore alternative statistical models.
Revised objectives
The aim of the economic evaluation was to determine the cost-effectiveness of AM-PICCs compared
with S-PICCs over a patient’s lifetime. The specific objectives were to:
l estimate the cost of hospital care over the follow-up of the trial (reported in Cost of hospital care)
l predict the long-term costs and quality-adjusted survival of babies with AM-PICCs or S-PICCs
(reported in Cost-effectiveness of antimicrobial-impregnated versus standard peripherally inserted central
venous catheters over a lifetime)
l explore the extent to which the consequences of uncertainty indicate that there is value in
additional research (reported in Value of information).
Cost of hospital care
Background
This section estimates the cost of hospital care for babies taking part in the PREVAIL trial (hereafter
termed ‘PREVAIL babies’) for whom routine health-care data were available and whose parents had
consented for their data to be shared with the research team.
Methods
Overview
Figure 5 summarises the methods. The PREVAIL babies may have received a variety of hospital
care during the 6-month follow-up period. We sought data on hospitalisations from different data
sources, which included stay in the NNU, admission to a PICU, admissions to paediatric hospital care,
procedures such as surgery and diagnostic tests, outpatient appointments, and visits to the A&E
department. We obtained data on the nature and intensity of hospital care in these different settings
and used it to generate standardised units of cost called Healthcare Resource Groups (HRGs). We
obtained the unit costs of the HRGs from NHS reference costs 2015–16,62 which represent their
average cost to the NHS. The cost of hospital care for each baby is the sum of the costs of the HRGs.
Study population
The study population comprised the PREVAIL babies for whom the parents or guardians consented to
share their routine health-care data and for whom routine records were available.
Time horizon
The time horizon was from the randomisation date in the PREVAIL trial to 6 months’ follow-up or death,
whichever occurred first.
Data sources
The PREVAIL trial data
The PREVAIL babies’ characteristics, trial group and outcomes were obtained from LCTC. The data
were collected by the RNs using CRFs (forms 2, 3, 6, 7a, 7b and 10; details of the variables can be
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found in Appendix 4. The forms are available on the PREVAIL trial website.63). The individual-level trial
data were linked to data on hospitalisations using the trial participant study number. These data were
encrypted, password protected and transferred securely to the University of York (UoY).
Data on hospital care
Hospital care includes care in the NNU and/or PICU, procedures and diagnostic tests, outpatient
appointments, and visits to the A&E. To capture the full data on hospital care, data on the PREVAIL
babies were extracted from five different databases. The specific data fields obtained from each
database are detailed in Appendix 4. The databases and respective data custodians were as follows:
l Hospital critical care during the stay in the NICU was obtained from the NNRD. The NNRD is a
clinical data set (the National Neonatal Data Set) within the NHS Data Model and Dictionary
Service. The NNRD compiles information entered by clinicians and nurses onto the electronic
patient records of babies in the NNU. The National Neonatal Data Set is extracted quarterly from
the electronic records to form the NNRD, which covers England, Wales and Scotland.64 Details of all
data items are searchable online.65
l Hospital critical care during any stay in the PICU was obtained from PICANet. PICANet is an audit
database comprising details of care, such as need for ventilation, in PICUs in the UK and the
Republic of Ireland.66 PICANet has data on paediatric critical care during each day of hospitalisation
in the unit.
l Information on other hospital care during hospitalisations other than the critical care in the









Link HRGs to NHS
Reference Costs
Analysis
Babies recruited to PREVAIL trial whose parents consented to routine 
data collection
Follow-up period = 6 months from date of recruitment to trial
NNRD: stays in neonatal care unit
PICANet: stays in PICU
NHS Digital: inpatient hospital care except neonatal and paediatric intensive
care; outpatient appointments; visits to A&E
HRGs for stays in the neonatal care unit and in the PICU generated by data
providers HRG grouper 2016/17 used to generate HRGs for the hospital use
recorded in the NHS Digital data
Hospital care included only if within the 6-month follow-up period
HRGs matched to NHS Reference Costs to calculate a cost per episode of care
Calculate mean costs of hospital care over 6 months
FIGURE 5 Overview of the methods used to estimate the cost of hospitalisations.
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l Outpatient appointments were obtained from the HES outpatient database.
l Accident and emergency attendances were obtained from the HES A&E database.
l Date of randomisation was obtained from the PREVAIL trial data, collected by the UoL.
The HES APC, outpatient and A&E databases contain details of all admissions at NHS hospitals in
England. The data are collected during a patient’s time at hospital and submitted to NHS Digital for
processing.67
Data on whether or not death occurred within the 6-month follow-up
Data on deaths occurring within the follow-up period were obtained from both the PREVAIL trial
CRFs, which refer to date of death within the primary follow-up period, and from death registrations
supplied to the Personal Demographics Service linked to the HES databases. LCTC received death
registration data on date of death if death occurred within the 6-month follow-up (see Chapter 2,
Secondary outcomes). These data are used to inform the decision model (see Probability of death
between peripherally inserted central venous catheter insertion and 6 months of age).
Fair processing
The parents and guardians of the PREVAIL babies were asked for their consent to use data about
their babies’ admissions and visits to hospital from the date of PICC insertion for a period of 6 months.
For the babies whose parents gave consent, the team at LCTC sent the personal identifiers (NHS
number, name, date of birth, sex and postcode) and trial identifier to PICANet (for the stays in the
PICU) and NHS Digital (for all hospital stays, outpatient admissions, visits to A&E and date of death).
Babies in the PREVAIL trial were linked to the NNRD using patient identifiers (NHS number, sex, date
of birth and postcode) within Public Health England (PHE) for the generalisability study (see Chapter 5).
The NNRD received de-personalised trial identifiers linked to the NNRD baby identifiers from PHE to
identify PREVAIL babies for the NNRD extract for the health economics study.
Individual-level data containing the de-identified hospitalisation records and the trial identifier were
transferred from NNRD, PICANet (via LCTC) and NHS Digital to the UoY. These data were password-
protected, encrypted and transferred securely. The UoY transferred the data on the date of death,
obtained from NHS Digital via the Personal Demographics Service, to LCTC. All data transfers were
subject to data-sharing contracts between the various institutions. The privacy notice is available in
the parents’ section of the PREVAIL trial website [www.prevailtrial.org.uk/parents.html (accessed
16 August 2020)].
Generating Healthcare Resource Groups from the data on hospital care
The data on hospital care consists of information on the nature and length of the hospital stay.
The first step in costing hospital care is to generate HRGs from these hospital records. HRGs are
standard groupings of clinically similar treatments that use common levels of health-care resource.68
They form the payment structure of hospital care, and are relevant to all hospital stays, appointments
and A&E visits. The algorithm to generate the relevant HRGs, given the resources involved in the
hospitalisations, is released by the National Casemix Office in partnership with NHS Digital.68
There are two types of HRGs: ‘bundled’ and ‘unbundled’. Bundled HRGs represent the set of procedures,
treatments and other interventions for a given diagnosis and case mix. Unbundled HRGs represent high-
cost or specialist service elements in addition to the care recorded in the bundled HRG.68 Examples of
unbundled HRGs are diagnostic imaging and high-cost drugs.69 Activity in critical care units are captured
in the critical care HRGs, which are a type of unbundled HRG.
Given that costs can be obtained only for admissions with a HRG, the admissions with insufficient
information to derive a HRG were discarded. In principle, the hospitalisation data would be of
sufficient quality to derive HRGs for all admissions. In practice, however, errors in coding occur.
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These errors are likely to be random and unrelated to the babies’ characteristics and the admissions
themselves. Therefore, we assumed that the data were missing completely at random and removed
missing observations (i.e. the specific hospitalisation) from the analysis.70
Healthcare Resource Groups for the neonatal care stay (in the National Neonatal
Research Database)
The neonatal care HRGs are critical care HRGs that are added to the core HRG relating to the
hospitalisation. There are five neonatal critical care HRGs to represent the intensity of care over
a 24-hour period, and a neonatal critical-care transport HRG, which is paid per patient journey (see
Appendix 1, Table 43).69 Therefore, each neonatal critical care HRG represents a day in the neonatal
care unit or, if a transport HRG, a patient journey. Stays in the neonatal care unit can be aggregated
into episodes, which, in turn, can be aggregated into an admission (or spell).
The data on the PREVAIL babies’ stays in the NNU (which were received from NNRD) included two
files: the ‘episode file’ and the ‘daily file’. The ‘episode file’ contained the trial identifier, episode number,
anonymised date of admission and anonymised date of discharge. Given that the follow-up period
was restricted to 6 months after the date of randomisation, some of the episodes for which the date
of discharge was outside the follow-up period did not include the record for the date of discharge.
The ‘daily file’ contained the trial identifier, the episode number, the anonymised time stamp referring
to when the day of care was recorded and the HRGs corresponding to the care on each day. The two
files were processed and combined to obtain the length of stay and cost of stays in the neonatal care
unit over the 6-month follow-up of the trial.
In principle, all PREVAIL babies have neonatal HRGs referring to their stay in the neonatal care unit.
However, some units do not report to NNRD; hence, the data on the PREVAIL babies who had stays in
these non-reporting units were not available. Furthermore, errors in entering records or in registering
the details of the babies in the PREVAIL trial may result in some babies and some parts of their
neonatal care not being recorded in NNRD.
Critical Care Healthcare Resource Groups for the paediatric intensive care stay
(in the Paediatric Intensive Care Audit Network)
The paediatric care HRGs are critical care HRGs. Each day in the PICU is assigned to a paediatric
critical care HRG. There are eight daily HRGs, in addition to a paediatric transport HRG, which is paid
per patient journey.69
Similarly to the NNRD data, the PICANet data included two files. One file had information on the
episodes of care, trial identifier, episode number, date of admission and date of discharge. The other
file contained information on the activity in each day of care, trial identifier, episode number, daily date
and HRG.
Healthcare Resource Groups for hospital admissions (Hospital Episode Statistics
Admitted Patient Care)
The hospital admission comprises the entire continuous stay in a specific hospital. The admission can
include one or more finished consultant episodes (FCEs). A FCE is the period of care under a given
consultant. Patients can have more than one FCE at the same time. Generally, all FCEs can be assigned
to one or more HRGs. Typically, the FCE includes a bundled HRG, as well as one or more unbundled
HRGs for high-cost items, and critical care HRGs for stays in critical care units, such as the NNU and
PICU. It is not possible to link the FCE admissions in HES APC to the neonatal care episodes in NNRD
and paediatric care episodes in PICANet with certainty, because of the lack of a common identifier to
link episodes of care in critical care to FCEs in HES APC.
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The HES APC data on the PREVAIL babies included the information required to generate HRGs and
calculate length of stay for each FCE. The HRG4+ 2016/17 Reference Costs Grouper was used to
generate the HRGs at the FCE level.68 These included the bundled HRG and unbundled HRGs related
to high-cost items over and above critical care stays.
Healthcare Resource Groups for outpatient appointments
Outpatient appointments also need to be assigned to a HRG for costing. These were generated with
the HRG4+ 2016/17 Reference Costs Grouper.68
Healthcare Resource Groups for accident and emergency visits
The HRG4+ 2016/17 Reference Costs Grouper was also used to assign each A&E visit to the
relevant HRGs.68
The data-cleaning processes required to prepare the data for the HRG4+ 2016/17 Reference Costs
Grouper are detailed in Appendix 5.
Calculating length of stay
In the NNRD and PICANet, the length of stay (in the NNU and PICU, respectively) was calculated by
subtracting the date of discharge from the date of admission for each episode of care. In HES APC,
length of stay was calculated at the spell level, given that there can be more than one FCE at the
same time in the same spell. When the date of admission of the subsequent episode of care or spell
was earlier than the date of the discharge of the previous hospitalisation, the date of admission was
changed to the previous date of discharge.
The length of stay recorded in HES APC overlaps with the length of stay in the NNUs and PICUs.
This is because the days in these units are recorded in the NNRD and PICANet, respectively, in terms
of the critical care HRGs, as well as in HES APC for the core hospitalisation. To calculate the cost of
hospital care, however, the cost of care recorded in each database needs to be added up together,
as the cost of the FCE (from HES APC) reflects only the core HRG and the unbundled HRGs, but not
the critical care HRGs (which are recorded in the NNRD and PICANet).
Selecting hospital care that was within the trial follow-up
The period of follow-up was from randomisation for 6 months or until death, whichever happened
first. The dates of outpatient and A&E visits were examined to confirm that all referred to the period
between date of randomisation and the end of the 6-month follow-up.
The FCEs, which are captured in the HES APC data set, and the episodes of critical care, which are
captured in the NNRD and PICANet, span a period of time. This period of time can include days before
randomisation and/or days after the end of the follow-up period.
Stays in the NNUs and PICUs have records of daily activity and of the date of admission and discharge.
For each database, the records of daily activity and of dates of admission and discharge were compared
for consistency. The preferred option was to use the record of daily activity to select the days of care
that were within the follow-up period. If these data were inconsistent, the dates of admission and
discharge were used to select the episodes of care that were within the follow-up period. The dates of
admission and discharge were also used to select the FCEs in the HES APC data set that were within
the follow-up period.
The length of stay and cost of FCEs or episodes of care that fell partly outside the trial follow-up were
adjusted to account for the time period outside the trial follow-up. This was done to ensure that the
costs referred to the same time period for all babies. For the length of stay, this was done by removing
the days outside the follow-up period. The costs were rescaled by the proportion of the episode of
care or FCE within the follow-up period. The proportion of the episode of care or FCE within the
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follow-up period was calculated by adding 1 day to the length of stay within and outside the period of
follow-up. This was to account for episodes in which the date of discharge corresponds to the date of
randomisation or in which the date of admission corresponds to the date of end of follow-up.
Costing hospital care
Data were cleaned prior to costing (see Appendix 5). The HRGs were matched with the relevant costs
using the NHS reference costs for 2015–16.62 NHS reference costs for 2015–1662 were the most recent
year for which costs were available when the economic work commenced. HRGs from 2016–17, which
were different from 2015–16, were replaced or the costs deflated (see Appendix 5, Tables 41 and 42).
Appendix 5, Table 43, reports the unit costs of the HRGs relating to the stay in the neonatal and paediatric
critical care unit. The other unit costs are not reported here because of their large number, but are
freely available online.62
Analysis
Hospital care by database
Hospital care was analysed separately by database. For each database, the number of PREVAIL babies
with hospital care recorded, the length of days in hospital (or the number of attendances for outpatient
and A&E), the HRGs and the cost are reported.
Cost of hospital care
As the FCEs in HES APC cannot be uniquely linked to the episodes of care in the NNRD and PICANet, the
cost of hospital care was calculated on a per-baby basis, separately, for each data set. Subsequently, the
various data sets were merged to calculate the cost of hospital care in the PREVAIL trial population.
The analytical sample comprised the PREVAIL babies with at least one valid record in HES APC and in
the NNRD. Babies with no hospital care recorded in the PICANet, HES outpatient and HES A&E were
assumed not to have used this care; hence, the cost of hospital care referring to each database was
assumed to be zero. This was a complete-case analysis using the valid records in the NNRD and in the
HES APC as the reference. It assumed that the likelihood of having none or incomplete information is
unrelated to babies’ characteristics and costs.70
Results
Neonatal care recorded in the National Neonatal Research Database
Data preparation
Appendix 5 details the process of data preparation, including Figure 18. Thirteen PREVAIL babies (1.51%)
were not available in the NNRD extract: six were allocated to AM-PICC and seven to S-PICC. After
cleaning, the file with the episode dates (the ‘episode file’) contained data on 848 (98.49%) PREVAIL
babies, with a total of 1568 episodes. The file with the daily care record (the ‘daily file’) contained data
on 848 (98.49%) PREVAIL babies with 57,702 days in NNUs. The date of discharge was imputed using
the latest daily care date for 147 episodes without a date of discharge; of these, three episodes of
care had their date of admission corrected to the earliest date stamp for the daily care in the episode.
Episodes with a date of discharge before the date of randomisation were removed and permanently
deleted. The resulting file contained data on 837 PREVAIL babies, with 1388 episodes and 56,610 days
in the neonatal care unit.
Length of stay, care activity and cost of care
The breakdown of days of care by HRG code is presented in Appendix 6, Table 44. This breakdown
refers to the data without any adjustments for hospitalisations spanning beyond the 6-month follow-up
period, because the HRGs are recorded on a daily basis.
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Appendix 6, Table 45, shows the length of stay recorded in the NNRD and costs by episode of care,
with and without adjusting for the time outside the follow-up period. Without adjusting for the time
outside the follow-up period, the average length of stay per episode of care was 40 days and the
average cost per episode of care was approximately £36,000. Adjusting for the time outside the
follow-up period, the average length of stay per episode of care was 37 days and the average cost
per episode of care was approximately £33,000.
Table 15 shows the average length of stay and cost per baby, with adjustment for the follow-up period
(see Appendix 6, Table 45, for the results without adjustment). The average length of stay per baby was
61 days and the average cost per baby was £54,086. This was similar for both PICC types.
Paediatric critical care recorded in the Paediatric Intensive Care Audit Network
Data preparation
Appendix 5 details the process of data preparation, including Figure 19. A total of 177 PREVAIL babies
were recorded in PICANet, with 184 episodes of care and 1237 days in the PICU. After removing
the days of care outside the follow-up period, the PICANet files contained records on 94 (10.92%)
PREVAIL babies who had 126 episodes of care and 779 days in the PICU.
Intensity, length of stay and cost of care within the follow-up period
Table 15 shows the results. For the 94 PREVAIL babies for whom PICANet recorded days in paediatric
intensive care, the average length of stay, per baby, was 8 days and the average cost was approximately
£14,500. This was similar for both PICC types. The breakdown by HRG code is presented in Appendix 6,
Table 46.
Hospital care recorded in the Hospital Episode Statistics Admitted Patient Care
Data preparation
Appendix 5 details the process of data preparation, including Figure 20. A total of 834 (96.86%)
PREVAIL babies were recorded in HES APC, with a total of 2772 FCEs. During the data preparation
process prior to generating HRGs, 58 FCEs were removed, as well as the records referring to two
PREVAIL babies. The grouper was fed 2714 FCEs, relating to 832 babies. Of these, 20 FCEs were not
grouped into HRGs because of data errors, eight FCEs were removed because of missing admission
type, and four FCEs were removed because of lack of unit cost data. As a result, data on the hospital
admission for four PREVAIL babies were removed. In total, the HES APC included 2682 FCEs relating
to 828 (96.17%) PREVAIL babies.
Intensity, length of stay and cost of care within the follow-up period
All of the 2682 FCEs for the 828 PREVAIL babies were within the follow-up period of 6 months.
These corresponded to 2128 spells. The length of stay by spell is presented in Appendix 6, Table 47;
it was 29 days, on average, without any adjustment for spells with days outside the follow-up period.
There were 744 spells with admissions before the date of randomisation and 21 spells with discharge
after the end of follow-up. The average length of stay by spell, adjusting for days outside the follow-up
period, was 27 days. These spells with days outside the follow-up period corresponded to 732 FCEs
that started before the randomisation date and 21 FCEs that finished after the end of the 6-month
follow-up date. Therefore, the cost of these episodes that spanned outside the follow-up period were
adjusted, as explained in Selecting hospital care that was within the trial follow-up.
The costs were calculated at the FCE level (results are shown in Appendix 6, Table 48). The average
total cost per FCE was £8698, unadjusted, and £8129, adjusted. The number and cost per FCE by
admission type is shown in Appendix 6, Table 49. Most of the FCEs were non-elective inpatient long
stays [1798 (67.04%)], with an average cost of £12,122, followed by non-elective inpatient short stays
[952 (35.50%)], with an average cost of £10,635.
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TABLE 15 Length of stay and costs per PREVAIL baby recorded in each database within the follow-up period
Total AM-PICC S-PICC
Babies,a n (%) Mean SD Babies,a n (%) Mean SD Babies,a n (%) Mean SD
Hospital care recorded in the NNU recorded in NNRDa
Length of stay (days) 837 (97) 61.04 35.74 420 (98) 60.70 36.31 417 (97) 61.40 35.20
Cost (£) 837 (97) £54,086.19 £35,223.79 420 (98) £53,959.65 £36,046.58 417 (97) £54,213.65 £34,418.05
Hospital care recorded in the paediatric unit recorded in PICANet
Length of stay (days) 94 (11) 8.29 9.56 46 (11) 8.20 10.50 48 (11) 8.38 8.67
Cost (£) 94 (11) £14,547.84 £17,021.59 46 (11) £14,501.07 £18,531.86 48 (11) £14,592.66 £15,636.00
Hospital care recorded in HES APCa
Length of stay (days) 828 (96) 68.65 37.91 410 (95) 67.68 36.77 418 (97) 69.61 39.01
Cost (£) 828 (96) £26,332.09 £18,190.26 410 (95) £26,222.37 £18,055.68 418 (97) £26,439.72 £18,342.29
Outpatient appointments recorded in HES outpatient
Number of attendances 784 (91) 7.47 7.60 394 (92) 7.65 8.03 390 (90) 7.29 7.14
Cost (£) 784 (91) £1155.97 £1009.64 394 (92) £1166.57 £1027.54 390 (90) £1145.27 £992.44
A&E visits recorded in HES A&E
Number of attendances 320 (37) 1.68 1.17 163 (38) 1.72 1.19 157 (36) 1.64 1.14
Cost (£) 320 (37) £223.41 £162.09 163 (38) £227.34 £152.69 157 (36) £219.34 £171.70
a The number of babies is the number of PREVAIL babies recorded in each database with hospitalisations within the follow-up period of 6 months after randomisation who had
sufficient data for costing (see Appendix 5, Figures 18–21, for details). The percentage refers to the proportion of PREVAIL babies compared with the analysis population of 861






































































































































































































































































































































































Table 15 shows the length of stay and the costs per baby, after adjusting for the time outside the
6-month follow-up period (unadjusted results are presented in Appendix 6, Table 50). For the 828
PREVAIL babies for whom the hospitalisation was recorded in HES APC, the average length of stay,
per baby, was 69 days and the average cost of hospital admission, adjusted for the length of stay
outside the 6-month follow-up period, was £26,332 per baby. This is similar across both PICC types.
Outpatient attendances recorded in Hospital Episode Statistics outpatient
Data preparation
Appendix 5 details the process of data preparation, including Figure 21. A total of 799 PREVAIL babies
(92.80% of the PREVAIL trial population) were recorded in the HES outpatient data set, with a total
6425 outpatient appointments. Of these, 19 records (i.e. outpatient appointments) did not have valid
data to generate a HRG. The grouper derived HRGs for 6406 appointments, which correspond to
798 PREVAIL babies. A total of 547 appointments were removed because they were flagged as either
postponed or cancelled; hence, no cost was incurred. One outpatient appointment was associated
with an invalid HRG, and so was deleted. As a result, 5858 outpatient appointments, referring to
784 PREVAIL babies (91.06%), were taken forward for costing.
Intensity, length of stay and cost of care within the follow-up period
All 5858 outpatient appointments were within the follow-up period. The average cost per outpatient
appointment was £155, and was similar by PICC type (see Appendix 6, Table 51). Table 15 shows the
length of stay and the costs per baby. For the 784 PREVAIL babies for whom outpatient appointments
were recorded, the average number of outpatient appointments was 7.47 and the average cost per
baby was £1156; both values were similar by type of PICC.
Accident and emergency visits recorded in Hospital Episode Statistics accident
and emergency
Data preparation
Appendix 5 details the process of data preparation, including Figure 21. A total of 352 PREVAIL babies
(40.88% of PREVAIL trial population) were recorded in HES A&E, with a total of 622 A&E attendances.
No observations were deleted in the preparation of the data set for the grouper. The grouper derived
valid HRGs for 539 A&E attendances among 320 PREVAIL babies (37.17%).
Intensity, length of stay and cost of care within the follow-up period
All 539 A&E attendances, by 320 PREVAIL babies, were within the follow-up period. The average
cost per A&E attendance was £132.64, which was similar across both PICC types. Of the 539 A&E
attendances, 293 (54%) led to an inpatient admission and 246 (46%) did not; these values were also
similar by PICC type. Table 15 shows the number of A&E attendances and A&E costs per PREVAIL
baby recorded in HES A&E. For those 320 PREVAIL babies for whom A&E attendances were recorded,
the average number of A&E attendances was 1.68 per baby and the average cost was £223 per baby;
both values were similar by PICC type.
The number of babies is the number of PREVAIL babies recorded in each database with hospitalisations
within the follow-up period of 6 months after randomisation, which had sufficient data for costing
(see Appendix 5, Figures 18–21, for details). The percentage refers to the proportion of PREVAIL
babies compared with the analysis population of 861 babies (AM-PICC, n = 430; S-PICC, n = 431).
The length of stay and the costs of the hospital care in the NNU recorded in the NNRD and the hospital
care recorded in HES APC were adjusted by the proportion of time outside the trial follow-up window.
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Cost of hospital care
To calculate the total cost of hospital care, the files with the cost per baby from each data set were
merged into one single file. Of the 861 PREVAIL babies, 33 babies had records of hospital use in the
NNRD, but not in HES APC, and 24 babies had record of hospital use in HES APC, but not in the
NNRD. The analytical sample comprised the PREVAIL babies with data on the cost of hospital care
both in HES APC and in the NNRD. The analytical sample comprises 804 PREVAIL babies with data
on the cost of hospital care in HES APC and NNRD.
Table 16 summarises the costs of hospital care in the analytical sample. The average costs were
similar by PICC type. The average total cost per baby was £83,473. Most of the costs were incurred
in the NNU (£54,047; 64.75% of the total cost of hospital care), followed by hospital care other than
intensive care (£26,617; 31.89% of the total cost of hospital care). The cost was similar by PICC type.
Some of the costs per database are different between Tables 15 and 16. This is because Table 15 shows
the average costs per baby with an admission recorded in each database. For example, 94 babies were
recorded in the PICANet database, with an average cost each of £14,458 due to their PICU stay.
Conversely, Table 16 shows the average costs per baby in the analytical sample. For example, the
average cost of a PICU admission is £1641 over the 6 months’ follow-up for all of the 804 PREVAIL
babies who comprise the analytical sample, based on a mean of 0.93 days in PICU per baby.
Deaths during the 6-month follow-up period
The HES data sets included date of death according to the Personal Demographics Service. Within the
follow-up period of 6 months from date of randomisation, 66 deaths were recorded. The PREVAIL trial
CRFs recorded whether death had occurred in the neonatal care unit. The CRFs recorded 69 deaths.
Five deaths were recorded in the CRFs that were not recorded in the Personal Demographics Service
records (which were linked to HES), and two deaths were recorded in the Personal Demographics
Service records but not in the CRFs. In total, 71 deaths occurred. These data are used to inform the
economic model (see Probability of death between peripherally inserted central venous catheter insertion
and 6 months of age).
TABLE 16 Length of stay and cost of hospital care of the PREVAIL babies with hospitalisations recorded in the NNRD
and in HES APC
Type of hospital care
Total (n= 804) AM-PICC group (n= 400) S-PICC group (n= 404)
Mean SD Mean SD Mean SD
Length of stay (days)
NICU (recorded in NNRD) 66.53 36.52 66.05 36.80 67.01 36.27
PICU (recorded in PICANet) 0.93 4.19 0.90 4.37 0.97 4.00
In total for all hospital admissions
(recorded in HES APC)
69.52 37.81 68.43 36.64 70.60 38.94
Number of outpatient attendances
(recorded in HES outpatient)
7.03 7.70 7.22 8.16 6.85 7.23
Number of A&E attendances
(recorded in HES A&E)
0.64 1.09 0.68 1.13 0.60 1.03
Costs
NICU £54,047.15 £34,834.76 £53,526.62 £35,110.30 £54,562.53 £34,595.59
PICU £1641.37 £7417.34 £1590.98 £7718.18 £1691.25 £7116.19
Other inpatient hospital care £26,616.92 £18,268.35 £26,447.75 £18,152.15 £26,784.41 £18,403.65
Outpatient appointments £1082.63 £1027.28 £1098.27 £1056.66 £1067.15 £998.42
A&E appointments £84.68 £146.73 £89.36 £147.89 £80.05 £145.61
Total cost £83,472.75 £50,148.48 £82,752.99 £49,738.66 £84,185.39 £50,602.54
DOI: 10.3310/hta24570 Health Technology Assessment 2020 Vol. 24 No. 57
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Gilbert et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
37
Cost-effectiveness of antimicrobial-impregnated versus standard
peripherally inserted central venous catheters over a lifetime
Background
The primary objective of the cost-effectiveness analysis was to estimate the long-term costs and health
benefits of using AM-PICCs, compared with using S-PICCs, in babies in the NICU. The PREVAIL trial
provided data on the risk of BSI, the AM-PICC effectiveness and the hospital costs over 6 months of
babies who received AM-PICCs, compared with babies who received S-PICCs. To estimate the costs
and health benefits of using an AM-PICC or a S-PICC over a baby’s lifetime, information was needed
on the long-term consequences of using each PICC. This information was obtained from the published
literature and synthesised in a de novo cost-effectiveness model. This section reports the methods
used to develop the cost-effectiveness model and the results of the cost-effectiveness analysis.
The model was developed to evaluate the cost-effectiveness of any intervention for the prevention
of infection in neonates in the NNU. For the purposes of the cost-effectiveness model, infection is an
umbrella term that includes, not only BSI and clinically serious BSI, as defined in the PREVAIL trial,
but also sepsis (indicating BSI with clinical signs of tissue damage). The key assumption of the model
was that infection increases the risk of death and of developing neurodevelopmental impairment (NDI)
in early childhood. NDI is associated with lower life expectancy, worse health-related quality of life
(HRQoL) and higher costs to the NHS.71 Consequently, babies who had a BSI during their stay in the
NNU are expected to experience worse health outcomes and higher costs because of the long-term
consequences of infection. Therefore, interventions reducing the risk of infection may be cost-effective,
depending on the magnitude of risk reduction and costs.
Methods
Overview
The cost-effectiveness model simulated the costs, life expectancy and QALYs of preterm babies who
required a PICC during their stay in the neonatal care unit. Costs were expressed in Great British
pounds at a 2016 price base, from the perspective of the NHS. Future costs and QALYs were
discounted at 3.5% per annum.72 The time horizon was the babies’ predicted lifetime from birth.
The model was built in Microsoft Excel® (Microsoft Corporation, Redmond, WA, USA).
Population and subgroups
Gestational age is strongly associated with long-term costs and health outcomes.71 Therefore, the
target population was considered in terms of subgroups defined by gestational age. The gestational
age cut-off points were based on Mangham et al.,71 defined as extremely preterm babies (< 28 weeks),
very preterm babies (28–32 weeks) and preterm (33–37 weeks). Given that only 12% of the PREVAIL
babies were born at ≥ 33 weeks’ gestation, and the advice by clinical collaborators that the babies who
need a PICC of 1 French gauge are unlikely to be representative of the population of babies born at
33–37 weeks, the target population for the cost-effectiveness analysis was restricted to babies born
at ≤ 32 weeks’ gestation.
Model conceptualisation
Consequences of infection in preterm neonates
A 2016 study on the clinical effectiveness and cost-effectiveness of AM-PICCs in children reviewed
the existing cost-effectiveness studies and found no published reports on the effectiveness in preterm
babies.73 Therefore, a systematic review on cost-effectiveness models in interventions that reduce the
risk of BSI in preterm babies was not conducted.
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The association between infection in preterm neonates and increased risk of NDI and death is supported
by various observational studies.10,74–77 Published meta-analyses78–80 estimated that infection (specifically
sepsis) significantly increases the risk of post-discharge death (RR 2.05, 95% CI 1.28 to 3.28)80 and NDI,
which manifests in early childhood (various definitions pooled, OR 2.09, 95% CI 1.65 to 2.65).78–80 NDI
may develop into physical and mental impairment in childhood, adolescence and adulthood, leading to a
reduction in HRQoL and life expectancy, and a greater need for health and social care.9,10,81,82
The long-term outcomes of sepsis have been the subject of various studies, as have the consequences
of infection, which is defined as an event requiring the use of antibiotics for at least 3–5 days.10,78–80
No studies were found that used the same definition of BSI as used in the PREVAIL trial. The PREVAIL
trial did collect data on clinically serious BSIs; a clinically serious BSI was defined as a BSI for which a
baby is treated for > 72 hours with intravenous antibiotic, or dies during treatment (see section 4.1 of
the trial protocol59). Consequently, clinically serious BSI was taken as the key intermediate outcome
for the cost-effectiveness model, rather than BSI. In practice, however, there was little difference between
the incidence of BSI and clinically serious BSI in the PREVAIL trial (see Chapter 2, Primary outcome).
Hence, for consistency with the rest of the report, the term BSI is used throughout, although it refers
to clinically serious BSI in this chapter.
Model design
The cost-effectiveness model simulated long-term outcomes in preterm babies by assuming that the
occurrence of a BSI during the stay in the NNU increases the risk of developing NDI and increases the
risk of death at 2 years of age. The model assumed that having a BSI during the stay in the NNU has
no direct consequences after 2 years of age. After 2 years of age, the model was driven by the NDI
state that children experience at 2 years of age, which can improve or deteriorate and is associated
with an increased risk of death compared with the general population.
In the cost-effectiveness model, NDI was defined as a composite outcome encompassing different
types of impairment, namely visual, hearing, mobility and cognitive.83 Each item is assigned a level
ranging from no impairment to severe impairment, following standardised paediatric assessment tests;
the most serious level of impairment recorded defines the overall NDI classification for an infant.
This classification was previously used and validated as part of the Victorian Infant Collaborative
Study Group (VICSG)83–85 and in the UK economic analysis by Mangham et al.71
A summary of the main model assumptions is available in Appendix 11, Box 1.
Model structure
Predicting outcomes in early childhood
The model included a short- and a long-term component. The short-term component was a decision
tree. Babies enter the model at the time of PICC insertion. The model estimated the proportion of
children alive at 2 years of age, and their distribution by level of NDI (none, mild, moderate or severe)
(Figure 6). PICC type (AM-PICC or S-PICC) determines the probability of BSI and costs, as observed
in the PREVAIL trial. BSI is assumed to increase the probabilities of death and of experiencing NDI.
Predicting lifetime costs and health outcomes beyond 2 years of age
The long-term component of the model simulated the lifetime health outcomes and costs given
the children’s NDI levels. It assumed that previous BSI does not influence longer-term lifetime costs
and health outcomes. The model was a Markov model,86 based on the model depicting the costs of
prematurity by Mangham et al.71 Children enter the model at 2 years of age in one of the NDI states,
according to the proportion of babies computed by the decision tree (Figure 7). At each cycle, children
can transition between NDI states or die. The transitions represent the improvement or deterioration
in the neurodevelopmental state of the child, as well as inaccuracies in the assessment, which might
become apparent over time. After reaching 8 years of age, children were assumed to no longer
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FIGURE 6 Model structure for predicting outcomes in early childhood. The square denotes the decision: use either an AM-PICC or a S-PICC. The circle denotes a probability (or chance)










































transition between NDI states; therefore, the only transition after age 8 years is to the absorbing
death state. The risk of death depends on both age and NDI state.
Model inputs for predicting outcomes in early childhood
Table 17 presents the short-term model parameters used to predict the outcomes at 2 years of age.
Each parameter is shown in Table 17 and discussed in detail in the following text. The base case refers
to the primary analysis.
Effect of antimicrobial-impregnated peripherally inserted central venous catheter in preventing
bloodstream infection
The effect of AM-PICC in preventing BSI was obtained from the PREVAIL trial: RR 1.06 (95% CI 0.70
to 1.60). As discussed earlier, it refers to the RR of clinically serious BSI, as defined in the PREVAIL








FIGURE 7 Model structure for predicting lifetime costs and health outcomes. The arrows depict the possible transitions
between model states in each cycle.
TABLE 17 Parameters for predicting outcomes in early childhood
Parameter Value (95% CI); distribution Source
Effect of AM-PICC on the probability of a BSI occurring
(1) RR of AM-PICC vs. S-PICC on
BSI; same for both gestational
age subgroups
1.06 (0.70 to 1.60); log-normal PREVAIL trial: calculated from the number
of babies who had a clinically serious BSI in
the PREVAIL trial
Effect of BSI on NDI and death
(2) RR of the effect of BSI on
death at 6 months; same for
both gestational age subgroups
Base case: 1 (fixed) Assumed that BSI has no causal effect on
death at 6 months
(3) OR of BSI on NDI index at
2 years of age; same for both
gestational age subgroups
1.51 (1.33 to 1.70); log-normal Meta-analysis of Stoll et al.10 and
Schlapbach et al.74
(4) OR of BSI on probability of
death at 2 years of age; same for
both gestational age subgroups
2.74 (1.43 to 5.24); log-normal Meta-analysis of Schlapbach et al.74 and
Bassler et al.76
continued
DOI: 10.3310/hta24570 Health Technology Assessment 2020 Vol. 24 No. 57
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Gilbert et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
41
TABLE 17 Parameters for predicting outcomes in early childhood (continued )
Parameter Value (95% CI); distribution Source
Baseline probabilities
(5) Probability of having a BSI with S-PICC
Gestational age ≤ 27 weeks 0.14 (0.09 to 0.20); beta PREVAIL trial: proportion of babies who
had a BSI who were allocated to S-PICC,
by gestational age. For consistency with
the costs, the probabilities refer to the
subpopulation with gestational age of
≤ 32 weeks for whom costs of hospital
care could be calculated
Gestational age ≥ 28 weeks 0.04 (0.02 to 0.08); beta
(6) Probability of death between PICC insertion and 6-months if BSI had not occurred
Gestational age ≤ 27 weeks 0.20 (0.16 to 0.23); beta l Santhakumaran et al.87 for gestational age
23–27 and 28–32 weeks on survival
to discharge
l PREVAIL trial for the probability of BSI
and the RR of BSI on death
Gestational age ≥ 28 weeks 0.03 (0.03 to 0.04); beta
(7) Probability that children who did not have a BSI during PICC use die between 6 months and 2 years
Gestational age ≤ 27 weeks 0.02 (0.01 to 0.03); beta Mangham et al.71
Gestational age ≥ 28 weeks 0.01 (0.00 to 0.02); beta
(7) Probability that children aged 2 years who did not have a BSI during PICC use are diagnosed with NDI
Gestational age ≤ 27 weeks 0.45 (0.42 to 0.49); Dirichlet Mangham et al.71
Gestational age ≥ 28 weeks 0.26 (0.25 to 0.28); Dirichlet
(8) Distribution by NDI levels, given that NDI was diagnosed (independent of previous BSI during PICC use)
Mild NDI l Mangham et al.,71 assumed to be similar for
both infection and non-infection groups
l Severe NDI is the remaining proportion,
so that the total sums to 1
Gestational age ≤ 27 weeks 0.54 (0.51 to 0.58); Dirichlet
Gestational age ≥ 28 weeks 0.73 (0.70 to 0.76); Dirichlet
Moderate NDI
Gestational age ≤ 27 weeks 0.29 (0.28 to 0.30); Dirichlet
Gestational age ≥ 28 weeks 0.16 (0.15 to 0.17); Dirichlet
Costs
(9) Difference in cost between
AM-PICC and S-PICC
£53.70 Vygon (UK) Ltd, 2015, personal
communication
(10) Health-care costs between PICC insertion and 6 months
Base case PREVAIL trial: generalised linear model
with Gaussian distribution and log-link;
explanatory variable is gestational age
group. Estimated in the subpopulation with
gestational age of ≤ 32 weeks for whom
costs of hospital care could be calculated
Gestational age 23–27 weeks £105,873.47 (£101,444.99 to
£110,495.27); gamma
Gestational age 28–32 weeks £62,255.37 (£54,711.87 to
£70,838.93); gamma
(11) Health-care costs between 6 months and 2 years
Gestational age 23–27 weeks £5989.17 (£5989.14 to £5994.98) l NHS Reference Costs 2015 to 201662
l Inpatient admission, outpatient and
A&E visit from an unpublished study
about variation in neonatal and
paediatric admission (Katie Harron,
personal communication)
Gestational age 28–32 weeks £3026.17 (£3024.21 to £3028.73)
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Long-term consequences of bloodstream infection
Systematic reviews of the association between BSI during the NNU stay and NDI were used to identify
studies using a similar NDI measure as the study by Mangham et al.,71 the source of the transition
probabilities between NDI levels for the Markov model. In Mangham et al.,71 NDI was defined as an
impairment affecting one of four functional dimensions: motor ability (including cerebral palsy), visual
ability, hearing ability or development delay and cognitive ability, based on Doyle et al.83 (see Appendix 7,
Table 52, for details). Therefore, only studies that reported the association between infection during
the neonatal stay and impairment including all the aforementioned four dimensions were selected and
meta-analysed (see Appendix 7, Table 53, for details).86
Effect of clinically serious bloodstream infection on the risk of neurodevelopmental impairment
Two studies were identified: Stoll et al.10 and Schlapbach et al.74 Stoll et al.10 is a retrospective study
describing the outcomes at 18–22 months of age of 6093 babies in a US registry of very low-birthweight
infants born between 1993 and 2001 weighing 401–1000 g at birth. Stoll et al.10 report an adjusted
OR for infection on NDI of 1.50 (95% CI 1.20 to 1.70). Schlapbach et al.74 report a prospective cohort
study in Switzerland of 541 babies born between 2000 and 2007 at 24–27 weeks’ gestational age; the
OR for sepsis on NDI is 1.69 (95% CI 0.96 to 2.98). The base case uses the meta-analysed OR using
Stoll et al.10 and Schlapbach et al.74 at 1.51 (95% CI 1.33 to 1.70; fixed effects; see Appendix 7, Table 55).
Both estimates used the ORs, adjusted for differences in observed characteristics using multivariate
logistic regression.
Effect of clinically serious bloodstream infection on the risk of death at 6 months of age As discussed
in Deaths during the 6-month follow-up period, 71 deaths were recorded in the PREVAIL trial population,
according to the PREVAIL trial CRFs and NHS Digital’s Personal Demographics Service. However, some
of these deaths occurred in babies who were born at ≥ 33 weeks’ gestation, who are outside the scope
of the economic model. In the modelled population of babies born at ≤ 32 weeks’ gestation, 63 deaths
occurred among 735 babies (8.57%). There was no clear evidence that BSI (specifically, clinically serious
BSI as defined in the PREVAIL trial) increased the risk of death, controlling for gestational age (see
Appendix 7). Furthermore, we found no evidence in the literature that BSI increased the risk of death at
6 months of age. Therefore, the model assumes that BSI does not increase the risk of death at 6 months
and the assumption is tested in the sensitivity analysis.
Effect of bloodstream infection on the risk of death at 2 years of age given survival to 6 months
Two studies were identified (see Appendix 7, Table 54): Schlapbach et al.,74 which also provided the link
to NDI, and Bassler et al.76 Stoll et al.10 did not examine the probability of death. Schlapbach et al.74 report
that the OR for infection on death before 2 years of age (conditional on survival past 36+0/7 weeks) is
5.38 (95% CI 0.55 to 52.07). The study by Bassler et al.76 is a Canadian prospective cohort study in
944 babies born between 1996 and 1998 weighing 500–999 g at birth who participated in a Trial
of Indomethacin Prophylaxis in Preterms.88 The OR for infection on death before 18 months of age,
conditional on survival to 36 weeks, was 2.57 (95% CI 1.31 to 5.07).76 Schlapbach et al.74 and Bassler
et al.76 do not report these ORs. Instead, the ORs were calculated for the present study using the count
data reported in these studies.74,76 The base case uses the meta-analysed OR using Schlapbach et al.74
and Bassler et al.76 This OR is 2.74 (95% CI 1.43 to 5.24; fixed effects; see Appendix 7, Table 56).
Probability of bloodstream infection with standard peripherally inserted central venous catheter
The probability of BSI with a S-PICC was obtained directly from the PREVAIL trial data: 0.14 (95% CI
0.09 to 0.20) and 0.04 (95% CI 0.02 to 0.08) for babies with gestational age at birth of 23–27 weeks
and 28–32 weeks, respectively (see Appendix 8, Table 57).
Probability of death between peripherally inserted central venous catheter insertion and
6 months of age
The probability of death between PICC insertion and 6 months of age for babies with gestational age
of 23–27 and 28–32 weeks was obtained from Santhakumaran et al.,87 which reports the outcomes
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from the English NNRD for the years 2008–14. The PREVAIL trial data were not used owing to the
small sample size for each gestational age subgroup (see Appendix 8, Tables 58 and 59). The probability
of death without prior BSI was calculated as 0.20 (95% CI 0.16 to 0.23) and 0.03 (95% CI 0.03 to 0.04)
for babies with gestational age at birth of 23–27 and 28–32 weeks, respectively (see Appendix 8,
Tables 60 and 61, for details).
Probability of death between 6 months and 2 years of age
The probability of death between 6 months and 2 years of age, without prior BSI, was based on
Mangham et al.:71 0.02 (95% CI 0.01 to 0.03) and 0.01 (95% CI 0.00 to 0.02) for babies with gestational
age at birth of 23–27 and 28–32 weeks, respectively. Mangham et al.71 estimated the probability of
death for children born preterm between hospital discharge and 2 years of age using individual-level
data from three cohort studies: the first EPICure cohort from the UK and Ireland in 1995,89,90 the
1991–2 VICSG cohort in Australia83 and the Oxford Record Linkage Study from 1990 to 1993.91–93
Hospital discharge in the Mangham et al.71 study was assumed to occur at 6 months for the purposes
of our model, and refers to a mixed population with and without prior BSI.
Probability that children suffered neurodevelopmental impairment who had not suffered prior
bloodstream infection
Evidence is available suggesting that NDI can occur even without prior BSI being diagnosed.10 The
occurrence of BSI increases the risk of impairment over and above this baseline level associated with
prematurity per se. Three alternative sources for the probability that NDI occurred were identified.10,71,74
Stoll et al.10 and Schlapbach et al.74 report the probability of NDI separately for babies with and babies
without prior BSI.13,94 Mangham et al.71 report the probability of NDI occurring, the distribution over
NDI level and the probability of progression of NDI by gestational age for a mixed population (with
and without BSI).71 Although Mangham et al.71 refers to the probability of NDI occurring for a mixed
population, it was preferred because it provides the probabilities by gestational age subgroup. Hence,
the probability of NDI without prior BSI in the model is 0.45 (95% CI 0.42 to 0.49) and 0.26 (95% CI
0.25 to 0.28) for babies with gestational age at birth of 23–27 and 28–32 weeks, respectively.
Distribution of neurodevelopmental impairment by severity level
In the absence of evidence to the contrary, BSI during the neonatal stay was assumed not to
change the probability of having a mild, moderate or severe NDI, given that some level of NDI
has occurred. NDI encompasses four different outcomes, as defined by Doyle et al.:83 cerebral
palsy (classified according to Kitchen et al.95), blindness (visual acuity of < 20/200 in the better eye),
deafness (hearing loss requiring amplification) and developmental delay (Mental Developmental Index,
of the Bayley Scales of Infant Development, score of < –1 SD relative to the control group mean).
The scale classifies each of these outcomes on a scale: no, mild, moderate or severe NDI. Doyle et al.83
use the worst recorded severity across the four outcomes as the reference to define the overall level
of impairment in an infant. The same scale was subsequently adopted by the Mangham et al.71 study
and, as a result, translates in the current model when babies are assumed to be assigned a level of
impairment following a neurological assessment. The proportion of babies at each NDI level, given
that NDI was diagnosed, was 0.54 (95% CI 0.51 to 0.58) and 0.29 (95% CI 0.28 to 0.30) for mild and
moderate NDI, respectively, for babies with gestational age at birth of 23–27 weeks, and 0.73 (95% CI
0.70 to 0.76) and 0.16 (95% CI 0.15 to 0.17) for mild and moderate NDI for babies with gestational
age at birth of 28–32 weeks.
Costs between peripherally inserted central venous catheter insertion and 2 years of age
Additional cost of antimicrobial-impregnated versus standard peripherally inserted central venous
catheters The cost of S-PICCs and AM-PICCs was provided by their manufacturer [Vygon (UK) Ltd];
each AM-PICC is £53.70 more costly than a S-PICC [Vygon (UK) Ltd, personal communication].
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Costs between peripherally inserted central venous catheter insertion and 6 months The costs
between PICC insertion and 6 months were estimated from the PREVAIL trial data linked to the
NNRD; PICANet; and HES APC, outpatient and A&E (see Cost of hospital care). Costs were estimated
using a generalised linear model with a Gaussian distribution and log link, controlling for gestational
age at birth, survival and BSI status across different specifications (details can be found in Appendix 9,
Tables 64 and 65). Base-case estimates amounted to £105,873.47 (95% CI £101,444.99 to £110,495.27)
and £62,255.37 (95% CI £54,711.87 to £70,838.93) for gestational age at birth of 23–27 weeks and
28–32 weeks, respectively.
Costs between 6 months and 2 years of age The costs between 6 months and 2 years of age were
based on the hospital admissions of babies aged between 6 months and 2 years by gestational age and
valued with 2016 NHS reference costs.69 Estimated costs amounted to £5989.17 (95% CI £5983.44 to
£5994.98) for babies born between 23 and 27 weeks of gestation and to £3026.43 (95% CI £3024.21
to £3028.73) for babies born between 28 and 32 weeks of gestation (see Appendix 9, Table 68). Details
are in Appendix 9, Tables 66–68.
Model inputs for predicting outcomes beyond 2 years
The parameter inputs for the long-term component of the model include the transition probabilities
between NDI states or death, and the respective costs and utilities. Each parameter is shown in
Table 18 and discussed in detail in the following text.
Transitions between neurodevelopmental impairment states or death
Patients aged 2–8 years The 1-year transition probabilities were computed from the counts of babies
at each level of NDI from the 1991–2 cohort of the VICSG observed at 2, 5 and 8 years of age in
Mangham et al.71 (see Appendix 8, Tables 62 and 63).71
Patients aged ≥ 8 years The transitions between NDI states stop once a child reach 8 years of age,
which corresponds to the last time point for the transition probabilities from Mangham et al.71 As far as
we are aware, no data are available on progression beyond this age. This assumption of no progression
beyond 8 years of age was confirmed with the PREVAIL trial clinical team. From this age onwards,
the cohort in the model is subject only to the probability of death, which depends on their NDI level.
Probability of death by neurodevelopmental impairment level from age 18 onwards The probability
of death was obtained from the UK lifetables 2013–15,99 to which the excess risk due to NDI is added.
The additional risk of death by NDI level was obtained from Reid et al.98
The study by Reid et al.98 was a prospective population-based study including 3507 individuals with
cerebral palsy related to factors in the antenatal, perinatal or neonatal period born in the state of
Victoria (Australia) between 1970 and 2004, and identified from the Victorian Cerebral Palsy Register.
It assesses the impact of clinical variables, including motor, visual, hearing and intellectual impairment,
on mortality. The classification system is similar between this study and the VICSG one, allowing for the
extrapolation of the adjusted HRs from the Reid et al.98 study to the current model. Each impairment
level from the Doyle et al.83 study can include up to four health outcomes with different level of severity:
blindness, deafness, developmental delay and cerebral palsy. For the purpose of this study, we matched
each of these outcomes to the covariates used in the Cox regression model performed by Reid et al.,98
with levels of the categorical covariates corresponding to different level of impairment. For each level
of impairment (no, mild, moderate, severe), the largest HR across the health outcomes was then taken
as representative of the overall impairment level, and used to adjust the baseline probability of death
by NDI level.
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Costs and health-related quality of life
Patients aged 2–10 years Annual costs by NDI level between ages 2 and 10 years were sourced from
Mangham et al.,71 which reports resource use and HRQoL by NDI level collected for the first EPICure
study at 6 years of age using a questionnaire completed by the parent(s).100,101
Patients aged ≥ 11 years Annual costs between 11 and 18 years of age and HRQoL by NDI level were
obtained from Petrou et al.,96 who estimated costs and HRQoL at 11 years of age of the children in the
first EPICure cohort using a questionnaire filled in by the parent(s) and related it to a NDI classification
similar to the one in our model.
TABLE 18 Parameters for predicting lifetime costs and health outcomes
Parameter Value (95% CI); distribution Source
HRQoL values (utilities)
HRQoL value with no NDI 0.96 (0.94 to 0.97); beta Baseline HRQoL from Petrou et al.96 It
also corresponds to the utility value for
non-impaired babies as their decrement
was set at 0 (fixed)
Reduction in HRQoL due to mild NDI 0.18 (0.14 to 0.31); gamma Petrou et al.96 HRQoL decrement: 0.179
(SE 0.042)
Reduction in HRQoL due to moderate
NDI
0.30 (0.24 to 0.46); gamma Petrou et al.96 HRQoL decrement: 0.298
(SE 0.055)
Reduction in HRQoL due to severe NDI 0.56 (0.44 to 0.77); gamma Petrou et al.96 HRQoL decrement: 0.558
(SE 0.084)
Annual costs between ages 2 and 10 years
No NDI £388 (£285 to £509); gamma Petrou et al.;97 inflated to 2016 prices
Mild NDI £753 (£584 to £946); gamma Petrou et al.;97 inflated to 2016 prices
Moderate NDI £814 (£560 to £1063); gamma Petrou et al.;97 inflated to 2016 prices
Severe NDI £1487 (£1096 to £1943); gamma Petrou et al.;97 inflated to 2016 prices
Annual costs from age 11 years
No NDI £686 (£440 to £993); gamma Petrou et al.;96 inflated to 2016 prices
Mild NDI £987 (£782 to £1222); gamma Petrou et al.;96 inflated to 2016 prices
Moderate NDI £1252 (£933 to £1624); gamma Petrou et al.;96 inflated to 2016 prices
Severe NDI £1976 (£1411 to £2648); gamma Petrou et al.;96 inflated to 2016 prices
HRs for mortality for all gestational age subgroups
Type of motor impairment: moderate 1.51 (0.71 to 3.24); log-normal Reid et al.98 – baseline: mild impairment
Type of motor impairment: severe 6.21 (3.28 to 11.77); log-normal Reid et al.98 – baseline: mild impairment
Type of cognitive impairment: mild/
moderate
1.11 (0.62 to 1.97); log-normal Reid et al.98 – baseline: no impairment
Type of cognitive impairment: severe/
profound
3.01 (1.74 to 5.22); log-normal Reid et al.98 – baseline: no impairment
Vision impairment: blind 0.94 (0.58 to 1.53); log-normal Reid et al.98 – baseline: not blind
Hearing impairment: deaf 2.61 (1.44 to 4.74); log-normal Reid et al.98 – baseline: not deaf
SE, standard error.
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Annual costs and HRQoL values after the age of 18 years were assumed to be the same as those used
in the model for children aged between 11 and 18 years. These parameters have a minimal impact in
the model because of discounting.
Analytical methods
Base case
The model was probabilistic in that the base-case results are computed as the mean costs and QALYs
over 10,000 Monte Carlo simulations.86 Cost-effectiveness was evaluated at two cost-effectiveness
thresholds: the cost-effectiveness threshold of the National Institute for Health and Care Excellence
(NICE)102 at £20,000 per QALY and the empirical estimate of the opportunity cost to the NHS of
bearing additional costs, at £13,000 per QALY. Results are presented in terms of incremental net
health benefit, calculated as the difference in expected QALYs between the AM-PICC and S-PICC
groups and the difference in costs, expressed in terms of QALYs using the NICE cost-effectiveness
threshold and the empirical estimate of the opportunity cost to the NHS.102,103
Cost-effectiveness acceptability curves are presented, which represent the probability that AM-PICCs
are cost-effective for each gestational age subgroup over the range of cost-effectiveness thresholds
from null to £30,000 per QALY. The probability that AM-PICCs are cost-effective was calculated
as the proportion of simulations in which the AM-PICC has the highest net benefit (i.e. it is the
cost-effective option).
Sensitivity analysis
A bivariate sensitivity analysis on the effect of the AM-PICC and its additional cost compared with the
S-PICC was conducted to determine the maximum acquisition price of AM-PICCs for a given reduction
in the risk of BSI. This analysis can help inform future decisions on whether or not to commission more
costly interventions that may reduce the risk of BSI.
A univariate sensitivity analysis was conducted to identify which parameters have the greatest impact on
the results in addition to the direct effect and cost of AM-PICCs versus S-PICCs. For this, all parameters
predicting the outcomes in early childhood were varied across the extremes of their 95% CIs.
Scenario sensitivity analyses were conducted to understand the impact of the key assumptions (see
Appendix 11, Table 69). This includes assuming that BSI has no effect on the risk of NDI or of death,
stopping backward transitions from the severe NDI state, employing 3-year transition probabilities,
allowing for transitions between NDI states until 18 years of age, applying the age and sex decrement
on HRQoL and removing the increased risk of death by NDI level.104 Additional scenarios regarding the
effect of BSI on death and costs before 6 months were also implemented (see Appendix 11, Table 70).
One scenario used linked data from the PREVAIL trial to calculate an unadjusted RR of BSI on death
before 6 months (2.51, 95% CI 1.44 to 4.38); see Appendix 8, Application to the Model. Two scenarios
were tested to consider the possibility that BSI and death before 6 months of age have an impact on
the hospital cost over 6 months.
Model validation
Model acceptability and face validity were ascertained during a series of meetings with members of
the PREVAIL team. The model underwent quality control to ensure internal consistency and external
validity following the recommendations of Vemer et al.105 This is described in Appendix 10.
Results
Predicting outcomes in early childhood
Table 19 shows the distribution of children at 2 years of age by NDI level and gestational age group,
according to S-PICC or AM-PICC allocation. The outcomes are similar between PICC types, although
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there is a small disadvantage for AM-PICCs given their marginally higher risk of developing BSI, which
is not statistically significant.
Predicting lifetime costs and health outcomes
Figure 8 shows the outcomes by NDI level over the children’s expected lifetime. The model predicts
that children who are assessed as having no NDI at 2 years of age live to 76 years, on average (95% CI
73 to 78 years). As the NDI level increases, life expectancy reduces. Children who are assessed as
having a severe NDI at 2 years of age are predicted to live to 61 years (95% CI 47 to 74 years).
The differences in costs and health outcomes between mild NDI and no impairment are £3690 lower
costs and 2.16 additional QALYs. This means that if one child has mild NDI, then, on average, and
compared with having no NDI, the child loses 2.16 QALYs over their lifetime and costs an additional
£3690 to the NHS. If a QALY is valued at £20,000 by the NHS, avoiding mild NDI in one child warrants
£46,890 (2.16 QALYs × £20,000 + £3690) in investment by the NHS.
Cost-effectiveness of antimicrobial-impregnated versus standard peripherally
inserted central venous catheters
Table 20 shows the cost-effectiveness results. The AM-PICC is not cost-effective when compared
with the S-PICC; rather, the S-PICC dominates at both gestational ages (23–27 and 28–32 weeks).
The AM-PICC increases costs by a small extent, to £54.85 (95% CI £25.95 to £89.12) for babies born
at 23–27 weeks of gestation and to £54.81 (95% CI £48.21 to £64.28) for those born at 28–32 weeks
of gestation. The AM-PICC also reduces health outcomes by a small extent, at –0.01 (95% CI –0.09
to 0.04) and 0.00 (95% CI –0.01 to 0.01), for babies born at 23–27 and 28–32 weeks of gestation,
respectively. The cost-effectiveness of an AM-PICC versus a S-PICC can be synthesised in terms of its
incremental net benefit, given the cost-effectiveness threshold.103 At a cost-effectiveness threshold of
£13,000 per QALY, the incremental net benefit of AM-PICCs versus S-PICCs is –0.01 QALYS (95% CI
–0.09 to 0.04 QALYs) and –0.01 QALYs (95% CI –0.02 to 0.00 QALYs) for babies with gestational age
at birth of 23–27 and 28–32 weeks, respectively. This means that using the AM-PICC has a small,
non-significant detrimental effect on health outcomes, given its direct impact on babies’ health
outcomes and its indirect impact on the health-care system as a result of its additional costs.
TABLE 19 Distribution of children by NDI level at 2 years of age
Intervention
NDI at 2 years
of age
Gestational age (weeks), mean over the probabilistic simulations (%) (95% CI)
23–27 28–32
S-PICC No 41.43 (38.36 to 44.79) 70.41 (68.71 to 72.06)
Mild 19.80 (18.80 to 21.03) 18.63 (18.08 to 19.16)
Moderate 10.56 (9.28 to 11.79) 4.16 (3.59 to 4.75)
Severe 6.14 (4.75 to 7.50) 2.80 (2.29 to 3.34)
Dead 22.07 (18.08 to 25.39) 3.99 (3.33 to 5.10)
Total 100% 100%
AM-PICC No 41.32 (38.19 to 44.76) 70.38 (68.64 to 72.04)
Mild 19.85 (18.80 to 21.14) 18.65 (18.09 to 19.19)
Moderate 10.58 (9.29 to 11.81) 4.16 (3.60 to 4.76)
Severe 6.15 (4.77 to 7.52) 2.81 (2.30 to 3.35)
Dead 22.10 (18.12 to 25.42) 4.00 (3.34 to 5.11)
Total 100% 100%
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FIGURE 8 Costs and health outcomes by NDI level over expected lifetime. The NHS costs and the lifetime QALYs
accrued in the future are discounted at 3.5% in line with current guidelines. The life expectancy from PICC insertion is
not discounted. The vertical lines indicate the 95% CIs. Adapted from Grosso et al.106 © Author(s) (or their employer(s))
2020. Re-use permitted under CC BY. Published by BMJ. This is an open access article distributed in accordance with
the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix,
transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence
is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/. Minor
formatting changes have been made.
TABLE 20 Cost-effectiveness results over the lifetime time horizon
Cost-effectiveness results
Gestational age at birth (weeks), mean (95% CI)
23–27 28–32
AM-PICC
Total costs (£) 127,182.65 (120,983.15 to 133,919.12) 83,588.20 (77,048.17 to 90,839.31)
Total health outcomes (QALYs) 16.48 (15.41 to 17.59) 21.46 (20.67 to 22.17)
S-PICC
Total costs (£) 127,127.79 (120,935.61 to 133,866.31) 83,533.39 (76,993.85 to 90,784.10)
Total health outcomes (QALYs) 16.49 (15.44 to 17.60) 21.46 (20.67 to 22.17)
AM-PICC vs. S-PICC
Difference in costs (£) 54.85 (25.95 to 89.12) 54.81 (48.21 to 64.28)
Difference in health outcomes (QALYs) –0.01 (–0.09 to 0.04) 0.00 (–0.01 to 0.01)
Incremental net health benefit at
£13,000 per QALY [probability
that AM-PICC is cost-effective]
–0.01 (–0.09 to 0.04) [0.32] –0.01 (–0.02 to 0.00) [0.09]
Incremental net health benefit at
£20,000 per QALY [probability
that AM-PICC is cost-effective]
–0.01 (–0.09 to 0.04) [0.34] –0.00 (–0.02 to 0.00) [0.15]
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For babies born at 23–27 weeks’ gestation, the probability that the AM-PICC is cost-effective is
< 0.40, irrespective of the cost-effectiveness threshold; for babies born at 28–32 weeks’ gestation, it
remains < 0.20 as the cost-effectiveness threshold asymptotes to £30,000 per QALY. The probability of
cost-effectiveness reflects the uncertainty in the parameter estimates, particularly the large CI around
the RR of AM-PICCs versus S-PICCs in preventing infection.
Sensitivity analysis
The sensitivity analysis results are presented in detail in Appendix 11. The key results are discussed in
this section.
Bivariate sensitivity analysis: effectiveness and price
At the current price, the minimum level of effectiveness at which the AM-PICC is cost-effective, at a
cost-effectiveness threshold of £20,000 per QALY, is a relative reduction of 3% in the risk of BSI for
babies with gestational age at birth of 23–27 weeks, that is a maximum RR of 0.97. For babies with
gestational age at birth of 28–32 weeks, the minimum reduction is of 15%, that is a maximum RR of
0.85. At the cost-effectiveness threshold of £13,000 per QALY, the minimum relative reduction is 4%
and 20% for babies with gestational age at birth of 23–27 and 28–32 weeks, respectively (Figure 9).
The maximum acquisition price would increase if the effectiveness increased. For example, if the
AM-PICC reduced 5% of BSI cases (RR 0.95), the maximum acquisition price at a cost-effectiveness
threshold of £20,000 per QALY would be £165, if used solely in babies born at 23–27 weeks’ gestation,
or £65 in babies born at 28–32 weeks’ gestation. At a cost-effectiveness threshold of £13,000 per
QALY, and for the same effectiveness, the maximum price would be £120 and £55 if used solely in the
gestational age groups 23–27 and 28–32 weeks, respectively. At the prices currently charged for the
AM-PICC, and at a cost-effectiveness threshold of £20,000 per QALY, the AM-PICC would have to
reduce 2% and 15% of cases to be cost-effective for babies born at 23–27 and 28–32 weeks’ gestation,
respectively. At a cost-effectiveness threshold of £13,000 per QALY, the AM-PICC would have to
reduce at least 3% and 20% of cases to be cost-effective for babies born at 23–27 and 28–32 weeks’
gestation, respectively.




































FIGURE 9 Maximum acquisition price per AM-PICC effectiveness (gestational age at birth of 23–27 weeks).
Reproduced from Grosso et al.106 © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published
by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported
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Univariate sensitivity analysis
For both gestational age groups considered, the key cost-effectiveness driver was the RR of the
AM-PICC in preventing BSI (see Appendix 11, Figures 23 and 24).
Scenario analysis
The AM-PICC was found to be not cost-effective (i.e. negative incremental net benefit), irrespective
of the scenario implemented (see Appendix 11, Table 73). In most scenarios, the incremental net
benefit was similar to the base case. Large decreases in incremental net benefit were observed in
the scenarios assuming that BSI increased the risk of death, and, to a smaller extent, in the scenarios
assuming different hospital costs depending on whether or not death and BSI had occurred. This
happens because the PREVAIL trial indicates that the AM-PICC results in a slightly higher number
of BSIs (as per Table 17). In scenarios in which BSI increases the risk of death, the costs are lower
because children who die do not incur subsequent hospital costs. However, there is a large loss
of QALYs, owing to the increased proportion of babies who die in infancy. In these scenarios, the
AM-PICC appears to be more detrimental to babies than in the base-case assumption of no direct
effect of BSI on death at 6 months.
Value of information
The VoI analysis aims to estimate the health losses, in QALYs, associated with decision uncertainty
about which is the most cost-effective PICC type, whether or not future research is worthwhile,
and which parameters should be prioritised for research.
The analysis of the value of implementing the cost-effective PICC type (originally planned as objective 4;
see Introduction) was not carried out, as the S-PICC was found to be the cost-effective option. Given that
the S-PICC is currently in use in the NHS, its value of implementation is, by definition, null.61
Methods
Expected value of perfect information for the population
The VoI analysis quantifies the consequences of making the wrong decision (using AM-PICCs or
S-PICCs) in terms of the health losses if the wrong intervention is deemed cost-effective, and the
investment required to resolve this uncertainty.107 The expected cost of uncertainty is defined as the
expected value of perfect information (EVPI), conceived as the difference between the incremental
net benefit if every uncertainty was resolved, and the actual incremental net benefit under current
uncertainty.107 A necessary condition for conducting further research is that the cost of research does
not exceed the EVPI. The EVPI is computed with the online Shefflied Accelerated Value of Information
(SAVI) tool.108 The analysis is run for a time horizon of 10 years in the population of preterm babies
who require a PICC of 1 French.
Expected value of partial perfect information for the population
An approach similar to EVPI can be employed to determine which model parameters are the most
important drivers of uncertainty, which are those for which resolving uncertainty would provide the
greatest benefit in terms of making the ‘right’ decision. Expected value of partial perfect information
(EVPPI) is defined as the difference in net benefits under perfect and current information, but where
the uncertainty is resolved for one (or more) parameters at a time only, and averaging across all
possible values for the others.86 As above, EVPPI provides a measure of the maximum amount a
funder should be willing to pay for conducting further research related to a specific parameter
(or group of parameters).
DOI: 10.3310/hta24570 Health Technology Assessment 2020 Vol. 24 No. 57
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Gilbert et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
51
Patient population
Based on the analysis of the full NNRD by a member of the PREVAIL trial team, 2212 infants with
gestational age of 23–27 weeks and 3888 infants with gestational age of 28–32 weeks were estimated
to require a PICC each year. Therefore, the population EVPI is presented as a weighted average of the
individual EVPI for the two gestational age subgroups considered, using the number of infants requiring
a PICC as the weight for each group.
Time horizon
The EVPI and EVPPI are calculated over a time horizon of 10 years, assuming a constant incident
population. The value related to future incident populations was discounted to present values at
3.5% per annum.72
Results
Expected value of perfect information
The EVPI for the annual population of preterm babies who require a PICC is £274,126, or 13.71
QALYs, at the cost-effectiveness threshold of £20,000 per QALY gained. Over 10 years, the EVPI is
£2,359,587.27, or 117.98 QALYs. At a cost-effectiveness threshold of £13,000 per QALY, the EVPI is
£156,902.00, or 12.07 QALYs, per year, or £1,350,564.85, or 67.53 QALYs, over 10 years.
Expected value of partial perfect information
The main component of the EVPI is the RR parameter; its EVPPI is 99% of the EVPI of the decision.
At the cost-effectiveness threshold of £20,000 per QALY, the yearly EVPPI amounts to £268,430.00
(or 13.42 QALYs); over 10 years, it amounts to £2,310,564.28 (115.53 QALYs). At the cost-effectiveness
threshold of £13,000 per QALY, the EVPPI on the RR parameter is £151,490.00 (11.65 QALYs) per year,
and amounts to £1,303,974.33 (100.31 QALYs) over 10 years.
Summary of findings
Babies born preterm show a high level of resource use over the first 6 months of life, mainly driven by the
length of their stays in NICUs and hospital inpatient care (about 70 days on average). This translates to
an average total cost per infant of ≈£84,000, of which ≈£54,000 relates to neonatal care and ≈£27,000
relates to costs due to other hospital care during the hospitalisations. The costs of paediatric intensive
care, outpatient care and A&E appointments are much lower in comparison. There is no evidence that the
type of PICC has any impact on the intensity of hospital care, as measured by the HRGs, or on the length
of hospitalisation over the 6-month follow-up. This is consistent with the results of the PREVAIL trial, in
that the type of PICC had no effect on either the primary or the secondary outcomes.
Based on information from the trial and on a review of the external literature, a decision-analytic
model was built to determine the cost-effectiveness of AM-PICCs compared with S-PICCs, over a
baby’s lifetime. The key assumption of the model was that BSI is associated with an increase in the
risk of death and of developing NDI. Under this assumption, an intervention preventing BSI can reduce
total NHS costs and result in an increase in life expectancy and associated HRQoL, via a reduction in
both death and NDI cases.
Findings from the PREVAIL trial suggest that the AM-PICC increases costs and does not improve
quality-adjusted survival over the babies’ lifetimes. Therefore, the AM-PICC is not cost-effective.
Results are robust with respect to the key model assumptions, as tested through a series of scenarios
and sensitivity analyses, which further highlight the pivotal role of PICC effectiveness in driving the
model results. At current prices, it would be enough to reduce the probability of BSI by 3% to make
the AM-PICC a cost-effective intervention for babies born at 23–27 weeks’ gestational age.
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The VoI analysis suggests that, for the population of preterm babies in England and Wales eligible
to receiving the 1-French PICC under evaluation, the EVPPI on the RR is £2,310,564.28 over a time
horizon of 10 years. This does not represent the value of a RCT concerning the RR for this parameter;
instead, it represents the value of knowing this RR with perfect certainty, which may not be possible
with further research. This said, the EVPPI suggests that it is worthwhile to invest in additional
research on this parameter, which was the primary outcome of the PREVAIL trial.
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Chapter 5 Generalisability analysis
Introduction
The PREVAIL trial recruited 861 babies, over 17 months, from 18 NICUs out of a total of 43 NICUs
in England. However, if AM-PICCs were effective and adopted, they would be used in all babies who
receive the smallest PICC in neonatal care. This is because hospitals are likely to make a policy decision
about which PICCs to use and bulk purchase the same type of PICC for all babies who need one. To
make this purchasing decision, clinicians need to decide whether or not the results from the trial are
generalisable and applicable, and, if so, what is the absolute risk difference given that the baseline risk
of BSI may vary between babies and over time. Generalisability refers to whether or not the babies
in the PREVAIL trial were similar to the population from which they were drawn, that is, babies in
participating NICUs. Applicability refers to whether or not the relative effect can be applied to all
babies who receive PICCs in NNUs in England, that is, babies in LNUs in addition to babies in NICUs.
Results from the PREVAIL trial may not be generalisable to other babies in NICUs or applicable to
babies in LNUs for several reasons. First, babies in the PREVAIL trial may be treated differently from
other babies receiving PICCs in NICUs or LNUs because of trial participation; therefore, they may have
a different risk of BSI. Second, there could be differences in characteristics between participating and
non-participating babies (e.g. if babies in the PREVAIL trial have lower gestational ages) that were also
related to the effectiveness of the AM-PICC (e.g. if the AM-PICC was more effective in babies of a
younger gestational age). In this example, we would not be able to extend the results from the trial to
other babies in NICUs and LNUs. Third, if BSI risk factors and, hence, the baseline rate of BSI in babies
in the PREVAIL trial differed from other babies receiving PICCs in NICUs and LNUs, the absolute
benefit (or risk difference) would be different.
We sought the following evidence to indicate whether or not the relative effect of AM-PICCs was
likely to differ between subgroups. First, in post hoc analyses of the PREVAIL trial, the effect of
AM-PICCs did not differ between babies with a gestational age of < 28 weeks and babies with a
gestational age of ≥ 28 weeks (see Chapter 3, Primary outcome). Second, we compared risk factors
for BSI and causative organisms in PREVAIL babies randomised to receive S-PICCs with those of
other babies with PICCs in NICUs. The proposed mechanism for CVCs leading to BSI is microbial
colonisation of the CVC surface spreading to the bloodstream. Certain organisms are more sensitive
to the antimicrobials used to impregnate the AM-PICC, for example CoNS is more susceptible
to rifampicin–miconazole impregnation than Enterobacteriaceae.94 Therefore, differences in the
distribution of pathogens between PREVAIL and other babies could result in different effects of
AM-PICCs than those seen in the PREVAIL trial.
To determine whether or not the baseline rate of BSI differed in babies in the PREVAIL trial compared
with other babies receiving PICCs in NICUs and LNUs, we compared crude and risk-adjusted rates
during the PREVAIL trial recruitment period. Differences between these groups could reflect selection to
the trial based on unmeasured characteristics or different management of PREVAIL babies, resulting in
higher or lower rates of BSI in PREVAIL babies than in other babies in participating NICUs. For example,
despite the PREVAIL trial protocol requiring blood samples only when clinically necessary, samples may
have been taken more often in PREVAIL babies. This could result in detection of asymptomatic BSI or
contaminated blood samples that would otherwise not be detected in practice. Conversely, staff may
have followed hygiene protocols more closely for babies enrolled in the PREVAIL trial and, therefore,
the risk of BSI could be lower.
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We also examined trends in BSI over time. Rates of BSI may have declined since the start of the
trial because of improved infection control practices.12,48 Improvements in CVC care may reduce BSI
associated with PICCs, but have less effect on BSI due to other causes. To inform targeting of BSI
interventions, we determined the contribution of BSI during PICC use to the overall rate of BSI during
intensive or high-dependency care in NICUs and LNUs.
Aims and objectives
We aimed to determine whether or not rates of BSI in PREVAIL trial participants were generalisable
and applicable to all babies receiving PICCs in NICUs and LNUs in the NHS in England.
Objectives
l To determine the generalisability and applicability of the trial results by comparing BSI risk factors,
causative organisms and BSI rates among babies in the PREVAIL trial with those of other babies
receiving PICCs.
l To determine the applicability of BSI rates in the PREVAIL trial to rates of BSI in the NHS in
England by comparing trends in the rates of BSI in babies receiving PICCs in PREVAIL trial NICUs,
non-PREVAIL trial NICUs and LNUs.
l To provide context through understanding of changes in BSI over time by evaluating trends in rates
of BSI per 1000 days of intensive or high-dependency care and per 100 admissions for all babies
receiving intensive or high-dependency care in NICUs and LNUs.
l To determine the contribution of PICCs to the overall rate of BSI per admission during intensive
and high-dependency care.
The generalisability study originally aimed to predict the number of BSIs prevented and the reduction
in cost to the NHS if AM-PICCs were adopted and used in place of S-PICCs. This was not feasible,
because the PREVAIL trial detected no difference in the risk of BSI between AM-PICCs and S-PICCs,
and, based on these results, AM-PICCs are unlikely to be adopted. A further reason is that the cost of
BSI could not be calculated in the health economics study (see Chapter 4).
Methods
Data sources
There is no single data source to study risk-adjusted rates of BSI in NNUs in England. The NNRD
provides clinical data on babies in NICUs. Historically, data on BSI in the NNRD was poorly completed,
but entry of data on BSI is improving: 74 NNUs reported entering data on all positive cultures in 2017,
compared with 25 in 2016.16,109,110 PHE operate a national infection surveillance system, known as the
Second Generation Surveillance System. We linked these two data sources to create a linked data set
of babies in all available NICUs and LNUs (112/124) in England. A combination of deterministic and
probabilistic linkage methods were used to link babies recorded in the NNRD to records of BSI
reported to the national infection surveillance system during their NNU admission.111 The linkage
process is described in Appendix 12. In brief, deterministic links, based on an exact match on NHS
number, were used as reference standards to calculate match weights in probabilistic linkage, based on
agreement on postcode prefix, postcode suffix, date of birth, laboratory/hospital and sex.112 Match
weights were summed across each comparison pair and the frequency of the summed weights were
examined to determine an upper and lower threshold. Pairs with weights above the upper threshold
were classified as links, pairs with weights below the threshold were classified as non-links and pairs
between the two thresholds were manually reviewed (using rules presented in Appendix 12, Table 74).
Links identified in deterministic and probabilistic linkage were combined to produce a NNRD data set
enhanced with BSI from the national infection surveillance.
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Three NICUs [3/49 (6%)] and nine LNUs [9/78 (12%)] were excluded from our NNRD data. The number
of NNUs changed over time: there were 49 NICUs during the generalisability study period (2010–17),
but only 43 during the PREVAIL trial. Two NICUs and eight LNUs were excluded because we did
not receive responses to our requests for consent to linkage of their data. One NICU and one LNU
were excluded because of poor reporting of BSI in the surveillance data. A further three NICUs and
six LNUs had reporting gaps in the BSI surveillance data; we excluded months when reporting was
poor, but included periods with good reporting. We did not include any SCBUs and we restricted our
analyses of the linked data to babies receiving intensive or high-dependency care, as PICCs are not
routinely used in special care. Three LNUs became SCBUs during the trial period; they were removed
when they became SCBUs. We obtained data from the NNRD in two extractions, (1) March 2010
to December 2015 and (2) January 2016 to June 2017, which resulted in missing data for babies
admitted in the first extract but discharged in the second extract. More than 5% of baby days between
September 2015 and December 2015 were missing a discharge date, probably due to missing records
in 2016. We therefore excluded admissions during the 6 months between September 2015 and
February 2016. We excluded all babies who were missing a discharge date as we were unable to
correctly calculate time at risk.
Case definition
We defined BSI as a link to a record of positive blood or CSF culture reported to the national infection
surveillance system. Multiple cultures of the same organism from the same baby within 14 days were
classified as one episode. We use five terms to describe BSI depending on time at risk (Figure 10;
see also Appendix 20, Table 81):
1. BSI during PICC days at risk, which included BSI cultured in samples taken between 1 day after
PICC insertion and 2 days after PICC removal.
2. Early-onset BSI (no PICC), defined as BSI in babies aged < 2 days. If a baby had a PICC inserted on
the day of birth and a BSI on the following day, the BSI would be classified as during PICC days at
risk, not as early onset.
3. Late-onset BSI describes BSI from samples taken between 2 days of age and 2 days after discharge
from the NICU or LNU, given that the BSI is not during PICC days at risk.
4. Total late-onset BSI included BSIs that were either during PICC days at risk or late onset.
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FIGURE 10 Time at risk for PICC days at risk, early-onset BSI (no PICC) and late-onset BSI (no PICC).
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Our definition of PICC days at risk (see Figure 10 and Appendix 20, Table 81) differed slightly from
the definition used in the trial (see Figure 2), as we used linked infection surveillance data (not BSI
recorded on CRFs in the trial) to ensure comparability between PREVAIL babies and other groups.
Surveillance data do not record the exact time of blood or CSF culture sampling, and the NNRD
records whether or not a PICC was present each day, but not the time of insertion. Therefore,
we used 1 or 2 days, rather than 24 or 48 hours, to define the interval for samples related to
the PICC: 1 day after PICC insertion to 2 days after PICC removal (as recorded in the NNRD).
We categorised all organisms recorded in the surveillance data as ‘clearly pathogenic’ or ‘other’ with
the guidance of a microbiologist (JG). We used the term ‘clearly pathogenic organisms’ to indicate that
a BSI would be diagnosed without the requirement of repeat samples or clinical signs. A full list of
clearly pathogenic and other organisms is given in Appendix 13, Boxes 2 and 3. We restricted trend
analyses to clearly pathogenic organisms because of a change in the surveillance system in 2014 that
resulted in a sharp increase in the reporting of organisms with uncertain clinical significance (e.g. skin
commensals) (see Appendix 14, Table 75 and Figure 25).
Identifying babies in the PREVAIL trial
We linked babies who were randomised to receive S-PICCs in the PREVAIL trial to the NNRD. We
used deterministic linkage on NHS number or postcode, sex and date of birth. We excluded babies
randomised to receive AM-PICCs in the PREVAIL trial and any babies who had no daily records of
intensive or high-dependency care, were present only in months excluded because of missing NNRD
days between 2015 and 2016, were present only in months excluded because of poor BSI reporting,
had missing discharge dates, or had no record of receiving a PICC. We compared the distribution of
baseline baby characteristics [gestation, admission to surgical NICU, sex and small for gestational age
(birthweight in the < 10th centile for gestation)] using the chi-squared test to determine whether or
not there was a significant difference (p < 0.05) between included and excluded PREVAIL babies.
Generalisability and applicability
To determine the generalisability of results of the PREVAIL trial to other babies in NICUs, we
compared babies admitted to NICUs who were randomised to receive S-PICCs in the PREVAIL trial
with babies who received S-PICCs in the PREVAIL trial NICUs who were not enrolled in the trial, and
those in non-PREVAIL trial NICUs, during the recruitment period. Approximately 10% of babies were
admitted to more than one NICU or LNU. We evaluated admissions to NNUs, rather than evaluating
babies, to ensure that BSI, PICC days and other clinical factors were attributed to the correct NICU
or LNU. To determine applicability, we extended the comparison of PREVAIL babies to babies receiving
S-PICCs in LNUs during the recruitment period. We compared the prevalence of baby and clinical
characteristics, causative organisms and the rate of BSI per 1000 PICC days during the PREVAIL trial
recruitment period (August 2015 to January 2017). We used the start and end date specific to each
participating NICU, as these dates varied between units. For non-PREVAIL trial NICUs and LNUs, we
included the total recruitment period. We also compared trends in rates of BSI per 1000 PICC days
from March 2010 to June 2017.
Comparing clinical characteristics in PREVAIL and non-PREVAIL babies
We compared the prevalence of clinical characteristics in the following babies: those receiving S-PICCs
who were enrolled in the PREVAIL trial, those who were in a PREVAIL trial NICU but not enrolled
in the PREVAIL trial, those who were in a non-PREVAIL trial NICU and those who were in a LNU.
The characteristics we included were gestational age at birth (in weeks), sex, small for gestational age,
age (in days) at first PICC insertion, PICC days per admission, invasive ventilation days per admission,
non-invasive ventilation days per admission and whether or not the NICU provided surgery. We tested
for a significant difference (p < 0.05) in the distribution of the characteristics between babies not
enrolled in PREVAIL trial NICUs, babies in non-PREVAIL trial NICUs or LNUs and PREVAIL babies,
using the chi-squared test.
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Comparing causative organisms in PREVAIL and non-PREVAIL trial neonatal
intensive care units and local neonatal units
We compared the distribution of causative organisms in PREVAIL trial NICUs, non-PREVAIL trial
NICUs and LNUs. In these analyses, we grouped together all babies admitted to NICUs who were
participating in the PREVAIL trial, whether or not they were enrolled in the trial, to avoid small cell
counts that could be disclosive. We used the chi-squared test to determine whether or not there was a
significant difference (p < 0.05) in the distribution of organisms in non-PREVAIL trial NICUs or LNUs,
in comparison to PREVAIL trial NICUs.
Comparing rates of bloodstream infection during the PREVAIL trial in PREVAIL
and non-PREVAIL babies
We calculated BSI rates per 1000 PICC days for BSI during PICC days at risk during the PREVAIL
period separately for all BSI and BSI caused by clearly pathogenic organisms (listed in Appendix 13,
Box 2). We calculated risk-adjusted rates of BSI using forward stepwise multilevel Poisson regression
to decide which baby characteristics (gestational age at birth in weeks, small for gestational age,
age in days at first PICC insertion, invasive ventilation days per admission, non-invasive ventilation
days per admission, and whether or not the NICU provided surgery) were significant risk factors for
BSI. We considered the risk factor significant if the 95% CI did not include 1. NNU was included as a
random effect to account for clustering of admissions in NNUs.
Changes over time in bloodstream infection rates in PREVAIL and non-PREVAIL
trial neonatal intensive care units and local neonatal units
To determine trends from March 2010 to June 2017, we calculated the rates of BSI per 1000 PICC
days per month of admission for BSI caused by clearly pathogenic organisms during PICC days at risk.
We used forward stepwise regression to decide which covariates (as mentioned previously) were
significant in the trend analysis, as significant risk factors may differ from the model restricted to
the PREVAIL trial period. We included an interaction between NNU group (PREVAIL trial NICU, non-
PREVAIL trial NICU and LNU) and month to allow for different trends in BSI rate between the groups.
Trends were modelled per admission month, but results are presented per year to aid interpretation.
Trends in rates of bloodstream infection in all babies admitted to neonatal intensive
care units and local neonatal units
To contextualise the trial, we extended the analyses to include all babies who received intensive
and high-dependency care in NICUs and LNUs, regardless of whether they received a PICC. First,
we examined how BSI risk factors had changed from 2010 to 2017 for all babies who received
high-dependency or intensive care in LNUs and NICUs. Second, we evaluated trends in total
late-onset BSI per 1000 days of intensive and high-dependency care days and per 100 admissions.
Changes over time in bloodstream infection risk factors
We examined how risk factors have changed over time in babies receiving intensive or high-
dependency care in NICUs and LNUs from 2010 to 2017 by plotting the proportion of babies admitted
to NICUs and LNUs according to gestational age at birth, grouped as: < 26, 26 to < 28, 28 to < 32,
32 to < 37, and ≥ 37 weeks. We plotted the mean number of days of stay, PICC days, central line
days, non-invasive ventilation days, invasive ventilation days, and age in days at first PICC insertion
by gestational age in weeks in 2010 and 2017. We used two-way analysis of variance (ANOVA) to
determine whether or not the mean of each risk factor was significantly different (p < 0.05) by
week of gestation in 2010 compared with 2017.
Changes over time in total late-onset bloodstream infection
We evaluated the change over time in rates of total late-onset BSI per 1000 intensive and high-
dependency care days and per 100 admissions. In the model per 100 admissions, we included only the
first BSI per admission to evaluate whether or not the number of admissions in which a baby develops
a BSI has changed over time. We modelled late-onset BSI rates by month of admission restricted to
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clearly pathogenic organisms. For each model, we used forward stepwise multilevel Poisson regression
to identify significant risk factors. We included an interaction between NNU group (PREVAIL trial
NICU, non-PREVAIL trial NICU and LNU) and month to allow for different trends in BSI rate between
the groups.
The contribution of peripherally inserted central venous catheters to total bloodstream infection
We calculated the proportion of total BSI that was early onset (no PICC), during PICC days at risk
or late onset (no PICC). We included BSI caused by all organisms for the period of August 2015 to
June 2017. We excluded the period before the start of the PREVAIL trial to give an up-to-date snapshot
of recent BSI and to ensure that results were not affected by the change in surveillance methodology
in 2014. To determine the contribution of PICCs to the overall rate of BSI per admission, we first
calculated the BSI rate per admission for early-onset BSI (no PICC), BSI during PICC days at risk and
late-onset BSI (no PICC), for all babies admitted to NICU or LNUs and stratified by gestation at birth
(< 32 or ≥ 32 weeks).
Results
Identifying babies in the PREVAIL trial
We identified 423 babies in the NNRD out of the 431 babies recorded as randomised to receive the
S-PICC in the PREVAIL trial CRFs. All babies randomised to receive the AM-PICC in the PREVAIL
trial were excluded from the generalisability analyses using linked data from the NNRD. We included
269 out of 423 (64%) babies randomised to S-PICCs (see Appendix 21, Figure 26). The reasons for
excluding 154 babies were as follows: present only in months excluded because of missing days
between 2015 and 2016 (n = 97), present only in months excluded because of poor BSI reporting
(n = 24), missing discharge dates (n = 2) and no recording of PICCs (n = 31). Only 16 babies randomised
to S-PICCs were recorded as not receiving a PICC in the PREVAIL trial CRFs. Therefore, 15 of the
31 babies with no PICC recorded in the NNRD (4% of the total of 423 babies) had a PICC recorded in
the trial CRFs but not in the NNRD. There were no significant differences in the distributions of gestation,
small for gestational age or sex between the 269 babies with S-PICCs included in our analysis and the
154 excluded PREVAIL babies for whom we had baseline data available (see Appendix 15, Table 76).
Excluded babies were significantly less likely to be in surgical NICUs. Eighteen NICUs participated in the
PREVAIL trial; however, only 16 were included in our analysis, as one NICU did not consent to linkage
of its data and one was excluded because the corresponding laboratory was a poor reporter during the
PREVAIL trial period.
Generalisability and applicability
Peripherally inserted central venous catheters were used for at least 1 day in 8443 admissions
involving 8206 babies receiving intensive and high-dependency care during the PREVAIL trial period
(August 2015 to January 2017) (see Appendix 25, Figure 35).
Comparing baby and clinical characteristics in PREVAIL and non-PREVAIL babies
Comparing babies in the PREVAIL trial with babies in the same NICUs who were not enrolled in
the PREVAIL trial and with babies in other NICUs, more of the PREVAIL babies were born before
32 weeks of gestation, received invasive ventilation and were admitted to a surgical unit (Tables 21 and
22). Admissions to NICUs not in the PREVAIL trial had an earlier median age at first PICC insertion
than PREVAIL babies. Use and duration of non-invasive ventilation were significantly higher in NICUs
not participating in the PREVAIL trial and in LNUs than among PREVAIL babies (see Table 22). Babies
enrolled in the PREVAIL trial were more likely to be born before 32 weeks of gestation, to be older
when a PICC was inserted, to retain the PICC for longer, to be small for gestational age and to have
more days of ventilation than babies in LNUs (see Tables 21 and 22).
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TABLE 21 Comparison of baby characteristics of babies who received S-PICCs in NICUs and LNUs according to
enrolment in the PREVAIL trial during the PREVAIL trial period
Characteristic
NICUs (n= 16) participating
in the PREVAIL trial
NICUs (n= 28) and LNUs
(n= 68) not participating









Total babies (n) 269 1608 3745 2358
Total admissions (n) 325 1522 4051 2460
Total PICC days (n) 3809 18,115 49,902 17,187
Gestation (weeks)
< 26, n (%) 73 (22) 235 (15) 776 (19) 40 (2)
26 to < 28, n (%) 91 (28) 195 (12) 804 (20) 253 (10)
28 to < 32, n (%) 136 (42) 488 (30) 1320 (33) 1374 (56)
32 to < 37, n (%) 17 (5) 378 (24) 614 (15) 610 (25)
≥ 37, n (%) 8 (2) 312 (19) 536 (13) 183 (7)
p-value (chi-squared test)a < 0.001 < 0.001 < 0.001
Small for gestational age, n (%) 62 (19) 251 (16) 640 (16) 358 (15)
p-value (chi-squared test)a 0.245 0.278 0.032
Male sex, n (%) 170 (52) 920 (57) 2203 (55) 1361 (55)
p-value (chi-squared test)a 0.094 0.423 0.283
Surgical NICU, n (%) 144 (44) 1037 (65) 2056 (51) N/A
p-value (chi-squared test)a < 0.001 0.025
N/A, not applicable.
a Chi-squared test comparing distribution of risk factors in each group with babies enrolled in the PREVAIL trial.
Note
Period for NICUs that participated in the PREVAIL trial depends on NICU start and end date of recruitment. Period for
other NICUs and LNUs is August 2015 to January 2017 (whole PREVAIL trial recruitment period).
TABLE 22 Comparison of clinical characteristics in babies who received S-PICCs in NICUs and LNUs, according to
enrolment in the PREVAIL trial during the PREVAIL trial period
Characteristic
NICUs (n= 16) participating
in the PREVAIL trial
NICUs (n= 28) and LNUs
(n= 68) not participating




PREVAIL trial NICU LNU
Age at first PICC (days)
0, n (%) 19 (6) 115 (7) 398 (10) 171 (7)
1–2, n (%) 56 (17) 410 (26) 1144 (28) 857 (34)
3–5, n (%) 104 (32) 482 (30) 1249 (31) 773 (31)
6–11, n (%) 77 (24) 318 (20) 707 (17) 385 (16)
≥ 12, n (%) 69 (21) 283 (18) 553 (14) 274 (11)
Median (IQR) 5 (3–9) 4 (2–7) 3 (1–7) 3 (2–6)
p-value (chi-squared test)a 0.013 < 0.001 < 0.001
continued
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Comparing causative organisms in PREVAIL and non-PREVAIL trial neonatal
intensive care units and local neonatal units
We found no differences in the distribution of organisms between PREVAIL trial NICUs, non-PREVAIL
trial NICUs and LNUs (see Appendix 22, Table 82). CoNS was the most prevalent organism in all NICUs
and LNUs.
TABLE 22 Comparison of clinical characteristics in babies who received S-PICCs in NICUs and LNUs, according to
enrolment in the PREVAIL trial during the PREVAIL trial period (continued )
Characteristic
NICUs (n= 16) participating
in the PREVAIL trial
NICUs (n= 28) and LNUs
(n= 68) not participating




PREVAIL trial NICU LNU
PICC days per admission
1–4, n (%) 72 (22) 461 (29) 905 (22) 863 (35)
5 or 6, n (%) 59 (18) 199 (12) 571 (14) 497 (20)
7 or 8, n (%) 37 (11) 217 (14) 575 (14) 445 (18)
9–12, n (%) 59 (18) 281 (17) 786 (19) 409 (17)
≥ 13, n (%) 98 (30) 450 (28) 1214 (30) 246 (10)
Median (IQR) 8 (5–15) 8 (4–14) 8 (5–14) 6 (4–9)
p-value (chi-squared test)a 0.015 0.249 < 0.001
Invasive ventilation days per admission
0 75 (23) 456 (28) 1045 (26) 1368 (56)
1–4, n (%) 107 (33) 523 (33) 1428 (35) 904 (37)
5–8, n (%) 37 (11) 229 (14) 520 (13) 129 (5)
9–12, n (%) 23 (7) 116 (7) 282 (7) 30 (1)
≥ 13, n (%) 83 (26) 284 (18) 776 (19) 29 (1)
Median (IQR) 3 (1–14) 3 (0–8) 3 (0–9) 0 (0–2)
p-value (chi-squared test)a 0.010 0.089 < 0.001
Non-invasive ventilation days per admission
0, n (%) 54 (17) 528 (33) 878 (22) 520 (21)
1 to 5, n (%) 59 (18) 397 (25) 1034 (26) 783 (32)
6 to 15, n (%) 63 (19) 267 (17) 783 (19) 622 (25)
16 to 49, n (%) 107 (33) 320 (20) 1035 (26) 466 (19)
≥ 50, n (%) 42 (13) 96 (6) 321 (8) 69 (3)
Median (IQR) 14 (3–34) 3 (0–16) 6 (1–24) 5 (1–13)
p-value (chi-squared test)a < 0.001 < 0.001 < 0.001
a Chi-squared test comparing distribution of risk factors in each group to babies enrolled in the PREVAIL trial.
Note
Period for NICUs that participated in the PREVAIL trial depends on NICU start and end date of recruitment. Period for
other NICUs and LNUs is August 2015 to January 2017 (whole PREVAIL trial recruitment period).
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Comparing rates of bloodstream infection during the PREVAIL trial in
PREVAIL and non-PREVAIL babies
Crude and risk-adjusted rates of BSI per 1000 PICC days were similar in PREVAIL babies compared
with non-PREVAIL babies in the PREVAIL trial NICUs and babies in non-PREVAIL trial NICUs (Figure 11)
(see Appendix 23, Table 83 and Figure 27). BSI rates were lower in LNUs; however, the difference between
babies in LNUs and babies enrolled in the PREVAIL trial was not significant. The risk factors included
in the risk-adjusted model were gestational age at birth, age at fist PICC, and days of invasive and
non-invasive ventilation. Full details of model-building are presented in Appendix 16, Table 77.
Changes over time in bloodstream infection rates in PREVAIL and non-PREVAIL
trial neonatal intensive care units and local neonatal units
From March 2010 to June 2017, there were 55,058 admissions involving 47,669 babies who received
PICCs (see Appendix 25, Figure 36). There was no significant change in the risk-adjusted rates of BSI per
1000 PICC days in PREVAIL trial NICUs, non-PREVAIL trial NICUs or LNUs (Table 23 and Figure 12).
The trend in non-PREVAIL trial NICUs was not significantly different at the 5% level from the trend
in PREVAIL trial NICUs or LNUs. The selected model adjusted for gestational age at birth and days of
invasive and non-invasive ventilation (see Appendix 17, Table 78).
Trends in rates of bloodstream infection in all babies admitted to neonatal intensive care
units and local neonatal units
Changes over time in bloodstream infection risk factors
Risk factors for BSI changed from 2010 to 2017 in babies who received intensive or high-dependency
care in NICUs and LNUs. First, the proportion of babies born at term or later (≥ 37 weeks’ gestation)
increased over time (see Appendix 24, Figure 28). The proportion of babies born at 32 to < 37 weeks
and at < 26 weeks of gestation remained fairly stable, but the proportion born at 28 to < 32 weeks
and at 26 to < 28 weeks of gestation declined. Second, patterns of care between NICUs and LNUs
changed. Extremely preterm babies (< 28 weeks’ gestation) had longer stays in LNUs (see Appendix 24,
Figure 29), but fewer PICC and central line days in LNUs in 2017 than in 2010. By contrast, babies in
0
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p = 0.184 p = 0.875 p = 0.684
Non-PREVAIL babies
FIGURE 11 Crude and risk-adjusted rates of BSI (for all organisms) per 1000 PICC days in babies who received S-PICCs in
NICUs and LNUs, according to enrolment in the PREVAIL trial during the PREVAIL trial period. Adjusted for gestational
age at birth, age at first PICC, and days of invasive and non-invasive ventilation. p-value for effect of group (PREVAIL
babies in NICU, babies in non-PREVAIL trial NICUs, babies in LNUs) on BSI rate in comparison to babies in the PREVAIL
trial. Period for NICUs that participated in the PREVAIL trial depends on NICU start and end date of recruitment; period
for other NICUs and LNUs is August 2015 to January 2017 (whole PREVAIL trial recruitment period).
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NICUs had more PICC days in 2017 than in 2010 (see Appendix 24, Figures 30 and 31). In both LNUs
and NICUs, babies born at ≥ 32 weeks of gestation had fewer PICC and central line days in 2017 than
in 2010. Across all gestational ages, PICCs were first inserted at a younger age in 2017 than in 2010
(see Appendix 24, Figure 32). Third, extremely preterm babies in LNUs had more days with non-invasive
ventilation and fewer days with invasive ventilation in 2017 than in 2010 (see Appendix 24, Figures 33
and 34).
TABLE 23 The unadjusted and risk-adjusted annual percentage change in rate of BSI (clearly pathogenic organisms)
during PICC days at risk per 1000 PICC days in PREVAIL trial NICUs, non-PREVAIL trial NICUs and LNUs from
March 2010 to June 2017
Clearly pathogenic BSI




NICUs (n= 28) LNUs (n= 68)
Babies (n) 14,667 21,267 15,594
Admissions (n) 15,927 23,537 14,892
Number of PICC days 195,360 296,824 121,750
Number of BSIs 495 736 211
Unadjusted
BSI rate (95% CI) 2.53 (2.31 to 2.76) 2.48 (2.30 to 2.66) 1.73 (1.50 to 1.97)
Annual percentage change
(95% CI)
2.33% (–1.98% to 6.82%) 2.14% (–1.32% to 5.72%) –5.14% (–11.10% to 1.22%)
p-valuea 0.972 0.093
Risk-adjustedb
BSI rate (95% CI) 2.50 (2.28 to 2.72) 2.44 (2.26 to 2.62) 1.64 (1.41 to 1.87)
Annual percentage change
(95% CI)
2.73% (–1.62% to 7.27%) 2.63% (–0.86% to 6.25%) –2.19% (–8.37% to 4.40%)
p-valuea 0.969 0.202
a p-value comparing trend with that of PREVAIL trial NICUs.
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FIGURE 12 Risk-adjusted rate of BSI (clearly pathogenic organisms) during PICC days at risk per 1000 PICC days, by
year of admission in PREVAIL trial NICUs, non-PREVAIL trial NICUs and LNUs. Adjusted for gestational age at birth
and days of invasive and non-invasive ventilation. Shading denotes the period of enrolment in the PREVAIL trial.
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Changes over time in total late-onset bloodstream infection
From March 2010 to June 2017, there were 161,117 admissions (see Appendix 25, Figure 37) who
were at least 2 days old or had a PICC inserted on their day of birth; 2.4% (3798) of these admissions
had at least one total late-onset BSI caused by clearly pathogenic organisms. The overall rate was
2.3 (4170/1,849,611) per 1000 days of intensive and high-dependency care.
Risk-adjusted rates of total late-onset BSI (clearly pathogenic organisms) per 1000 days of intensive
and high-dependency care remained stable in PREVAIL and non-PREVAIL trial NICUs, but decreased
in LNUs (Table 24 and Figure 13). These rates were adjusted for gestational age at birth and days of
invasive and non-invasive ventilation (see Appendix 18, Table 79). Risk-adjusted, total late-onset BSI
TABLE 24 The annual change in the rate of late-onset BSI (pathogens) per 1000 days of intensive and high-dependency





NICUs (n= 28) LNUs (n= 68)
Babies (n) 37,497 53,967 58,320
Admissions (n) 40,787 58,845 61,485
Number of days 558,303 813,776 477,532




Total late-onset BSI per 1000 intensive and high-dependency care days
Unadjusted
BSI rate (95% CI) 2.38 (2.25 to 2.51) 2.20 (2.10 to 2.30) 2.20 (2.07 to 2.33)
Annual percentage change
(95% CI)
–1.87% (–4.46% to 0.80%) 1.68% (–0.58% to 3.99%) –4.44% (–7.21% to –1.59%)
p-valuea 0.036 0.233
Risk-adjustedb
BSI rate (95% CI) 2.30 (2.18 to 2.43) 2.18 (2.08 to 2.28) 2.11 (1.98 to 2.24)
Annual percentage change
(95% CI)
–1.40% (–4.01% to 1.29%) 2.20% (–0.07% to 4.52%) –2.91% (–5.73% to 0.00%)
p-valuea 0.035 0.342
Total late-onset BSI per 100 admissionsc
Unadjusted
Total late-onset BSI per
100 admissions (95% CI)
2.92 (2.75 to 3.08) 2.74 (2.61 to 2.87) 1.62 (1.52 to 1.72)
Annual percentage change
(95% CI)
–4.84% (–7.48% to –2.12%) –0.60% (–2.90% to 1.75%) –7.12% (–9.88% to –4.28%)
p-valuea 0.015 0.565
Risk-adjustedb
Total late-onset BSI per
100 admissions (95% CI)
2.83 (2.67 to 2.99) 2.66 (2.53 to 2.79) 1.56 (1.46 to 1.65)
Annual percentage change
(95% CI)
–2.86% (–5.57% to –0.08%) 1.44% (–0.93% to 3.86%) –3.28% (–6.16% to –0.32%)
p-valuea 0.015 0.774
a p-value comparing trend with that of PREVAIL trial NICUs.
b Adjusted for gestational age at birth and for days of invasive and non-invasive ventilation.
c Only one BSI counted per admission.
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rates per 100 admissions (clearly pathogenic organisms) declined significantly in PREVAIL trial NICUs
and LNUs (Table 24 and Figure 14). These rates were adjusted for gestation and for days of invasive
and non-invasive ventilation (see Appendix 19, Table 80).
Rates of total late-onset BSI per 100 admissions were lower in LNUs than in NICUs, whereas rates of
total late-onset BSI per 1000 days of intensive and high-dependency care were similar. This discrepancy
shows that the denominator has an important effect on rates and on trends. In this example, Table 24
shows a similar number of admissions in LNUs and non-PREVAIL trial NICUs, but LNU admissions
were shorter, with fewer days of intensive and high-dependency care (477,532 in LNUs, compared
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FIGURE 13 Risk-adjusted rate of total late-onset BSI (pathogens) per 1000 intensive and high-dependency care
days of stay, by year of admission in PREVAIL trial NICUs, non-PREVAIL trial NICUs and LNUs. Rates are adjusted for
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FIGURE 14 Risk-adjusted rate of late-onset BSI (pathogens) per 100 admissions, by year of admission in PREVAIL trial
NICUs, non-PREVAIL trial NICUs and LNUs. Rates are adjusted for gestational age at birth and for days of invasive and
non-invasive ventilation; only the first BSI per admission was included.
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The contribution of peripherally inserted central venous catheters to total bloodstream
infection rates
There was a total of 2476 BSIs in 40,008 admissions receiving intensive and high-dependency care in
NICUs and LNUs during the PREVAIL trial recruitment and follow-up period (August 2015 to June
2017): 18% (456) were early onset (no PICC), 46% (1143) were late onset during PICC days at risk,
and the remaining 35% (877) were late onset (no PICC) (Table 25). Early-onset BSI was the most
frequent type of BSI in babies born at ≥ 32 weeks’ gestation, whereas BSI during PICC days at risk
was most frequent in babies born before 32 weeks’ gestation.
TABLE 25 The BSI rate and proportion of total BSIs (all organisms) per 100 admissions for babies receiving intensive or
high-dependency care in NICUs and LNUs from August 2015 to June 2017
Admissions
Early onset (no PICC,
< 2 days of age)
During PICC days
at risk
Late onset (no PICC,




Number of admissions 31,107 12,291 26,969 40,008
Number of BSIs (% of total BSIs) 456 (18) 1143 (46) 877 (35) 2476 (100)
BSI rate per 100 admissions
(95% CI)
1.5 (1.3 to 1.6) 9.3 (8.8 to 9.8) 3.3 (3.0 to 3.5) 6.2 (6.0 to 6.4)
Admissions born before 32 weeks’ gestation
Number of admissions 8891 8373 11,145 13,237
Number of BSIs (% of total BSIs) 130 (8) 939 (55) 631 (37) 776 (100)
BSI rate per 100 admissions
(95% CI)
1.5 (1.2 to 1.7) 11.2 (10.5 to 11.9) 5.7 (5.2 to 6.1) 12.8 (12.3 to 13.4)
Admissions born at 32 weeks’ gestation or later
Number of admissions 22,161 3918 15,824 26,771
Number of BSIs (% of total BSI) 326 (42) 204 (26) 246 (32) 776 (100)
BSI rate per 100 admissions
(95% CI)
1.5 (1.3 to 1.6) 5.2 (4.5 to 5.9) 1.6 (1.4 to 1.7) 2.9 (2.7 to 3.1)
Notes
Admissions who were counted in early onset received intensive or high-dependency care before 2 days of age.
Admissions who were counted in PICC days at risk received a PICC. Admissions counted in late onset received
intensive or high-dependency care at ≥ 2 days of age.
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Main findings
Clinical effectiveness randomised controlled trial
We found no evidence of benefit or harm from rifampicin- and miconazole-impregnated PICCs in babies
receiving intensive or high-dependency neonatal care. The 95% CI for the primary outcome excluded a
27% reduction or 67% increase in the time to BSI associated with using an AM-PICC, compared with
using a S-PICC. Sensitivity analyses did not change these results. We found no differences in mortality
at 6 months, or in clinical outcomes recorded at discharge home from the NNU.
Economic analysis
Preterm babies in the PREVAIL trial had an average hospital cost of approximately £84,000 over
6 months, mostly related to critical care in the neonatal care unit. The economic model predicted
that preventing BSI is both beneficial, as it generates QALY gains, and cost-saving. As AM-PICCs were
found in the PREVAIL trial not to prevent BSIs, the model found that AM-PICCs are not cost-effective.
At the current price, AM-PICCs would be cost-effective if they achieved a RR reduction of 3% in BSI
rate for babies born at < 28 weeks of gestation, or a reduction of 15% for babies born at ≥ 28 weeks
of gestation. The largest driver of uncertainty on the costs and health outcomes is whether or not
there is any differential effect between AM-PICCs and S-PICCs in preventing BSIs.
Generalisability analysis
The trial findings were generalisable to babies in NICUs in England. This was based on the fact that
there were no differences between babies enrolled in the PREVAIL trial and other babies receiving
PICCs in NICUs. We found no differences at the 5% level in the distribution of causative organisms
isolated from BSI, or in crude and adjusted rates of any BSI per 1000 PICC days. In addition, post hoc
trial analyses found no evidence for an interaction between the primary outcome (HR for time to
first BSI) and birth before 28 weeks of gestation compared with birth at ≥ 28 weeks of gestation,
suggesting that the relative effect observed in the trial could be generalised to babies receiving PICCs,
despite varying gestational ages at birth.
We found stable trends in rates over time in BSI per 1000 PICC days (for clearly pathogenic organisms)
in PREVAIL trial NICUs, non-PREVAIL trial NICUs and LNUs from 2010 to 2017. The rate of late-onset
BSI (for clearly pathogenic organisms) per 100 admissions declined from March 2010 to June 2017 in
LNUs and PREVAIL trial NICUs.
Overall, late-onset BSI during PICC days at risk accounted for 46% of BSIs during days of stay for
babies admitted to NICUs or LNUs who received intensive or high-dependency care. Corresponding
proportions for babies born before and after 32 weeks of gestation were 55% and 26%, respectively.
These findings demonstrate that the time when a PICC is present is a high-risk period for BSI; they do
not demonstrate that PICCs are necessarily a cause of BSI.
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Clinical effectiveness randomised controlled trial
Strengths and limitations
The trial was adequately powered to detect a halving of the BSI risk and included a representative
sample of babies receiving PICCs. The trial provides important new evidence for preterm infants born
before 32 weeks of gestation, a group at high risk of infection, with frequent use of PICCs, but for
whom trial evidence has been lacking.29,30 The pragmatic design reflected routine practice, as we had
no additional sampling, and used a primary outcome that is routinely used to guide antibiotic treatment
in neonatal care.
A further strength was the implementation of the trial. Central web-based randomisation ensured
allocation concealment and balanced treatment allocation. We achieved near complete follow-up and
assessment for the primary outcome, adhered to a prespecified statistical analysis plan for intention-
to-treat analyses and halted recruitment once the sample size was achieved. Slightly fewer babies in
the antimicrobial arm received the allocated PICC, probably because the randomised PICC had to be
inserted within 48 hours, thereafter the standard PICC was used. The sample size and statistical
analysis methods were based on the proportional hazards assumption, which was reasonably upheld.
One limitation was that the intervention was open label, so clinicians could distinguish the type of
PICC. We found a slightly increased rate of blood culture sampling in the antimicrobial arm, but the
proportions of babies with at least one sample or any PICC tip culture were similar and there were
no differences in the timing of PICC removal between trial arms. A further limitation was the lack of
power to detect significant differences in rifampicin-resistant organisms isolated from blood or CSF
cultures. The small number of resistant organisms was due to few positive cultures, and because only
44–54% of these cultures were tested for rifampicin resistance. The risk of rifampicin resistance in
isolates from positive blood or CSF cultures did not differ between trial arms, but was significantly
increased in positive tip cultures from AM-PICCs. Selection of rifampicin-resistant Gram-positive
bacteria during treatment, when rifampicin is used as the sole antibacterial agent, is well recognised.113
Testing for resistant organisms was considered by the investigators, the TSC and the IDSMC, but the
resistance results were not monitored as the risk of AEs arising was viewed as being low because the
limited release of rifampicin from the catheter surface would be unlikely to affect bacteria at any site
other than the catheter itself. Even if rifampicin-resistant Gram-positive bacteria did cause infection in
an individual patient, routine antibiotic use would be unaffected because rifampicin is rarely used for
treatment in the neonatal setting.
Findings in context
The finding that rifampicin- and miconazole-impregnation did not reduce BSI is consistent with other
studies (see Table 1).1,30,36,37 In contrast, RCTs of the effectiveness of minocycline- and rifampicin-
impregnated CVCs versus standard CVCs have reported substantial reductions in catheter-related
BSIs and, in one trial in PICUs, any BSI.33,34,114 First, these apparent differences in the effectiveness
of rifampicin–miconazole and minocycline–rifampicin impregnation may reflect true differences in
antibacterial effects. Miconazole is used to prevent invasive fungal infection in preterm babies, but has
the disadvantage that rifampicin is then the sole antibacterial agent when combined with miconazole.
Rifampicin is more active against Gram-positive than against Gram-negative bacteria and has synergistic
action against staphylococci when combined with another antibacterial such as minocycline, especially
against meticillin-resistant strains.113,115
Second, it is possible that, although minocycline–rifampicin is the most effective type of antimicrobial
impregnation in systematic reviews,32,35 this type of impregnation might not effectively reduce overall
rates of BSI or sepsis.116 Trials in adults show beneficial effects of antimicrobial impregnation for
catheter-related BSI, but few trials measure the effect on any BSI. Catheter-related infection requires
the same isolates from blood and CVC tip and could be biased because of inhibition of positive tip
cultures by leaching of antimicrobial from the tip during plating-out for culture. Only the large CATCH
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trial used any clinically indicated BSI as the primary outcome and found a 57% reduction in time to
infection (see Table 1)34,38 Third, the reductions in infection rates in NNUs associated with improved
catheter asepsis practices and shorter duration of PICC use may have narrowed the potential for
further benefits from antimicrobial impregnation.47 It is also possible that PICCs are not an independent
risk factor for infection in sick preterm babies because of the babies’ high susceptibility to infection
from multiple sources, including numerous invasive procedures and devices, gut permeability and
immune immaturity.117
Practice context
Since 2012, the Premistar PICC has been the only AM-PICC available for preterm babies in Europe.
Its use has been reported in Germany and Italy,30 but use in the UK was limited to the PREVAIL trial.
We are not aware of adoption of the AM-PICC by any UK NNUs outside the context of the trial.
Economic evaluation
Strengths and limitations
The aim of the economic evaluation was to inform the decision of whether or not the NHS should
purchase AM-PICCs rather than S-PICCs for preterm babies in NNUs. The specific objectives were
to estimate the hospital costs of the PREVAIL babies over the time horizon of the trial, to determine
the cost-effectiveness of AM-PICCs against S-PICCs and the minimum effectiveness of an AM-PICC
required to make it cost-effective, and to assess the value of future research.
The use of routine health-care data to estimate the hospital costs of the PREVAIL babies was a
strength of the economic evaluation. The economic evaluation secured access to the routine databases
that record admissions to NNUs and to PICUs, hospitalisations involving procedures, outpatient
appointments and visits to the A&E department. Accessing data from all these routine databases
ensured that the estimation of hospital costs was as thorough as possible. It maximised the accuracy of
the data on hospital use by avoiding recall bias and by having access to data on the resources involved
with each hospitalisation. Furthermore, using routine health-care data precluded asking the parents
and guardians to fill in lengthy questionnaires on the number and duration of hospitalisations at a time
of personal distress.
A key strength of the economic evaluation was the development of a new decision-analytic model to
predict the quality-adjusted life expectancy and NHS costs of using AM-PICCs or S-PICCs over the
babies’ expected lifetimes. The model synthesised the most up-to-date estimates of costs and outcomes
of BSI in infants in the neonatal care unit, informed by data from the PREVAIL trial linked to routine
health-care databases, and from the published literature. The model also considered the different risks
associated with gestational age.118 Although the model was developed to compare PICC types, it can
be used to evaluate any interventions to prevent BSI in babies by estimating the minimal reduction
in the risk of BSI that is required so that an intervention could be considered cost-effective, and the
relationship between minimal risk reduction and maximum price difference.
A further strength is the use of the economic model to estimate the VoI from future research.
Specifically, the VoI analysis quantified the magnitude of the health losses following a wrong adoption
decision due to parameter uncertainty, the maximum bound of investment that should be warranted to
resolve this uncertainty and the key uncertain parameters for which resolving uncertainty will provide
the greatest reduction in the risk of making suboptimal decisions.
There were several limitations to the economic analysis. First, it was not possible to estimate the
causal effect of BSI and death on hospital costs over 6 months from PICC insertion, and the causal
effect of BSI on the risk of death at 6 months. This was because of the lack of difference between
PICC groups (precluding an instrumental variable approach), limited number of events and time
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constraints (given that the routine health-care data were received 3 months before the project’s
deadline). Consequently, the model base case assumes that babies incur the same costs irrespective of
BSI or survival status, and assumes that BSI does not cause death at 6 months (although it includes an
increased risk of death due to BSI at 2 years). As a consequence, the benefits of preventing BSI may
be underestimated.
Second, the model assumes that BSI increases the risk of death and NDI at 2 years of age. The
evidence of this causal link was based on the published literature, which, given the enormity of the
potential evidence base, was identified from a citation search rather than from a systematic review,
which would have been outside the scope and timeline of the project. As a consequence, there is a
risk of having omitted some studies in the final evidence review and meta-analysis. Nonetheless, the
starting point for the citation search (the so-called ‘pearls’) was informed by the PREVAIL trial clinical
team, and great care was taken in matching the outcomes identified in the literature review with
those collected in the trial. Moreover, the citation search identified three systematic reviews and one
umbrella review, published between 2013 and 2016,78–80,119 thereby providing some reassurance that
most, if not all, of the relevant studies were included. The literature on the link of BSI to death and
NDI is necessarily observational, and scarce. If this link is not causal, or if it is smaller in magnitude,
the value of preventing BSI may have been overestimated. Therefore, the minimum risk reduction for
interventions, such as an AM-PICC, to be cost-effective may have been underestimated. This structural
uncertainty was explored in the scenario analysis, but was not considered in the VoI framework. This
means that the value of future research in the effectiveness of interventions to prevent BSI may have
been overestimated, compared with the value of future research on the causes of NDI and death in
early years.
Third, the model structure constrains the impact of preventing BSI in increasing the risk of NDI and
death at 2 years of age. There are some studies suggesting that antibiotics, given to treat infection,
increase the risk of NEC, which would, in turn, increase the risk of NDI.25,26,120 However, no studies
were identified that enable the direct effect of BSI on NDI to be disentangled from the indirect effect
via antibiotic treatment; hence, the model structure excludes NEC. If NEC was confirmed to play a
role in the pathway leading to NDI over and above the direct effect of BSI, and if BSI causes NEC,
preventing BSI may be more cost-effective than this study suggests. Conversely, if NEC is on the
causal pathway for NDI and death at 2 years, but it is unrelated to BSI, preventing BSI will be
less cost-effective.
A fourth limitation was restriction to the perspective of NHS hospitals for costs during the 6-month
follow-up period. Ideally, the model would include all the costs falling on the NHS, including not only
hospital costs, but also costs of community health care. This was not possible because there are no
routine health-care databases that compile the use of community health-care services. Furthermore,
at project conception, it was deemed excessively burdensome to ask parents for details of their use
of community health-care services. Nevertheless, the lack of data on community health-care costs is
unlikely to have a large impact on the results, given the high costs related to hospitalisations. Costs
falling on other sectors, such as social care and education, are likely to be relevant. However, their
inclusion would represent a departure from the NHS perspective and would require the consideration
of how to account for costs falling on different sectors.121
Fifth, the model was also restricted to health benefits for the child, by considering the impact of BSI on
death and NDI, and its consequences on the babies’ length of life and HRQoL. Children’s health may
have spillover effects on their parents.122,123 Therefore, avoiding BSI may have beneficial consequences
to parents’ HRQoL. If this is the case, the benefits in terms of QALYs for parent and child of preventing
BSI may have been underestimated and the magnitude of the necessary risk reduction for interventions
to be cost-effective may have been overestimated.
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A sixth limitation relates to the measure of NDI, which was retained from the previous model of
Mangham et al.71 It is relatively crude and might have been superseded by more recent advances in
paediatrics. As far as model results are concerned, most babies are classified as having no impairment
at 2 years of age. However, less evident cognitive or motor deficits might become apparent at school
age, even in this group, causing additional burden in terms of both health-related and education costs,
and QALYs lost. Again, if this is the case, the model will underestimate the benefits from preventing
these additional minor deficits related to the occurrence of BSI, which, if accounted for, would further
increase the cost-effectiveness of interventions to prevent it.
Using routine health-care data to estimate hospital costs had some limitations. Given that linkage of
the PREVAIL babies’ data was conducted by the data providers, there was limited information on the
reasons for missing data. Furthermore, as the costing of hospital care is based on HRGs, hospitalisations
with insufficient data to derive a HRG were discarded. Nonetheless, complete data were retrieved for
most PREVAIL babies. Moreover, any missing data are likely to be related to errors in data entry at the
hospital level, which are unlikely to be related to the babies’ characteristics and their hospital care, and
hence can be assumed to be missing completely at random. Another limitation was the inconsistencies
in the dates in some records, which were needed to calculate the hospital length of stay. However, for
the estimation of hospital costs, the dates of hospitalisations are used only to select the hospital care
within the trial follow-up period of 6 months. Therefore, the approach taken to analyse the dates is
unlikely to have a large impact on the results.
Findings in context
We found no published economic analyses that compared PICC impregnation in newborn babies.
Previous cost-effectiveness studies for impregnated PICCs were in older populations and used
different antimicrobials for impregnation, precluding meaningful comparisons.124–127
A previous study71 estimated the health outcomes and costs of care of preterm babies, but it
did not assess the cost-effectiveness of interventions to improve outcomes of preterm babies.
The results of Mangham et al.71 are similar to the results of the present study under the standard
care (S-PICC) policy, even though some of the model inputs are different. Mangham et al.71 predicted
that at 18 years of age 36% of babies born at gestational age 23–27 weeks (66% of babies born at
gestational age 28–32 weeks) would have no NDI, 10% born at gestational age 23–27 weeks (17%
born at gestational age 28–32 weeks) would have mild NDI, 5% born at gestational age 23–27 weeks
(6% born at gestational age 28–32 weeks) would have moderate NDI and 4% born at gestational age
23–27 weeks (4% born at gestational age 28–32 weeks) would have severe NDI. In the present study,
the model predicted that, under the current policy of using S-PICCs, 45% of babies born at gestational
age 23–27 weeks (67% of babies born at gestational age 28–32 weeks) would have no NDI, 17% born
at gestational age 23–27 weeks (20% born at gestational age 28–32 weeks) would have mild NDI, 9%
born at gestational age 23–27 weeks (6% born at gestational age 28–32 weeks) would have moderate
NDI and 7% born at gestational age 23–27 weeks (3% born at gestational age 28–32 weeks) would
have severe NDI. For babies born at < 28 weeks’ gestation, the Mangham et al.71 model estimates the
total average cost per survivor to 18 years at £136,790 (95% CI £50,222 to £261,873), compared
with an average lifetime cost per baby (using S-PICCs) predicted in our model of £126,168 (95% CI
£120,133 to £132,655).
Results from the economic analysis show that the RR of BSI is the main contributor to overall
parameter and decision uncertainty. If BSI in infancy increases the risk of NDI and death, as suggested
by observational studies and included in the model, interventions that prevent such BSI offer a large
potential for cost-effectiveness, even if their efficacy is small.10,74,78 Therefore, future applied research
should focus on the evaluation of the effectiveness of interventions to prevent BSIs. However, the
increase in risk of NDI and death reported by observational studies may not be a true reflection
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of the effect of BSI. It is possible that there is some residual confounding, in that babies who have
poorer health are more likely to suffer a BSI, as well as being more likely to have NDI or die. If this is
the case, the association between BSI and NDI/death may be overestimated, thereby leading the
cost-effectiveness model to overestimate the benefits of preventing BSI in the long term. For these
reasons, more research is needed on the effect of BSI on long-term health outcomes.
Reflecting the structural uncertainty on the link between BSI, NDI and death is a key challenge. The
methodological literature is unclear about how to reflect structural uncertainty from observational
studies, although some approaches have been proposed in the past.128 Further research is warranted
to develop adequate methods that are able to incorporate and assess potential biases due to the
inclusion of observational evidence, both directly (i.e. in the model structure) and indirectly (i.e. in
the evidence synthesis process). In this respect, clinical research could help inform future models, for
example via longitudinal studies following preterm babies over time. These would record various types
of data, including linkage to hospitalisation, community and primary care data for health outcomes,
and measures relevant to health captured in non-health data, for example cognitive function measured




A key strength of our study is the national coverage of 92% of NICUs and LNUs across the NHS in
England over 7 years; this minimised referral biases, provided a large enough sample to evaluate
subgroups and used routinely submitted laboratory reports, thereby minimising clinician response bias.
Our data on BSI are laboratory confirmed and we have data on the organism cultured and dates from
both infection surveillance and clinical records, which enables us to tailor specific definitions of BSI.
Limitations include a lack of precise timing of culture sampling (day rather than hour), no consent
to use data from 12 units, and lack of full data for 162 PREVAIL trial participants. Furthermore, the
presence of a PICC was not recorded in 6% of PREVAIL babies known to have a PICC from trial CRFs.
It is unlikely that these errors are limited to PREVAIL babies; hence, some PREVAIL and non-PREVAIL
babies were misclassified as not having a PICC.
A further limitation is linkage error, which can have an important impact on trend analyses. In our
study, linkage error arises predominantly from missed links, and, to a lesser extent, from false links
due to incorrect or missing identifiers. In the linked data, the BSI rate in PREVAIL babies randomised
to receive a S-PICC was 8.1 per 1000 PICC days, compared with 10.6 in the PREVAIL trial, highlighting
the underestimation of our results. This is probably a result of missed links due to incomplete identifiers
or under-reporting to the infection surveillance system. The quality and completeness of identifiers
improved in both data sets (NNRD and infection surveillance) over time. This improvement could have
led to a spurious increase in BSI rates. Therefore, we need to be cautious in interpreting the stable,
increasing and declining BSI rates. Further research is needed to understand the case mix, practice
and service factors affecting changing rates of BSI over time, taking into account all periods at risk
throughout neonatal care. Stable rates in NICUs may reflect a combination of better infection control,
allowing use of PICCs in more high-risk periods. For example, when PICCs are used for shorter durations,
it is likely that the PICCs are used during higher-risk periods, such as during stabilisation after birth.
We would expect rates of BSI per 1000 PICC days to be higher during shorter, but higher-risk, periods,
even though overall BSI risk during NNU stay would decrease. Similarly, replacement of umbilical venous
catheters with PICCs may decrease BSI rates if all catheter days were counted. However, the rate of BSI
per 1000 PICC days would increase because BSIs that were previously counted during umbilical venous
catheter days would be counted while a PICC is in situ.
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Findings in context
The total rate of BSI (clearly pathogenic organisms) of 2.4 per 100 admissions was slightly higher
than the rate of 1.8 per 100 admissions reported in a retrospective cohort study of 34 NICUs and
LNUs in the UK from 2005 to 2014.12 This may reflect the more stringent definition used in the study
of 34 NICUs that required a prescription of at least 5 days of antibiotics, or the reliance on voluntary
reporting by clinicians to the study. In addition, we excluded babies who received special care from
our study, who would have fewer infections. Excluding special care made the data more comparable
between NNUs, and over time, as babies are kept in special care for varying lengths of time; however,
this excluded 11.5% of total late-onset BSIs in all NNUs. Our finding of a declining trend in total BSIs
per 100 admissions in PREVAIL trial NICUs and LNUs is similar to trends reported in the study of
34 UK NICUs and LNUs.12
Before-and-after studies have reported reductions in rates of BSI per 1000 PICC days following the
introduction of care bundles.47,48 However, this was not seen in our study. This may be due to the
improved ascertainment of BSI over time masking true trends. Alternatively, our study represents
all centres across England, where rates may differ from those voluntarily participating in a study.
In our study, a mix of decreasing and increasing rates in different NNUs may have resulted in a stable
average rate. Furthermore, the BSI rates may have only temporarily decreased, thereby not affecting
the long-term trends.
Relevance to future research
Had the trial found one type of PICC to be more effective, the RR could have been applied to rates of
BSI per 1000 PICC days at risk in non-participating NICUs and LNUs to estimate the expected risk
difference. Our methods for linking NNRD, infection surveillance, and trial data can be used for future
trials in contexts of changing infection rates to assess generalisability and applicability. Linkage should
be continued to monitor the impact on BSI of infection control, changes in service configuration and
practice and to target high-risk groups for infection.
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We found no evidence of benefit or harm of rifampicin- and miconazole-impregnated PICCsduring neonatal care. Interventions with a small effect on BSI could be cost-effective over the
life course. Our trial findings are generalisable to neonatal care in England.
Implications for practice
l There is no evidence that PICC impregnation with miconazole and rifampicin is more effective than
S-PICCs, and it is more costly; hence, it is not cost-effective. These findings indicate that AM-PICCs
should, therefore, not be adopted in neonatal care.
l Rifampicin resistance in organisms cultured from blood, CSF or PICC tips was not significantly
increased in the AM-PICC compared with the S-PICC group, but organisms isolated from only the
PICC tip were more likely to be rifampicin resistant. As rifampicin is not routinely used in UK
neonatal care, this is probably of limited clinical relevance in the UK setting.
l The economic model shows that, if there is a causal link between BSI and adverse long-term health
outcomes, then interventions that achieve small reductions in the risk of BSI are potentially
cost-effective.
l Findings from the PREVAIL trial are generalisable to neonatal intensive care in the NHS in England.
l Application of RRs from PICC interventions to predict absolute rate reductions in the future,
or locally, need to be based on risk-adjusted rates of BSI per 1000 PICC days.
l Bloodstream infections that occur during PICC days at risk contribute to nearly half (46%) of total
BSIs during neonatal intensive and high-dependency care. Preventative strategies for reducing the
risk of BSI in newborn babies should focus on all aspects of care before, during and after the period
of PICC use.
Recommendations for research
1. One in 10 babies in the PREVAIL trial had a BSI, and some may suffer serious lifelong NDI or lung
disease as a result. Low-cost interventions that reduce the risk of BSI in preterm babies, even by a
small amount, would be likely to be cost-effective over a child’s life course, based on the assumption
of reduced risk of NDI and death. Investment in further research to develop other types of
antimicrobial PICC impregnation or alternative approaches for preventing infection in neonatal care
would, therefore, be worthwhile.
2. Our finding of no evidence of benefit associated with rifampicin- and miconazole-impregnated
PICCs contrasts with substantial reductions in rates of BSI or catheter-related BSI reported in
previous trials in children and adults randomised to rifampicin- and minocycline-impregnated CVCs,
compared with standard CVCs. We recommend that further research be undertaken to develop and
evaluate rifampicin- and minocycline-impregnated PICCs for use in preterm babies.
3. We recommend that further research be carried out to strengthen evidence on the causal link
between BSI and NDI and death, and on methods to reflect the uncertainty in these causal links in
cost-effectiveness models.
4. Record-level linked data combining electronic clinical records from neonatal care, HES and infection
surveillance data should be made routinely available for research and infection surveillance
in England.
5. Further research is required to understand which practices contribute to changes (or lack of changes)
in rates of BSI over time in neonatal care.
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Clinical effectiveness randomised controlled trial
Participants
We would like to thank the 861 babies who participated in the PREVAIL trial, along with their parents
and families, for their invaluable contribution to this research.
Trial sites
We are grateful to the PIs and RN teams at each trial site who recruited participants and supported
them and their families throughout the trial (in order of number of patients recruited): Bradford
Royal Infirmary (Sam J Oddie and Rachel Wane); Leicester Royal Infirmary (Marie Hubbard and
Rosalind Astles); Birmingham Women’s Hospital (Andrew Ewer and Rachel Jackson); St Mary’s
Hospital, Manchester (Ranganath Ranganna and Nicola Booth); Liverpool Women’s Hospital
(Kiran Yajamanyam and Karen Harvey); Homerton University Hospital (Narendra Aladangady and
Asha Mathew); The Jessop Wing, Sheffield (Elizabeth Pilling and Pauline Bayliss); Royal Oldham
Hospital (Natasha Maddock and Louise Woodhead); The Royal London Hospital (Ajay Sinha and
MaySze Chang); Royal Preston Hospital (Sandeep Dharmaraj and Claire Lodge); Queen’s Medical
Centre, Nottingham (Jon Dorling and Helen Navarra); John Radcliffe Hospital (Charles Roehr and
Sheula Barlow); Royal Bolton Hospital (Mahesh Yadav and Claire Abbott); Leeds General Infirmary
(Kathryn Johnson); Nottingham City Hospital (Dushyant Batra and Yvonne Hooton); St Michael’s
Hospital, Bristol (Pamela Cairns and Jennifer Chapman); Queen’s Hospital, Romford (Bal Krishnan
Sharma and Helen Smith); and Newham General Hospital (Imdad Ali and Ivone Lancoma-Malcolm).
We thank the 53 hospital trusts across the UK that agreed to act as continuing care sites for the
trial and assisted with collection of important follow-up data when participants were transferred
away from their recruiting site.
Liverpool Clinical Trials Centre
We thank the LCTC staff: Zoe Craig, Sue Howlin and Kate Silvera-Cull for their work as data managers
on this study; Anna Rosala-Hallas and Elizabeth Conroy who acted as randomising statisticians and
produced the randomisation lists; and Ashley Best who undertook quality control checks.
Public engagement
We thank BLISS, a patient advocacy charity for babies born premature or sick, for its support of the
trial, assistance with review of public-facing documents and dissemination of results (registered charity
number 1002973; www.bliss.org.uk/).
Trial Steering Committee
We thank Mike Sharland (chairperson), Stephanie Chadwick, Edmund Juszczak and Win Tin for their
oversight and guidance.
Independent Data and Safety Monitoring Committee
We thank Nicholas Embleton (chairperson), Alison Balfour and Louise Stanton for their oversight
and guidance.
Economic and generalisability analyses
We would like to thank María José Aragón for assistance in the analysis of HES data; Lee Norman
and Roger Parslow at PICANet for their help in providing data; Neena Modhi, Kayleigh Ougham
and Richard Colquhoun at the Neonatal Data Analysis Unit (NDAU) for their help in providing and
DOI: 10.3310/hta24570 Health Technology Assessment 2020 Vol. 24 No. 57
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Gilbert et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
79
answering our questions about the data; the NHS Digital data access and data production teams, for
similar help; Stavros Petrou for helpful discussions on data sources to inform the model; Nicky Welton
and Caroline Clarke for an excellent discussion of our paper at the Health Economics Study Group
Summer 2018 meeting and at the 5th EuHEA PhD Student-Supervisor Conference, respectively;
and all the colleagues who took part in the discussion. We would like to thank PHE for providing data,
the Antimicrobial Resistance team within PHE for their support for the generalisability analyses and
Mehdi Minaji for his assistance managing the data. We would also like to thank Ruth Blackburn for her
guidance and advice throughout the generalisability analyses.
Other
We thank the manufacturer of the PICCs [Vygon (UK) Ltd] for allowing participating units to purchase
AM-PICCs at the same price as S-PICCs during recruitment to the trial. Neither the funder (NIHR) nor
the manufacturer had any involvement in the study design, interpretation of the results or writing of
the report. Research at UCL Great Ormond Street Institute of Child Health is supported by the NIHR
Great Ormond Street Hospital Biomedical Research Centre.
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Clinical effectiveness randomised controlled trial
The use of HES data was approved by the Health and Social Care Information Centre (now known as
NHS Digital) for the purpose of this study (DARS-NIC-73974-P0L1Z-v0.9). HES data © 2018, reused
with the permission of the Health and Social Care Information Centre. All rights reserved.
Economic analysis
Electronic patient data recorded at participating NNUs that collectively form the UK Neonatal
Collaborative (UKNC) are transmitted to the NDAU to form the NNRD. Laura Bojke, Rita Faria
and Alessandro Grosso had full access to all the data in the study and take full responsibility for the
integrity of the data and accuracy of the data economic analysis. We are grateful to all the families
that agreed to the inclusion of their baby’s data in the NNRD, the health professionals who recorded
data and the NDAU team.
The PICANet is commissioned by the Healthcare Quality Improvement Partnership (HQIP) as part of
the National Clinical Audit and Patient Outcomes Programme; the Welsh Health Specialised Services;
NHS Lothian/National Services Division NHS Scotland; the Royal Belfast Hospital for Sick Children;
The National Office of Clinical Audit, Republic of Ireland; and HCA Healthcare UK.
The HQIP is led by a consortium of the Academy of Medical Royal Colleges, the Royal College of
Nursing, and National Voices. It aims to improve health outcomes and to promote quality improvement.
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Information Centre), © 2015–18, the Health and Social Care Information Centre. Re-used with the
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analysis. We are grateful to all the families that agreed to the inclusion of their baby’s data in the NNRD,
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Appendix 1 Additional information on
clinical effectiveness methods
TABLE 26 Substantial amendments to the trial protocol
Protocol version Key amendments
2.0 (5 May 2015) l Definition of BSI specified as ‘BSI per 1000 PICC days’
l Use of miconazole-resistance testing removed
l Rate of CSF culture sampling removed from secondary outcomes
l Requirement for treatment for retinopathy of prematurity before discharge removed from
secondary outcomes
l Primary end point (time to BSI) amended to include any positive bacterial or fungal
blood/CSF culture
l Time frame for collection of secondary end points specified as until 48 hours post
PICC removal
l Internal pilot to assess recruitment feasibility included
l Additional details to support transfers away from the recruiting site included
l Randomisation procedure for twins added
l Statement regarding willingness to consider co-enrolment with other studies added
l Further information relating to data collection procedures for health economics
analysis added
3.0 (12 October 2015) l Requirement for protocol to be signed by lead statistician added
l ‘Breast milk intake’ amended to ‘milk intake’
l Definition of successful PICC placement added
l Minor clarifications added to the AE reporting procedure
l Additional details regarding circumstances under which fathers of participants can/cannot
provide consent added
4.0 (19 August 2016) l Co-enrolment log to capture details of whether or not any participants were also recruited
into other RCTs added
l Clarification regarding eligibility confirmation added
l Clarification regarding informed consent added
5.0 (26 April 2017) l Time to death added as a secondary outcome
l Minor clarifications added to the AE reporting procedure
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TABLE 27 Pathogen classifications
Organism Pathogen group
Gram positive
CoNS Potential pathogen or likely contaminant
Staphylococcus aureus Clearly pathogenic organism
Group B streptococci Clearly pathogenic organism
Streptococcus pneumoniae Clearly pathogenic organism
Streptococcus (other) Potential pathogen or likely contaminant
Enterococcus spp. Clearly pathogenic organism
Micrococcus sp. Potential pathogen or likely contaminant
Bacillus sp. Clearly pathogenic organism
Diphtheroids Potential pathogen or likely contaminant
Propionibacterium acnes Potential pathogen or likely contaminant
Listeria monocytogenes Clearly pathogenic organism
Other Gram positive Individual isolates reviewed
Gram negative
Pseudomonas sp. Clearly pathogenic organism
Klebsiella spp. Clearly pathogenic organism
Enterobacter spp. Clearly pathogenic organism
Acinetobacter spp. Clearly pathogenic organism
E. coli Clearly pathogenic organism
Enterococcus spp. Clearly pathogenic organism
Serratia sp. Clearly pathogenic organism
Coliform Clearly pathogenic organism
Citrobacter sp. Clearly pathogenic organism
Burkholderia sp. Clearly pathogenic organism
Haemophilus sp. Clearly pathogenic organism
Other Gram negative Individual isolates reviewed
Fungi
Candida albicans Clearly pathogenic organism
Non-candida albicans species Clearly pathogenic organism
Candida (other) Clearly pathogenic organism
Other fungi Clearly pathogenic organism
Other fungal organism Clearly pathogenic organism
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Appendix 2 Additional information on
clinical effectiveness results
TABLE 28 Randomisation details for each site
Centre









00075 10 August 2015 9 January 2017 40 24 August 2015 6 January 2017 99
00031 11 August 2015 12 January 2017 57 12 August 2015 11 January 2017 92
00472 1 September 2015 9 January 2017 59 2 September 2015 25 November 2016 52
00308 7 September 2015 9 January 2017 63 9 September 2015 12 December 2016 65
00039 7 September 2015 9 January 2017 34 18 September 2015 28 November 2016 31
00213 8 September 2015 9 January 2017 36 13 September 2015 10 December 2016 40
00134 18 September 2015 9 January 2017 36 26 June 2015 6 December 2016 47
18937 23 September 2015 8 December 2016 40 3 October 2015 4 December 2016 50
00292 2 October 2015 9 January 2017 71 2 October 2015 6 December 2016 57
00228 12 October 2015 9 January 2017 61 23 October 2015 9 December 2016 58
18912 10 November 2015 8 December 2016 26 27 November 2015 12 November 2016 23
18938 11 November 2015 9 January 2017 27 15 November 2015 7 December 2016 44
00234 1 December 2015 9 December 2016 41 4 December 2015 23 November 2016 24
00169 3 December 2015 9 January 2017 33 11 January 2016 29 October 2016 37
20019 4 December 2015 8 December 2016 73 4 December 2015 5 December 2016 35
18854 4 January 2016 4 November 2016 33 4 January 2016 13 June 2016 8
00235 20 January 2016 9 January 2017 59 22 January 2016 11 December 2016 60
00227 8 February 2016 13 December 2016 69 18 February 2016 30 November 2016 39
Total 858 861
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TABLE 29 Screening and recruitment summary for each site
Centre code
Number of babies’ parents








00075 127 3 104 (81.9) 99 (95.2)
00031 132 38 105 (79.5) 92 (87.6)
00472 125 32 65 (52.0) 52 (80.0)
00308 104 46 69 (66.3) 65 (94.2)
00039 54 14 31 (57.4) 31 (100.0)
00213 54 16 40 (74.1) 40 (100.0)
00134 68 20 47 (69.1) 47 (100.0)
18937 72 19 50 (69.4) 50 (100.0)
00292 88 31 61 (69.3) 57 (93.4)
00228 117 87 81 (69.2) 58 (71.6)
18912 71 10 24 (33.8) 23 (95.8)
18938 65 9 48 (73.8) 44 (91.7)
00234 86 39 31 (36.0) 24 (77.4)
00169 40 20 37 (92.5) 37 (100.0)
20019 43 8 36 (83.7) 35 (97.2)
18854 16 2 8 (50.0) 8 (100.0)
00235 89 8 60 (67.4) 60 (100.0)
00227 53 85 40 (75.5) 39 (97.5)
Total 1404 487 937 (66.7) 861 (91.9)
TABLE 30 Reasons for parents not being approached
Reason Number (%) of babies (N= 487)
Parents not available to consent 163 (33.5)
Parents’ lack of understanding 8 (1.6)
Parents do not understand English/Urdu 18 (3.7)
Consultant preference 22 (4.5)
Missed by clinical team 134 (27.5)
Baby previously entered into the PREVAIL trial 10 (2.1)
No reason given 5 (1.0)
Other reason 148 (30.4)
Note
Reasons are not mutually exclusive.
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TABLE 31 Reasons for parents declining consent
Reason Number (%) of babies (N= 467)
No reason provided 67 (14.3)
Parent does not want to take part in research 195 (41.8)
Parent does not wish baby to be randomly assigned to treatment 9 (1.9)
Parent does not wish baby to have AM-PICC 18 (3.9)
Other reason 180 (38.5)
Note
Reasons are not mutually exclusive.
TABLE 32 Reasons babies not randomised despite parents providing consent
Reason Number (%) of babies (N= 76)
Baby requires different size PICC 8 (10.5)
Baby no longer requires a PICC 49 (64.5)
Baby died 6 (7.9)
Trial-trained staff not available 1 (1.3)
Unable to access randomisation system 0 (0.0)
PICC (Premicath 1 French) not available 0 (0.0)
Other reason 13 (17.1)
Note
Reasons are not mutually exclusive.
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Participants co-enrolled in other trials, n (%)
ELFIN129
Baby
OSCAR130 NAPPA131 Other Total
Birmingham Women’s Hospital 65 22 (33.8) 5 (7.7) 0 (0.0) 5 (7.7) 32 (49.2)
Bradford Royal Infirmary 99 80 (80.8) 0 (0.0) 0 (0.0) 0 (0.0) 80 (80.8)
Homerton Hospital 57 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
John Radcliffe Hospital, Oxford 39 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Leeds General Infirmary 35 11 (31.4) 0 (0.0) 0 (0.0) 0 (0.0) 11 (31.4)
Leicester Royal Infirmary 91a 38 (41.8) 0 (0.0) 0 (0.0) 0 (0.0) 38 (41.8)
Liverpool Women’s Hospital 58 0 (0.0) 0 (0.0) 1 (1.7) 4 (6.9) 5 (8.6)
Newham General Hospital 8 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Nottingham City Hospital 31 7 (22.6) 0 (0.0) 0 (0.0) 0 (0.0) 7 (22.6)
Queen’s Hospital Romford 23 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Queen’s Medical Centre,
Nottingham
40 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Royal Bolton Hospital 37 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.7) 1 (2.7)
Royal Oldham Hospital 50 0 (0.0) 0 (0.0) 0 (0.0) 2 (4.0) 2 (4.0)
Royal Preston Hospital 44 9 (20.5) 0 (0.0) 0 (0.0) 0 (0.0) 9 (20.5)
St Mary’s Hospital, Manchester 60 0 (0.0) 0 (0.0) 0 (0.0) 3 (5.0) 3 (5.0)
St Michael’s Hospital, Bristol 24 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
The Jessop Wing, Sheffield 52 3 (5.8) 0 (0.0) 0 (0.0) 0 (0.0) 3 (5.8)
The Royal London Hospital 47 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Total (n) 860a 170 5 1 15 191
Baby OSCAR, Outcome after Selective early treatment for Closure of patent ductus ARteriosus in preterm babies;
ELFIN, Enteral LactoFerrin In Neonates; NAPPA, Neonatal And Paediatric Pharmacokinetics of Antimicrobials study.
a Missing information for one baby.
TABLE 34 Oversight committee meetings and recommendations
Oversight committee Meeting dates Recommendations
IDSMC 29 April 2015 (joint with TSC)
12 May 2016 Trial to be continued
July 2016 (via e-mail) Trial to be continued
TSC 29 April 2015 (joint with IDSMC)
31 May 2016 Trial to be continued
9 August 2016 Trial to be closed to recruitment when
target is met, with no need to continue
recruitment until planned closure date
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TABLE 35 Sampling for outcomes and resistance testing for secondary outcomes
AM-PICC (N= 430) S-PICC (N= 431)
n n (%) n n (%)
Culture samples takena
Blood or CSF 379 198 (46.0) 329 190 (44.1)
Peripheral venous blood 321 183 (42.6) 268 178 (41.3)
CSF 40 33 (7.7) 38 34 (7.9)
Other 18 16 (3.7) 23 20 (4.6)
PICC tip 314 313 (72.8) 310 310 (71.9)
Rifampicin resistance tested in positive culturesb
Blood or CSF 48 21 (43.8) 46 25 (54.3)
Peripheral venous blood 44 21 (47.7) 42 23 (54.8)
CSF 0 0 (0.0) 3 1 (33.3)
Other 5 0 (0.0) 3 2 (66.7)
PICC tip 47 32 (68.1) 90 61 (67.8)
a Data are total samples taken (n) and the babies from whom samples were taken [n (%)] as a proportion of the total
number of babies with AM-PICCs or S-PICCs.
b Data are total babies with a positive culture (n) and babies with at least one positive culture tested [n (%)] as a
proportion of the total number of babies with a positive culture.






Any protocol deviation 171 (39.8) 175 (40.6)
At least one major deviation 61 (14.2) 25 (5.8)
Baby did not receive allocated 1-French Premicath 57 (13.3) 24 (5.6)
Blood/CSF samples either not sent for culture, lost, damaged or
not analysed
3 (0.7) 1 (0.2)
Baby was withdrawn from trial prior to completing clinical follow-up 1 (0.2) 0 (0.0)
Parent/legal representative of the baby did not give informed written
consent for the trial
0 (0.0) 0 (0.0)
Baby was previously entered into this trial 0 (0.0) 0 (0.0)
Baby had a known allergy or hypersensitivity to rifampicin
or miconazole
0 (0.0) 0 (0.0)
Date and time of PICC removal were not recorded 0 (0.0) 0 (0.0)
At least one minor deviation 132 (30.7) 155 (36.0)
PICC tip culture not taken at removal 72 (16.7) 95 (22.0)
Resistance testing not performed on positive culture 69 (16.0) 66 (15.3)
Baby has PICC inserted > 48 hours after randomisation 8 (1.9) 5 (1.2)
Baby was withdrawn from trial follow-up prematurely 4 (0.9) 3 (0.7)
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TABLE 37 Number of babies experiencing a BSI in each subgroup
Subgroup
AM-PICC (N= 46 participants
experiencing a BSI) (n)
S-PICC (N= 44 participants
experiencing a BSI) (n)
Gestational age of < 28 weeks 33 35
Gestational age of ≥ 28 weeks 12 8













































FIGURE 16 Kaplan–Meier plot for babies born at < 28 weeks of gestation. Values under the graph represent the number












































FIGURE 17 Kaplan–Meier plot for babies born at ≥ 28 weeks of gestation. Values under the graph represent the number
of participants remaining at risk at each time point: group 1, AM-PICC; group 2, S-PICC.
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TABLE 38 Rifampicin-resistant positive isolates
Sample type Resistant organism
Participants,a n (%)
AM-PICC S-PICC
Blood/CSF culture Entercoccus spp. 3 (75.0) 2 (22.2)b
Klebsiella spp. 1 (25.0) 2 (22.2)c
E. coli 0 (0.0) 2 (22.2)b
Acinetobacter spp. 0 (0.0) 1 (11.1)
CoNS 0 (0.0) 1 (11.1)
Enterobacter spp. 0 (0.0) 1 (11.1)b
Total (n) 4 9
PICC tip culture CoNS 10 (71.4) 2 (40.0)b
Candida albicans 0 (0.0) 1 (20.0)b
Corynebacterium tuberculostearicum 1 (7.1) 0 (0.0)
Enterobacteriaceae 1 (7.1) 0 (0.0)
Enterobacter spp. 0 (0.0) 1 (20.0)b
Enterococcus spp. 0 (0.0) 1 (20.0)
Klebsiella spp. 1 (7.1) 0 (0.0)
Raoultella ornithinolytica 1 (7.1) 0 (0.0)
Total (n) 14 5
a Data are n (%) of participants with a resistant organism.
b Numbers indicate when a single baby had multiple resistant organisms.
c A single baby had two samples that grew the same resistant organism.
TABLE 39 Number of BSIs each baby experienced
Number of BSIs per baby
Participants, n (%)
AM-PICC (N= 430) S-PICC (N= 431)
0 384 (89.3) 387 (89.8)
1 43 (10.0) 43 (10.0)
2 3 (0.7) 1 (0.2)
TABLE 40 Types of treatment for retinopathy of prematurity
Type of treatment
Participants, n (%)
AM-PICC (N= 430) S-PICC (N= 431)
Laser 38 (8.8) 28 (6.5)
Cryotherapy 0 (0.0) 0 (0.0)
Injection 4 (0.9) 2 (0.5)
Missing 0 (0.0) 1 (0.2)
Note
Some babies received more than one type of treatment, and so appear in the table more than once.
APPENDIX 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
104
Appendix 3 Additional information on
economic analysis: data access
Overview
Data sources
The economic analysis conducted by the team at the UoY for the PREVAIL project required routinely
collected health-care data from NHS Digital, PICANet and NDAU, as well as data collected in the
clinical trial by the UoL. The team at UCL developed the algorithm to select the babies enrolled in
the PREVAIL trial who were recorded in the NNRD held by NDAU.
Data flows
The data flow was as follows: the UoL sent the patient identifiers to NHS Digital, PICANet, NDAU
and UCL. NHS Digital selected the cohort using the identifiers and sent the administrative data
identified with trial identifier to the UoY; the process was similar with PICANet, but the data were
sent to the UoL, then the UoY. The UoY generated a database with the NHS Digital data on date of
death and sent it to UoL. UCL linked the PREVAIL trial cohort to NNRD as part of the PREVAIL trial
generalisability analysis and sent Badger identifiers (IDs) (a pseudonymised identifier) for PREVAIL
babies to NDAU; NDAU used the Badger IDs to select the cohort and sent the data to the UoY.
UoL sent the PREVAIL trial data to the UoY.
Data transfer
The UoY submitted the data-sharing applications to NHS Digital, PICANet and NDAU on 21 November
2016. The UoY received the NHS Digital data on hospitalisations on 24 May 2018, and the NHS Digital
data on date of death on 27 September 2018, the PICANet data on the 9 May 2018 and the NDAU
data on 24 August 2018. The UoY initiated the process to develop the data-sharing agreement between
the UoY and the UoL on 3 May 2018. The UoY received the data on the 16 August 2018.
NHS Digital
Preparing the data-sharing application
The UoY submitted the data-sharing application to NHS Digital on 21 November 2016.
Revising the data-sharing application
NHS Digital had a number of queries with the application, which had to be addressed before formal
submission to the Independent Group Advising on the Release of Data (IGARD). These issues were
related to ensuring that the project had informed consent for sharing of date of death; ensuring that
the trial participants had access to information about how their data were being used; processes for
withdrawal from the data-sharing process; explaining the rationale for the project in lay terms; and
detailing the benefits to the NHS, outputs and target dates of conducting the research. This took
place between November 2016 and September 2017.
Meeting the security requirements
The data-sharing application for NHS Digital required answering various information technology
queries from the NHS Digital by the UoY and the UoL. This took place between May and July 2017.
Submission to the Independent Group Advising on the Release of Data
The data-sharing application was submitted to the IGARD on 11 September 2017.
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Update to the framework contract
The IGARD approved the application on 20 September 2017. At this point, it emerged that the UoY
and UoL had not yet signed up to the the Data Sharing Framework Contract version 2. This meant that
the data-sharing agreement could not be issued until the two institutions signed up to it, which took
place in October.
Signing the data-sharing agreement
In December 2017, the UoY contracts’ office concluded that UCL and UoL had to sign the hard copies
of the data-sharing agreement so that UoY could sign it electronically. UCL signed it on 2 January
2018 and UoL on 5 February 2018. The data-sharing agreement was executed on 27 February 2018.
Transfer of hospitalisation data
The data were received at the UoY on 24 May 2018.
Date of death missing
On 6 June 2018, the UoY contacted NHS Digital to enquire about the data on date of death,
which were missing from the data sets, but were included in the data-sharing agreement.
On 27 September 2018, NHS Digital confirmed that the data were ready for transfer.
Transfer of date of death data
The data were received at Centre for Health Economics on 27 September 2018.
Transfer of the date of death to University of Liverpool
On 24 October 2018, the UoL confirmed that it still required the date of death data; the data were
transferred by the UoY on the same day.
Paediatric Intensive Care Audit Network
Data-sharing application to the Paediatric Intensive Care Audit Network
The UoY submitted the data-sharing application to PICANet on 21 November 2016. PICANet replied
on 22 November, explaining that data-sharing applications were now processed via HQIP, which
required another data-sharing application and agreement forms.
Data-sharing application to the Healthcare Quality Improvement Partnership
The UoY developed the data-sharing application and agreement between 29 November 2016 and
2 March 2018.
Approval from the Healthcare Quality Improvement Partnership
The UoY submitted the data-sharing application and agreement to HQIP on 14 March 2017.
HQIP approved the application on 16 June 2017. PICANet signed the agreement on 16 June,
and HQIP signed on 19 July 2017.
Data transfer
The UoL transferred PREVAIL trial identifiers to PICANet on 5 March 2018. The UoY received the
data on 9 May 2018.
Neonatal Data Analysis Unit
Data-sharing application
The UoY submitted the data-sharing application to NDAU on 21 November 2016. NDAU approved the
data-sharing application on 5 May 2017.
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Data-sharing contract
The UoY contacted NDAU for the data-sharing contract on 29 June 2017. The data-sharing contract
was signed on 10 January 2018.
Data-sharing agreement
On 7 March 2018, NDAU requested a data-sharing agreement in addition to the contract. The UoY
signed the data-sharing agreement on 19 March 2018.
New data-sharing agreement
On 23 May 2018, NDAU informed the UoY that, given that the General Data Protection Regulation
(GDPR)132 had already come into force, it required a new data-sharing agreement that was GDPR
compliant. On 26 June 2018, NDAU concluded that, rather than a new data-sharing agreement,
an amendment to the original contract, which had been signed on 10 January 2018, was needed.
The addendum to the original contract was executed on 24 August 2018.
Privacy notice
University College London, as the study sponsor, is required to approve the privacy notice. The UoY
sent the privacy notice to UCL for approval on 10 July 2018. It was approved on 13 August 2018.
Data transfer
The UoY received the data on 24 August 2018.
The PREVenting infection using Antimicrobial-Impregnated Long lines trial data
Developing the data-sharing agreement
It came to light in early May 2018 that the UoY needed to have an agreement in place with the UoL
to receive the PREVAIL trial data, given that the project was contracted separately between UCL and
each of the partner organisations. The UoY initiated the data-sharing agreement between the UoY and
the UoL on 3 May 2018.
Sign-off by University of Liverpool
The UoL signed off the agreement on 4 July 2018.
Sign-off by sponsor
University College London was contacted on 7 July 2018 to sign off the data-sharing agreement and
privacy notice (see Privacy notice). UCL commented on the data-sharing agreement on 1 August 2018.
Execution of contract between all parties
On 16 August 2018, the contract was fully executed.
Data transfer
The UoY received the PREVAIL trial data on 16 August 2018.
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Appendix 4 Additional information on
economic analysis: data
Hospital Episode Statistics Admitted Patient Care data on the
PREVenting infection using Antimicrobial-Impregnated Long lines trial
babies from NHS Digital
Admitted Patient Care data included trial identifier; HES identifier (anonymised); provider code; provider
type; patient’s sex, month and year of birth; age at admission; dates of admission and discharge; method
of admission and discharge; source of admission and discharge destination; dates that the episode started
and finished, its duration, and whether or not it finished within the HES data year; episode key; the
episode order within the spell and the episode type; indicator of the duration, start and end of the spell;
main specialty under which the consultant was contracted and the specialty under which the consultant
was working; patient classification; number of bed-days within the HES data year; primary and secondary
diagnosis; trust-derived HRG value and its version number; neonatal level of care; procedures codes
and dates; post-operative duration; and date of death according to the Personal Demographics Service.
The HES APC data do not include information on the stays in intensive care units.
Hospital Episode Statistics outpatient data on the PREVenting infection
using Antimicrobial-Impregnated Long lines trial babies from NHS Digital
The outpatient care data included trial identifier, record identifier, patient’s sex, date of the appointment,
whether or not the patient attended the appointment, whether it is a first attendance or follow-up,
trust-derived HRG value and its version number, main specialty under which the consultant was
contracted and the specialty under which the consultant was working, procedure codes, and date of
death according to the Personal Demographics Service.
Hospital Episode Statistics accident and emergency data on the
PREVenting infection using Antimicrobial-Impregnated Long lines trial
babies from NHS Digital
The A&E data included trial identifier, record identifier, age at the time of the A&E visit and at the time
of arrival, A&E patient group, date of A&E visit, code of the dominant procedure, trust-derived HRG
value and version number, record identifier of the APC episode that the A&E visit was linked to, tests
and investigations, and treatment code.
Paediatric intensive care data on the PREVenting infection using
Antimicrobial-Impregnated Long lines trial babies from the Paediatric
Intensive Care Audit Network
The paediatric intensive care data included trial identifier, record identifier, dates of admission and
discharge, admission type, discharge destination, critical care activity, and HRG code and description.
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Neonatal care data on the PREVenting infection using Antimicrobial-Impregnated
Long lines trial babies from the National Neonatal Research Database
The neonatal intensive care data included trial identifier, record identifier, date and time of birth, date
and time of admission, date and time of discharge, HRG code, person accompanying baby (if transported),
critical care episode identifier, critical care activity and diagnoses, NHS code of hospital receiving the
baby, NHS code of the hospital baby was admitted from, detail of exact location of hospital baby was
admitted from, reason for admission, destination on discharge, reason for discharge, type of ward baby
is discharged to and NHS code of hospital the baby is transferred to.
PREVenting infection using Antimicrobial-Impregnated Long lines trial data
The PREVAIL trial data included type of allocated PICC; screening number; randomisation number;
date of randomisation; time of randomisation; person performing the randomisation; sex; date of birth;
time of birth; birthweight; final agreed estimated date of delivery; inborn status; date and time of
admission to a NNU; mode of delivery; membrane rupture status; Apgar score; heart rate in beats
per minute (bpm) (> 100 bpm at 5 minutes of age); presence of major congenital anomalies and type;
use of antenatal corticosteroids; use of antibiotics within the 12 hours prior to delivery; presence of
surgical procedure in the 14 days prior to randomisation (and date, if present); presence of samples
taken for culture at any period within 72 hours prior to randomisation; antimicrobial use (antibiotics,
enteral antifungal) at any period within 72 hours prior to randomisation; respiratory support (and
highest level of support) at any period within 72 hours prior to randomisation; presence and type of
devices in situ at randomisation; PICC placement details (whether or not a PICC was inserted and
the reason for non-insertion, gauge type and justification, insertion site, whether or not allocation
respected randomisation, date and time of insertion); date, time, and reason for PICC removal; whether
or not the PICC tip was sent for culture and, if not, the reason why it was not sent; baby status
(whether discharged, transferred or dead) with date and time; reason for death (PICC use or baby’s
underlying conditions); cause of death as per death certificate; date of post-randomisation assessment;
in the case of transfer to other hospital, the details of the receiving hospital; PICC line status at
transfer; full milk feeds status and date baby first reached full milk feeds; stays in wards other than
NNU in admitting hospital; transfers for surgery during NNU stay at admitting hospital; NEC status
and date of diagnosis; clinical outcomes in admitting hospital; total duration (in days) of parenteral
nutrition in admitting hospital; date of withdrawal (if happened); person who made the withdrawal
decision; and reason for withdrawal.
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Appendix 5 Additional information on
economic analysis: data cleaning
Cleaning of National Neonatal Research Database data
Figure 18 summarises the data preparation. The file with the episode dates (the ‘episode file’) contained
data on 848 (98.49%) PREVAIL babies and 1575 episodes of care. Seven episodes were duplicates; for
five of these, it was uncertain if these referred to PREVAIL babies. All seven duplicate episodes were
permanently deleted. This left 1568 unique episodes about 848 PREVAIL babies.
PREVAIL babies
(n = 861)
Babies (n = 848)
Days in NNU (d = 57,702)
Babies (n = 846)
Days in NNU (d = 57,616)
Babies (n = 844)
Days in NNU (d = 57,445)
Episodes (e = 1555)
Babies (n = 848)
Episodes (e = 1575)
Babies (n = 848)
Episodes (e = 1568)
Babies (n = 837)
Days in NNU (d = 56,610)
Episodes (e = 1388)
Days of care in episodes with discharge 
before randomisation (d = 835)
Episodes with discharge before
randomisation (e = 167)
Babies (n = 7)
Babies not recorded in NNRD
(n = 13)
Episodes with date of discharge
imputed (e = 147)
Episodes with date of admission
corrected (e = 3)
Days not matched (d = 184)
Episodes not matched (e = 13)
Babies not matched (n = 2)
Episodes with admission before randomisation (e = 792)
Episodes with discharge after randomisation (e = 2)
Episodes without date of discharge (e = 147)
Days without a HRG (d = 86)
Babies (n = 2)
Duplicates (e = 7)
FIGURE 18 Preparation of the neonatal care data (received from NNRD).
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The file with the daily care record (the ‘daily file’) contained data on 848 (98.49%) PREVAIL babies
with 57,702 records; each record represents a day in the neonatal care unit. Of these, 86 records
were removed because no HRG was recorded. As a result, records were lost for two PREVAIL
babies. According to the anonymised time stamp, 5948 days were outside the follow-up of the trial
in the database. If these records were removed, the records on 22 babies would also be removed.
Given that the anonymised time stamp records the date and time when the record was made, and
not necessarily when the activity took place, the ‘episode file’ was preferred to select the records
within the follow-up period.
The subsequent step of data preparation was to merge the two cleaned files: the ‘episode file’
with records of 848 babies with a total of 1568 episodes of care with the ‘daily file’ with records of
846 babies with a total of 57,658 days in the NICU. After merging, 213 days of care, 13 episodes
and records on two babies could not be matched. The resulting file contained data on 844 PREVAIL
babies, with 1555 episodes and 57,445 days in the neonatal care unit.
Of the 1555 episodes of care, 147 episodes did not have a discharge date. This date was imputed
with the date stamp of the last day of care recorded in the episode of care. In 3 (of the 147) episodes
with date of discharge imputed, the date of admission was after the date stamp of the last day of care.
In these episodes, the date of admission was corrected to the earliest date stamp for the daily care in
the episode.
The next step was removing the 167 episodes (and 835 days of care) with a date of discharge before
the date of randomisation; this corresponded to the full data on seven PREVAIL babies. These data
were permanently deleted. As a result, the data on the NICU stays on the PREVAIL babies consisted
of the data on 837 PREVAIL babies, with 1388 episodes of care and 56,610 days in the unit.
Cleaning of Paediatric Intensive Care Audit Network data
Figure 19 summarises the data preparation. The file with the episode dates contained data on 177
(20.56%) PREVAIL babies and 184 episodes of care. The discharge date of three episodes was before
the date of randomisation, including of two babies for whom it consisted of all the information in
the file. These were removed from the data set. The admission date of 55 episodes was after the
end of follow-up, including information on 21 babies for whom it consisted of all the information in
the file. As a result, the data set on the episodes of care contained data on 177 babies, with a total of
184 episodes.
The file with the HRGs contained data on 177 PREVAIL babies with 1237 days in the paediatric care
unit. No inconsistencies were identified with the date of daily activity; hence, this information was
used to select the days of care within the follow-up period. All days of care were assigned to a valid
HRG. Thirteen days had an activity date before the randomisation date and 445 days had an activity
date after the end of follow-up; these were removed. All daily records were matched to the file with
the episode dates. In total, 94 (10.92%) PREVAIL babies had 126 episodes of care and 779 days in the
paediatric care unit.
Cleaning of Hospital Episode Statistics data
Cleaning prior to deriving Healthcare Resource Groups
As discussed in Chapter 4, Costing hospital care, hospital care was costed based on the HRGs. The HES
data sets, that is HES APC, HES outpatient and HRS A&E, did not include the costing HRGs. Therefore,
the hospital care recorded in the HES data sets was passed through the HRG grouper software to
derive them.
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Before being passed through the grouper software, the HES data sets were cleaned to ensure both
internal consistency and to fulfil the grouper software requirements. It was essential to ensure that
dates were chronologically sound (e.g. episode start happening before episode end, admission date
happening before discharge date, admission date happening before or on episode start date), that
poorly coded observations (e.g. record identifier, episode duration, episode end date missing) and
duplicates (in particular, episodes sharing the same identifier) were dropped, and that diagnosis and
procedure codes included only alphanumeric characters. Episodes sharing the same episode order
identifier as at least one other episode in the same spell, but showing an unspecified diagnosis code
(‘R69X6’), needed to be dropped. The grouper does not distinguish these particular episodes from the
other correct episodes in the same spell and will not generate a HRG for any episode of that spell.
Therefore, the data set was first sorted using trial identifier, NHS provider code and relevant dates,
and then episodes showing a primary diagnosis code of ‘R69X6’, and sharing the same NHS provider
code and episode order identifier of the immediately adjacent episode (above or below) in the data set,
were dropped.
Cleaning prior to costing
The data sets required additional cleaning before costing the HRG. Figures 20 and 21 summarise
the process.
First, it was necessary to create an indicator variable for the type of episode (elective vs. non-elective,
long vs. short stay) so that the appropriate unit cost would be attached to its respective HRG. Episodes
for which there was not enough information to declare the episode type were dropped from the data set.
Some of the HRG codes were different between the 2016/17134 and the 2015/16 reference costs.62
Therefore, the ‘new’ codes were replaced with their older counterpart before attaching the reference
cost table to the HRG codes (Table 41).
PREVAIL babies
(n = 861)
Babies (n = 117)
Days in PICU (d = 1237)
Babies (n = 117)
Episodes in PICU (e = 184)
Babies (n = 94)
Episodes in PICU (e = 126)
Started before randomisation (e = 0)
Finished after end of follow-up (e = 1)
Without date of discharge (e = 0)
Babies (n = 94)
Episodes of care (e = 126)
Days in the PICU (n = 779)
Babies not recorded in PICANet
(n = 744)
Days with activity date before
randomisation (d = 13)
Babies (n = 2)
Episodes with activity date after
the end of follow-up (e = 445)
Babies (n = 21)
Episodes with discharge date
before randomisation (e = 3)
Babies (n = 2)
Episodes with admission date
after the end of follow-up (e = 55)
Babies (n = 21)
FIGURE 19 Preparation of the paediatric intensive care data (received from PICANet).
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Babies (n = 834)
FCEs in HES admitted patient care (e = 2772)
• FCEs without an episode end date, e = 15; babies removed, n = 0
• FCEs duplicated based on admission dates and study identifier,
    e = 1; babies removed, n = 0
• FCEs removed due to invalid unique episode identifier, e = 10;
    babies removed, n = 2
• FCEs with an unknown diagnosis, e = 32; babies removed, n = 0
• FCEs were not grouped as invalid data for grouping, e = 20;
    babies removed, n = 4
• FCEs without admission type, e = 8; babies removed, n = 2
• FCEs with HRGs without costs in NHS Reference Costs
    2014/15,133 2015/1662 and 2016/17,134 e = 4; babies removed, n = 0
• Babies not recorded in HES admitted patient care, n = 27
Babies (n = 832)
FCEs fed into the HRG grouper (e = 2714)
Babies (n = 828)
FCEs (e = 2682)
FIGURE 20 Preparation of the HES APC data (received from NHS Digital).
PREVAIL babies
(n = 861)
Babies (n = 799)
Outpatient appointments (a = 6425)
All fed into the HRG grouper
Babies (n = 798)
Outpatient appointments with HRG (a = 6406)
Babies (n = 784)
Outpatient appointments (a = 5858)
Babies (n = 352)
A&E attendances (v = 622)
All fed into the HRG grouper
Babies (n = 320)
A&E attendances with HRG (v = 539)
Babies not recorded in HES A&E,
n = 509
Babies (n = 320)
A&E attendances (v = 539)
All HRGs had a valid code
Babies not recorded in HES
outpatient, n = 62
Duplicate data invalid to generate
a HRG, a = 19; babies removed, n = 1
A&E attendances with data invalid
for grouping, v = 83; babies, n = 32
Invalid HRG code, a = 1; baby
removed, n = 1
Appointments cancelled or
postponed, a = 547; babies
removed, n = 13
FIGURE 21 Preparation of the HES outpatient and A&E data (received from NHS Digital).
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A small number of HRG codes were introduced in 2016/17 and did not have a corresponding code in
the previous year’s schedule. They were therefore deflated to 2015/16 prices using the Hospital and
Community Health Service index (Table 42).135
Two pieces of information were required to correctly identify the HRG for the A&E data set: the type
of department and whether or not patients were admitted for subsequent investigations (Reference
Cost Guidance, section 769). It was assumed that all babies were admitted to a ‘Type 01’ structure,
representing hospital emergency departments.
In case an A&E admission was linked to a subsequent inpatient admission, the A&E data set presents
the unique APC episode identifier. Therefore, a non-missing APC episode identifier was taken as the
signal that that A&E admission led to a subsequent inpatient admission, in order to fulfil the second
criteria for the correct unit cost identification.
TABLE 41 Correspondence between 15/16 HRG code and 16/17 HRG code














TABLE 42 Derivation of the ‘deflated’ HRGs
Data set HRG
HCHS index [1987/88= 100
(i.e. 1987/88 taken as base year)] Unit cost (£)
2016/17 2015/16 2016/17 2015/16
APC – outpatient RD97Z 302.3 297.0 18.71 18.38
Outpatient JB71B 302.3 297.0 26.13 25.67
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Unit costs





XA01Z Neonatal critical care, intensive care 1218
XA02Z Neonatal critical care, high-dependency 872
XA03Z Neonatal critical care, special care, without external carer 560
XA04Z Neonatal critical care, special care, with external carer 384
XA05Z Neonatal critical care, normal care 437
XA06Z Neonatal critical care, transportation 990
Paediatric intensive care
XB01Z Paediatric critical care, advanced critical care 5 5440
XB02Z Paediatric critical care, advanced critical care 4 3748
XB03Z Paediatric critical care, advanced critical care 3 2538
XB04Z Paediatric critical care, advanced critical care 2 2151
XB05Z Paediatric critical care, advanced critical care 1 1899
XB06Z Paediatric critical care, intermediate critical care 1448
XB07Z Paediatric critical care, basic critical care 1173
XB08Z Paediatric critical care, transportation 2966
XB09Z Paediatric critical care, enhanced care 870
Reproduced from the Department of Health and Social Care.62 © Crown copyright. Contains public sector information
licensed under the Open Government Licence v3.0 (www.nationalarchives.gov.uk/doc/open-government-licence/version/3/).
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Appendix 6 Additional information on
economic analysis: type and length of stay
TABLE 44 The NNRD data on PREVAIL babies: breakdown of days in the neonatal care unit by critical care HRGs,
without adjustment for time outside the follow-up period
HRG code HRG description






n % n % n %
XA01Z Neonatal critical care, intensive care 17,781 31.41 9125 32.13 8656 30.69
XA02Z Neonatal critical care, high dependency 19,107 33.75 9524 33.53 9583 33.98
XA03Z Neonatal critical care, special care,
without external carer
18,827 33.26 9296 32.73 9531 33.79
XA04Z Neonatal critical care, special care,
with external carer
594 1.05 283 1.00 311 1.10
XA05Z Neonatal critical care, normal care 299 0.53 174 0.61 125 0.44
Total 56,608 100 28,402 100 28,206 100






a Transport HRGs are presented separately because some admissions have both a care HRG and a transport HRG.
Transport HRGs refer to the transfers of babies between units, and their unit cost is per patient journey.
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TABLE 45 The NNRD data on PREVAIL babies: length of stay and cost per episode and per baby, with and without adjustment for time outside follow-up
Quantity
Total AM-PICC S-PICC
n Mean SD n Mean SD n Mean SD
Per episode
Length of stay (days) per episode in NICU without adjustment for follow-up 1388 40.19 32.32 697 40.22 33.76 691 40.16 30.82
Length of stay (days) per episode in NICU adjusting for follow-up 1388 36.81 30.25 697 36.57 30.92 691 37.05 29.57
Cost per episode in NICU without adjustment for follow-up 1388 £35,933.59 £30,101.02 697 £36,107.66 £31,930.00 691 £35,758.01 £28,158.19
Cost per episode in NICU without adjustment for follow-up 1388 £32,615.38 £27,698.45 697 £32,515.14 £28,712.61 691 £32,716.48 £26,656.86
Per baby
Length of stay (days) per baby in NICU without adjustment for follow-up 837 66.65 37.38 420 66.75 38.55 417 66.54 36.21
Length of stay (days) per baby in NICU adjusting for follow-up 837 61.04 35.74 420 60.70 36.31 417 61.40 35.20
Cost per baby in NICU without adjustment for follow-up 837 £59,588.79 £37,409.92 420 £59,921.52 £38,893.53 417 £59,253.68 £35,897.37




































TABLE 46 The PICANet data on PREVAIL babies: breakdown of days in the paediatric intensive care unit by critical care
HRG codes within the follow-up period
HRG code HRG description







n % n % n %
XB04Z Paediatric critical care,
advanced critical care 2
124 15.92 70 18.57 54 13.43
XB05Z Paediatric critical care,
advanced critical care 1
361 46.34 162 42.97 199 49.50
XB06Z Paediatric critical care,
intermediate critical care
137 17.59 76 20.16 61 15.17
Total 779 100.00 377 100.00 402 100.00
Note
Only the top three HRG codes are shown to ensure suppression of small numbers, in line with the HES analysis guide.136




n Mean SD n Mean SD n Mean SD
Per spell
Length of stay (days) per spell in HES
APC without adjustment for follow-up
2128 28.95 34.15 1080 27.96 33.84 1048 29.96 34.45
Length of stay (days) per spell in HES
APC adjusting for follow-up
2128 26.71 31.54 1080 25.69 30.97 1048 27.77 32.09
Per baby
Length of stay (days) per baby in HES
APC without adjustment for follow-up
828 74.39 41.19 410 73.66 40.71 418 75.11 41.69
Length of stay (days) per baby in HES
APC adjusting for follow-up
828 68.65 37.91 410 67.68 36.77 418 69.61 39.01
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TABLE 48 The HES APC data on the PREVAIL babies: costs of FCEs
Results







cost (£) SD (£) FCEs (n)
Mean
cost (£) SD (£) FCEs (n)
Mean
cost (£) SD (£)
Unadjusted for time outside follow-up
FCE core cost
unadjusted
2682 8592.90 10,581.59 1332 8561.49 10,687.94 1350 8623.88 10,479.47
FCE unbundled
cost unadjusted
2682 105.40 415.90 1332 95.18 378.00 1350 115.49 450.09
FCE total cost
unadjusted
2682 8698.30 10,582.63 1332 8656.68 10,695.50 1350 8739.37 10,473.87
Adjusted for time outside follow-up
FCE core cost
adjusted
2682 8030.28 9962.54 1332 7981.18 9970.79 1350 8078.71 9957.86
FCE unbundled
cost adjusted
2682 99.10 405.48 1332 90.27 368.81 1350 107.80 438.64
FCE total cost
adjusted
2682 8129.37 9964.73 1332 8071.45 9981.07 1350 8186.52 9951.95
TABLE 49 The HES APC data on the PREVAIL babies: breakdown of FCEs by admission type and cost, unadjusted by the








Day case Number of FCEs Suppressed as a result of small numbers
Mean (£) Suppressed as a result of small numbers
SD (£) Suppressed as a result of small numbers
Elective inpatient Number of FCEs 952 952 952
Mean (£) 12,753.70 47.21 12,800.91
SD (£) 10,639.15 191.24 10,635.31
Non-elective inpatient long stay Number of FCEs 643 643 643
Mean (£) 880.56 121.99 1002.55
SD (£) 889.51 581.24 1057.61
Non-elective inpatient short stay Number of FCEs 1798 1798 1798
Mean (£) 12,023.43 99.16 12,122.59
SD (£) 10,811.21 357.77 10,816.73
Other long admission Number of FCEs 175 175 175
Mean (£) 4723.34 49.20 4772.55
SD (£) 11,578.98 179.26 11,568.97
Other short admission Number of FCEs 66 66 66
Mean (£) 533.92 262.86 796.78
SD (£) 285.78 368.10 396.96
Total Number of FCEs 2682 2682 2682
Mean (£) 8592.90 105.40 8698.30
SD (£) 10,581.59 415.90 10,582.63
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TABLE 50 The HES APC data on the PREVAIL babies: length and cost of admissions unadjusted and adjusted by time outside follow-up
Quantity
Total AM-PICC S-PICC
Babies (n) Mean SD Babies (n) Mean SD Babies (n) Mean SD
Length of stay per baby unadjusted for time
outside follow-up (days)
828 74.39 41.19 410 73.66 40.71 418 75.11 41.69
Length of stay per baby adjusted for time
outside follow-up (days)
828 68.65 37.91 410 67.68 36.77 418 69.61 39.01
Total cost per baby unadjusted for time
outside follow-up (£)
828 £28,174.93 £19,850.20 410 £28,123.64 £20,099.41 418 £28,225.24 £19,626.65
Total cost per baby adjusted for time outside
follow-up (£)
828 £26,332.09 £18,190.26 410 £26,222.37 £18,055.68 418 £26,439.72 £18,342.29
TABLE 51 The HES outpatient data on the PREVAIL babies: cost per outpatient appointment
Results
Total appointments by PREVAIL babies Appointments by babies allocated to AM-PICCs Appointments by babies allocated to S-PICCs
Number of
appointments Mean cost (£) SD (£)
Number of
appointments Mean cost (£) SD (£)
Number of
appointments Mean cost (£) SD (£)
Cost of HRG core 5858 150.29 62.59 3014 148.99 63.80 2844 151.67 61.25
Cost of unbundled HRG 5858 4.42 46.33 3014 3.50 38.41 2844 5.38 53.45








































































































































































































































































































































































Appendix 7 Additional information on
economic analysis: review and meta-analysis
Effect of infection on health outcomes
Methods
Pearl-growing review
A ‘pearl-growing’ review was conducted to identify evidence to inform the additional effect of BSI on
health outcomes such as death and NDI.137 Briefly, this technique requires a series of key papers to
be identified at the start (the ‘pearls’); from these key references, it is possible to look both forward
(through the papers’ citations) and backwards (through their own references). These steps are repeated
using the additional papers identified, until a comprehensive evidence base on the topic is gathered
and no new publications are found. This particular technique was chosen because a full systematic
review was outside the scope and timeline of this report.
Advice from the PREVAIL trial clinical team suggested that the key paper in the area is Stoll et al.10
This study was used as the starting point for finding studies on the effect of infection on NDI and
death. Systematic reviews were preferred.
Studies were included if their definition of infection matched the one used in the trial for clinically
serious BSI, and if the definition of NDI could be matched with the one used by Mangham et al.71
The choice of clinically serious BSI was because literature on the consequences of infection typically uses
the term sepsis or defines infection as an event requiring the use antibiotics for at least 3–5 days.10,78–80
Matching on the definition of NDI used by Mangham et al.71 was to allow the use of Mangham et al.’s71
transition probabilities to simulate the progression of impairment over time.
Definition of infection
The definition of infection follows the one of ‘clinically serious BSI’ as defined in the PREVAIL trial
protocol,59 section 4.1. A BSI case is defined as clinically serious if a baby is treated for at least
72 hours with intravenous antibiotic or dies during treatment.
Definition of neurodevelopment impairment
The definition of NDI was taken from Mangham et al.,71 whose source, Doyle et al.,83 considered
the 1991–92 cohort of the Victorian Infant Collaborative Study, covering births of 23–27 weeks’
gestational age in the Australian state of Victoria. Outcomes assessed at 2 years of age included
cerebral palsy, blindness, deafness and developmental delay (Table 52).
TABLE 52 Items included in the NDI measure
Outcome assessed Method of assessment
Cerebral palsy Criteria for diagnosis and severity assessment present in Kitchen et al.95
Blindness Visual acuity of < 20/200 in the BSE
Deafness Hearing loss requiring amplification
Developmental delay Assessed using the Bayley Scales MDI. Impairment defined as DQ of
< –1 SD computed relative to the mean (SD) for the respective controls on MDI
DQ, development quotient; MDI, Mental Developmental Index.
Note
Outcomes assessed at 2 years of age (Doyle et al.83) – VICSG 1991–92.
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Included studies
Three systematic reviews78–80 and an umbrella review119 were found on the effects of infection on
health outcomes. Data from the eligible studies were re-extracted and finally synthesised. The final
selection of studies for the effect of infection on NDI included Stoll et al.10 and Schlapbach et al.,74
whose definition of NDI matched the one used by Doyle et al.83 and Mangham et al.71 (Table 53).
The review on the effect of infection on the risk of death produced two studies74,76 (Table 54).
Meta-analysis results
The selected studies were meta-analysed following standard inverse variance estimator techniques.86
Tables 55 and 56 show the results.
TABLE 53 Studies on the effect of infection on NDI in preterm infants
Characteristics of the studies
Composite outcome: NDI
Schlapbach et al.74 Stoll et al.10
Assessment period 18–24 months 18–22 months
Definition of infection Positive culture and ≥ 5 days of
antibiotic therapy
Positive culture and ≥ 5 days of
antibiotic therapy
Cerebral palsy Presence of cerebral palsy Presence of cerebral palsy
Visual impairment Bilateral blindness Bilateral blindness
Hearing impairment Severe hearing loss requiring
auditory amplification
Bilateral hearing impairment
MDI score < 70 < 70
PDI score < 70 < 70
MDI, Mental Developmental Index; PDI, Psychomotor Developmental Index.
TABLE 54 Studies on the effect of infection on the risk of death in preterm infants
Schlapbach et al.74 Bassler et al.76
Assessment period 18–24 months 18 months
Definition of Infection Positive culture and ≥ 5 days of
antibiotic therapy
Positive culture
TABLE 55 Meta-analysis on the effect of infection on NDI
Element OR 95% CI
Studies
Schlapbach et al.74 1.69 0.96 to 2.98
Stoll et al.10 1.50 1.20 to 1.70
Results
Fixed- and random-effect estimator 1.53 1.36 to 1.73
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TABLE 56 Meta-analysis on the effect of infection on the risk of death at 2 years of age
Element OR 95% CI
Studies
Schlapbach et al.74 5.38 0.55 to 52.08
Bassler et al.76 2.58 1.31 to 5.07
Results
Fixed- and random-effect estimator 2.74 1.43 to 5.24
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Appendix 8 Additional information on
economic analysis: probability calculations
Probability of death at 6 months
The objective of this analysis was to obtain the probability of death from PICC insertion to 6 months’
follow-up in babies who did not have a clinically serious BSI, to inform the decision model.
Methods
Population and subgroups
The PREVAIL trial enrolled a mixed population of preterm babies. Of relevance to the model were
babies who were born at a gestational age of ≤ 27 weeks and babies who were born at 28–32 weeks
of gestation. This analysis uses only the data on the PREVAIL trial babies in these subgroups: 381
PREVAIL babies born at gestational age of ≤ 27 weeks and 354 PREVAIL babies who were born at
28–32 weeks of gestation.
Analysis
The analysis was initially descriptive on:
l The number of babies who had a clinically serious BSI with S-PICCs by gestational age subgroup,
which represents the probability of infection with a S-PICC in the model.
l The number of babies who died over the time horizon of 6 months, taking death as recorded either
in the PREVAIL trial CRFs or in the HES records via the Patient Demographics Service, by gestational
age subgroup. This represents the probability of death irrespective of the type of PICC and irrespective
of prior clinically serious infection.
In a second stage, a regression analysis was conducted on the probability of death given gestational
age subgroup and prior clinically serious infection. The regression analysis explored the impact of using
generalised linear models with binomial family or Poisson family and log link.
Results
Tables 57 and 58 show the results of the descriptive analysis. The probability of having a clinically serious
BSI with a S-PICC was 14.52% (95% CI 9.79% to 20.41%) in the younger gestational age subgroup and
was 3.80% (95% CI 1.54% to 7.68%) in the older gestational age subgroup. The probability of death over
the time horizon of 6 months is shown in Table 58.
TABLE 57 Probability of clinically serious BSI with S-PICCs
Statistics
Gestational age
≤ 27 weeks 28–32 weeks
Number of babies who had infection and received a S-PICC 26 7
Number of babies who received a S-PICC 184 182
Proportion 0.14 0.04
Standard error 0.03 0.01
95% CI 0.09 to 0.20 0.02 to 0.08
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Table 59 shows the results of the regression analysis of the probability of death given gestational age
and prior clinically serious BSI. The best-fitting regression is the regression including both explanatory
variables. It suggests that having a clinically serious BSI is associated with 78.4% greater risk of death
(RR 1.784), and that being born at a gestational age of 28–32 weeks is associated with an 85.5% lower
risk of death (RR 0.245).
It is not clear whether this is a correlation or a causal association. There may be other factors that
increase the risk of clinically serious BSI and increase the risk of death, for example other health
problems that the babies may have been born with. Without controlling for these other factors, it is
not possible to ascertain whether or not preventing clinically serious BSI reduces the risk of death to
the extent that the regression analysis suggests. Given the small number of deaths, the regression
analysis is constrained in the number of variables that can be included.
Application to the model
Method
The following equations explain the methodology.
P(death all) = P(deathjinfection) × P(infection) + P(deathjno infection) × ½1−P(infection). (1)
TABLE 58 Probability of death over the time horizon of 6 months
Statistics
Gestational age
≤ 27 weeks 28–32 weeks
Number of babies who died 52 11
Number of babies 381 354
Proportion 0.14 0.03
Standard error 0.02 0.01
95% CI 0.10 to 0.18 0.02 to 0.05






Controlling for both clinically
serious BSI and gestational
age category
Risk ratio SE Risk ratio SE Risk ratio SE
Clinically serious BSI 2.51** 0.71 – – 1.85* 0.54
Gestational age category – – 0.23*** 0.07 0.25*** 0.08
Constant 0.08*** 0.01 0.14*** 0.02 0.12*** 0.02
n 735 735
AIC 0.5793931 0.5519772 0.5606888
BIC –4415.851 –4436.002 –4550.999
*p < 0.05, **p < 0.01, ***p < 0.001.
AIC, Akaike information criterion; BIC, Bayesian information criterion; SE, standard error.
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P(death all) = RR(infection on death) × P(deathjno infection) × P(infection)
+ P(deathjno infection) × ½1−P(infection).
(2)
P(death all) = P(deathjno infection) × RR(infection on death) × P(infection) + ½1−P(infection). (3)
P(deathjno infection) =
P(death all)
RR(infection on death) × P(infection) + ½1−P(infection).
(4)
P(death all) is the probability of death in the mixed population of people with and without a clinically
serious BSI. P(death|infection) is the probability of death given a prior clinically serious BSI and
P(death|no infection) is the probability of death given no prior clinically serious BSI.
P(infection) is the probability of a clinically serious BSI occurring.
RR(infection on death) is the ratio between the probability of death with and death without a clinically
serious BSI.
Data inputs
Table 60 shows the distribution of babies based on their survival status at 6 months, conditional on
prior infection.
Based on the data from Table 60, it was possible to compute the RR for clinically serious BSI on death
before the end of follow-up (RR 2.51, 95% CI 1.44 to 4.38). As the number of events is limited, it was
not feasible to compute a gestational age-specific RR by splitting the overall sample. Therefore, the RR
calculated using the whole PREVAIL sample was applied to all gestational age groups.
P(death all) was obtained as 1 minus the probability of surviving to discharge extracted from
Santhakumaran et al.,87 and P(Infection) corresponds to the probability of experiencing a clinically
serious BSI, as resulted from the PREVAIL trial data. See points (6) and (5), respectively, in Table 17.
Results
The results of Table 61 are used as the baseline probability of death before the end of trial follow-up in
the model. The RR of death given clinically serious BSI is then applied to the baseline probability to
obtain the probability of death given infection. As detailed in Chapter 4, it was not possible to obtain
TABLE 60 Number of deaths before end of follow-up, by infection status (all gestational ages)
Occurrence of clinically
serious BSI
Death before end of follow-up (n)
No Yes Total
No 616 50 666
Yes 56 13 69
Total 672 63 735
TABLE 61 Probability of death before the end of follow-up, without infection
Gestational age (weeks) P(death|no infection) (95% CI)
23–27 0.20 (0.16 to 0.24)
28–32 0.034 (0.030 to 0.036)
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strong evidence about the existence and the size of this effect, neither from the PREVAIL trial nor
from the available literature. Therefore, the base case assumes that a clinically serious BSI does not
increase the risk of death at 6 months (i.e. a RR of 1 was assumed), whereas a scenario considers the
application of the RR computed from the PREVAIL data, as detailed in Table 60.
Transitions between neurodevelopmental impairment states or death
Mangham et al.71 report the counts of changes in impairment status for the babies belonging to the
VICSG84 1991–92 cohort, which includes all babies born at 23–27 weeks’ gestational age from the
state of Victoria in Australia. The impairment levels are classified according to the definition adopted
by Doyle et al.83
The counts reported in Mangham et al.71 are used to compute 3-year transition probabilities for the
period covering ages 2–5 and 5–8 years, respectively. After the age of 8 years, transition across
impairment states are assumed to stop; hence, babies either remain in their current impairment level or
will transition to the absorbing death model state. The 3-year probabilities are then converted to annual
transition probabilities using standard formulas as reported in Briggs et al.,86 and are reproduced in
Tables 62 and 63. The counts reported in Mangham et al.71 are supplemented by the average probability
of death between the ages of 2 and 5 years, 5 and 8 years and 8 and 18 years extracted from the
National Life Tables, UK: 2013–2015.99
TABLE 62 Annual transition probabilities across impairment states (age 2–5 years)
NDI
NDI
No Mild Moderate Severe Dead Total
No 0.91 0.08 0.01 0.00 0.00 1.00
Mild 0.17 0.75 0.07 0.01 0.00 1.00
Moderate 0.03 0.12 0.80 0.05 0.00 1.00
Severe 0.00 0.04 0.04 0.91 0.00 1.00
TABLE 63 Annual transition probabilities across impairment states (age 5–8 years)
NDI
NDI
No Mild Moderate Severe Dead Total
No 0.96 0.04 0.00 0.00 0.00 1.00
Mild 0.14 0.82 0.04 0.00 0.00 1.00
Moderate 0.01 0.08 0.83 0.07 0.00 1.00
Severe 0.00 0.02 0.06 0.92 0.00 1.00
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Appendix 9 Additional information on
economic analysis: costs
Costs over 6 months from peripherally inserted central venous
catheter insertion
The objective of this analysis was to estimate the mean, standard error and appropriate distribution
of the costs over 6 months from PICC insertion, to inform the cost-effectiveness model.
Methods
This analysis used the costs of the PREVAIL trial babies, which were calculated as reported in
Chapter 4, Costs of hospital care.
Population and subgroups
As these estimates aimed to inform the decision model, the analysis was conducted in the populations
with a gestational age of ≤ 27 weeks and with gestational age of 28–32 weeks who had sufficient
records in the NNRD and in HES APC data. The analytical sample comprises 381 babies with
gestational age of ≤ 27 weeks and 354 babies with gestational age of 28–32 weeks.
Choice of explanatory variables
Five explanatory variables were explored: gestational age subgroup (≤ 27 weeks or 28–32 weeks),
PICC type (AM-PICC or S-PICC), occurrence of clinically significant BSI and death at 6 months. Death
at 6 months was obtained from the PREVAIL trial CRFs and from the routine health-care records
(see Chapter 4, Deaths during the 6-month follow-up period). No other explanatory variables were explored,
given that the structure of the cost-effectiveness model for the 6 months from PICC insertion
differentiates babies only by these variables.
Description of the costs
The costs in the entire analysis sample and by the various exploratory variables were described in
terms of their summary statistics. Their distributions were plotted to understand if the costs followed a
normal distribution.
Estimation
Costs were regressed on the various exploratory variables using generalised linear models, namely
with identity distribution and Gaussian link (which is equivalent to linear regression) and identity
distribution and log link.
Results
Descriptive statistics
Table 64 presents the costs of hospital care in the sample of PREVAIL babies with gestational ages of
≤ 27 weeks and 28–32 weeks, who are those considered in the economic model, by gestational age
subgroup, type of PICC, whether or not a clinically serious BSI occurred during the primary follow-up
period and by whether or not death occurred during the 6-month follow-up.
l The cost of hospital care is lower for babies in the older gestational age group (£62,491 vs. £106,240).
l The cost of hospital care is similar, irrespective of the PICC type, at approximately £85,000.
l The cost of hospital care is higher for babies who had a clinically serious BSI (£105,468 vs. £83,066).
l The cost of hospital care is lower for the babies who died during the 6-month follow-up period
(£53,415 vs. £88,146).
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TABLE 64 Summary statistics of all hospital costs over 6 months from PICC insertion
Costs Number of babies Mean costs (£) SE (£) Number of babies Mean costs (£) SE (£) Number of babies Mean costs (£) SE (£)
Total Gestational age: ≤ 27 weeks Gestational age: 28–32 weeks
Cost of hospital care 735 85,169.36 1848.49 381 106,240.27 2784.30 354 62,491.35 1720.23
Total AM-PICC S-PICC
Cost of hospital care 735 85,169.36 1848.49 366 86,045.40 2640.83 369 84,300.44 2590.38
Total No clinically significant BSI Clinically significant BSI
Cost of hospital care 735 85,169.36 1848.49 666 83,066.31 1889.95 69 105,468.37 7002.05
Total Alive at 6 months Death during 6-month follow-up







































The best-fitting regression to predict costs was the generalised linear model with Gamma distribution
and log link according to plot of deviance residuals and normal plot. The best-fitting regression
according to the Park test was the Gaussian distribution and log link. The results for both regressions
were very similar. Hence, the Gaussian distribution and log link, which produces coefficients that are
easier to interpret, was the preferred estimation model.
Results
Table 65 shows the results of four regression equations with various combinations of the candidate
explanatory variables: gestational age, clinically significant BSI and death at 6 months. Gestational
age is used in all regression equations because it corresponds to the definition of the subgroups. The
coefficient on gestational age is similar across the four regression models. It suggests that babies born
at 28–32 weeks of gestation have 53–59% lower costs than babies born at younger gestational ages.
The association between clinically significant BSI and costs is uncertain. The coefficient is positive,
which indicates higher costs in babies who experienced a clinically significant BSI, but not statistically
significant. Regression 4, which includes only gestational age as the explanatory variable, has the
poorest fit (indicated by the higher Akaike information criterion and Bayesian information criterion).
Furthermore, this regression equation does not control for whether or not a clinically significant BSI
occurred or for babies’ characteristics that may increase their risk of death, and also increase their
costs. Hence, it is unclear if this association is confounded.
The regressions suggest that there is a negative association between whether or not death occurred
and costs. This association is statistically significant and stable to the inclusion of clinically significant
BSI as an explanatory variable. The association between death and costs may be related with the
shorter length of stay of babies who died than those babies who were alive at 6 months. However,
the association may be confounded by length of stay and by their characteristics. For example, the
babies who died may have been in too poor health to allow for surgical procedures, thereby reducing
their costs. Under this scenario, an intervention that prevents their death does not necessarily result in
an increase in costs if the babies still do not receive the surgical procedures.




1 2 3 4
Gestational age (= 1
if 28–32 weeks) (SE)
–0.580*** (0.0419) –0.520*** (0.0445) –0.594*** (0.0417) –0.531*** (0.0441)
Clinically significant
BSI (= 1 if
occurred) (SE)
0.144** (0.0508) 0.100 (0.0551)
Death at 6 months
(= 1 if occurred) (SE)
–0.726*** (0.104) –0.714*** (0.104)
Constant (SE) 11.63*** (0.0221) 11.56*** (0.0236) 11.65*** (0.0205) 11.57*** (0.0218)
N 735 735 735 735
AIC 17,753.6 17,840.8 17,758.8 17,841.9
BIC 17,772.0 17,854.6 17,772.6 17,851.1
*p < 0.05, **p < 0.01, ***p < 0.001.
AIC, Akaike information criterion; BIC, Bayesian information criterion; SE, standard error.
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Discussion
The base-case cost-effectiveness model assumes that the costs incurred by babies over 6 months
from PICC insertion are the same irrespective of the occurrence of a clinically significant BSI or
death. The costs will depend only on their gestational age. The implication is that a reduction in
the probability of clinically significant BSI or in the probability of death has no effect on the costs.
This is a conservative assumption.
Two scenarios are tested. One scenario assumes that babies who die have lower costs, as suggested by
regression equation 3 (see Table 65). The implication is that interventions that reduce the probability
of death result in an increase in costs over 6 months. The other scenario assumes that babies who die
have lower costs and that babies who have clinically significant BSI have higher costs, as suggested by
regression equation 1 (see Table 65). The implication is that interventions that reduce the probability of
a clinically significant BSI occurring result in a decrease in costs over 6 months.
Costs between 6 months and 2 years of age
Costs between 6 months and 2 years of age were computed using two sources of information: NHS
Reference Costs 2015–16,62 and resource use from an unpublished study about variation in neonatal
and paediatric admissions (Katie Harron, personal communication).
Methods
Information from the NHS reference costs was used to compute average costs weighted by level of
activity. This results in an estimate of average costs of inpatient care (for elective and non-elective),
average outpatient visit cost, and average A&E attendance cost (Table 66).
Unpublished results provided information on the number of babies accessing these services, by
gestational age groups 23–27 weeks and 28–32 weeks, and their resource use in terms of hospital
admission and type (planned vs. unplanned), A&E and outpatient attendances. This was used to
compute the number of hospital admissions by type, and visits per baby. Data about the proportion
of planned and unplanned admissions were used as weight when averaging the cost of elective and
non-elective hospital admission. Average costs were then multiplied by the relevant resource use
and summed across type of care to obtain total cost per baby.
TABLE 66 Unit cost weighted average by activity
Type of hospital use Average cost (£)
Elective inpatient 2790.72
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Results
TABLE 67 Resource use 6–24 months
Gestational age at
birth (weeks)
Admissions (%) Number, per baby
Planned Unplanned Episodes A&E visits
Outpatient
attendances
33–36 23 77 0.43 1.08 1.55
28–32 24 76 0.74 1.34 4.61
23–27 28 72 1.32 2.01 11.47
TABLE 68 Costs 6–24 months
Gestational age at birth (weeks) Cost (95% CI) (£)
23–27 5989.17 (5983.44 to 5994.98)
28–32 3026.43 (3024.21 to 3028.73)
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Appendix 10 Additional information on
economic analysis: model validation
Part A: validation of the conceptual model
A1: Have experts been asked to judge the appropriateness of the conceptual model?
Yes. The experts were Ruth Gilbert, Sam J Oddie and Ajay K Sinha. They were chosen because they
were co-applicants in the project and are epidemiologists (RG) or clinicians (SJO, AKS) with extensive
experience in this clinical area. The experts found the conceptual model to be generally appropriate,
and noted the uncertainty in the link between clinically significant BSI, NEC and NDI. There was some
debate about whether or not clinically significant BSI should be assumed to have a causal effect on the
risk of death at 6 months, given the limited data in the PREVAIL trial.
A2: Has this model been compared with other conceptual models found in the
literature or clinical textbook?
Partly. The model on predicting outcomes in early childhood was informed by the Stoll et al.10 study
on the effect of infection in early infancy on neurodevelopmental outcomes. However, no other
cost-effectiveness model on infection in preterm neonates was found for comparison. The model on
predicting lifetime costs and health outcomes beyond 2 years of age was informed by the model by
Mangham et al.71
Part B: input data validation
B1: Have experts been asked to judge the appropriateness of the input data?
Yes, the same experts as in A1 reviewed the input data. The experts agreed that the appropriate data
were used.
B2: When input parameters are based on regression models, have statistical tests
been performed?
Partly; the costs from PICC insertion to 6 months were obtained from the linked data (see Appendix 9).
The model type was chosen on the basis of the distribution of the costs, Park test and the plot of
deviance residuals versus normal plot. Four model specifications were tested. The most conservative
for the cost-effectiveness of interventions to prevent infections was selected for the base case, but the
impact of alternative specifications was tested in a sensitivity analysis to the cost-effectiveness model.
Part C: validation of the computerised model
C1: Has the computerised model been examined by modelling experts?
Yes, the cost-effectiveness model was examined by Rita Faria. Rita Faria is not an independent expert,
as she supervised the development of the cost-effectiveness model and collaborated in all economic
analyses. The cost-effectiveness model is valid.
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C2: Has the model been run for specific, extreme sets of parameter values in order to
detect any coding errors?
Yes. The tests included:
l Tree –
¢ Baseline risk of infection = 0. If the baseline risk of infection is set to 0, we expect both PICC groups
to give identical results, as there will be no difference in the rate of death and NDI at 2 years.
¢ RR of infection set to 0: AM-PICC becomes cost-effective.
¢ RR of infection, OR of infection on death (6 months), OR of infection on death (2 years) and OR
of infection on NDI (2 years) set to 1. AM-PICCs and S-PICCs are identical. There is only a
difference of £53.70 in costs, which is the additional cost of an AM-PICC.
l Markov model –
¢ Utilities = 1, disutilities = 0. Setting all utilities to 1 means that QALYs accrued in a cycle (without
half-cycle correction) should be equal to the number of people alive in a state (i.e. QALYs = life
expectancy). Alternatively, that the sum of the QALYs accrued in a cycle and the cumulative
number of deaths should always sum to 1. This is indeed the case in our model.
¢ Probability of death = 0. Setting UK lifetable value to 0. We expect cycle number of deaths and
cumulative number of deaths to remain at 0, with everyone dying in the last cycle. This is indeed
the case.
¢ No transitions to other states. As transitions are stopped, then babies should not move from the
initial distribution.
¢ 50% no NDI, 50% mild NDI. Results from this test are expected to be identical to the average of
having 100% of babies in ‘no NDI’ and 100% of babies in ‘mild NDI’.
¢ Setting all HRs to 1 – the mortality rate is identical for all severity levels.
Any errors identified were corrected.
C3: Have patients been tracked through the model to determine whether or not its
logic is correct?
Yes, the patients were tracked through the model at ages 5, 8 and 18 years. The model logic is correct.
C4: Have individual submodules of the computerised model been tested?
No.
Part D: operational validation
D1: Have experts been asked to judge the appropriateness of the model outcomes?
Yes; Ruth Gilbert, Sam J Oddie and Ajay K Sinha found the results to have face validity.
D2: Have the model outcomes been compared with the outcomes of other models that
address similar problems?
Yes. The results were compared with those reported by Mangham et al.,71 using the same input
parameters. The results were very similar.
D3: Have the model outcomes been compared with the outcomes obtained when using
alternative input data?
No, as no alternative input data were identified.
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D4: Have the model outcomes been compared with empirical data?
No.
Part E: other validation techniques
E1: Have any other validation techniques been performed?
No.
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Appendix 11 Additional information on
economic analysis: sensitivity analysis
BOX 1 Main model assumptions
l The occurrence of infection increases the risk of developing NDI or of dying by 2 years of age.
l The occurrence of infection has the same effect on the risk of NDI and death for all gestational
age subgroups.
l The occurrence of infection does not increase the risk of death by 6 months of age.
l The effectiveness of AM-PICCs is the same for all gestational age subgroups.
l The distribution of infants across levels of NDI at 2 years of age is the same for the two PICCs,
irrespective of previous infection.
l Infants are attributed the same costs between birth and 6 months of age, and between 6 months and
2 years of age, irrespective of the occurrence of infection or death.
l After age 2 years, long-term costs and health outcomes are influenced only by a child’s NDI level at
2 years of age.
l Children experience improvements or deteriorations in their NDI state only up to the age of 8 years.
After age 8 years, they can transition to the absorbing ‘death’ state only.
TABLE 69 List of sensitivity analyses
Sensitivity analysis Justification
Effect of infection on NDI and death
Reduce the effect of infection on either death at
2 years or NDI to null effect (OR 1)
To take into account possible bias in the observational nature
of the evidence regarding the impact of infection
Assume impact of infection on death at 6 months
equals the RR from PREVAIL trial data of 2.62
(95% CI 1.52 to 4.51)
To take into account information about the impact of infection
coming from the PREVAIL trial follow-up
Baseline probabilities
Transitions up to 18 years of age To test the sensitivity of results to the extrapolation of
transition probability data beyond childhood
Stop backward transitions for babies with severe NDI To take into account the clinical implausibility of improvement
in severe babies’ classification over time
Use 3-year transition probabilities instead of
yearly ones
To take into account the actual assessment point in the
references’ sources and the likelihood of movement between
disability states
Costs
Differentiate costs between PICC insertion and
6 months by survival and infection status
To take into account additional evidence coming from the
regression analysis of costs (see Appendix 9)
Parameters to predict long-term outcomes and costs
Increase/decrease costs after 18 years of age To take into account the possible changes in costs after
18 years, which were not taken into account in the base case
Apply HRQoL age and sex decrements from
Ara and Brazier104
To take into account the impact of age and sex on utility values
Assume NDI level does not increase the risk of
death after 2 years of age
To take into account the impact of assuming that NDI has an
additional impact on mortality according to its level
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TABLE 70 Details of the alternative scenarios on RR of death and costs
Parameter Value (95% CI; distribution) Source
Effect of infection on NDI and death
RR of the association of
clinically serious BSI on death
at 6 months; same for both
gestational age subgroups
l Base case: 1 (fixed)
l Scenario: 2.62 (1.52 to 4.51; log-normal)
l Assumed that clinically serious BSI has
no causal effect on death at 6 months
l PREVAIL trial
Costs
Health-care costs between PICC insertion and 6 months
Base case PREVAIL trial
Gestational age:
23–27 weeks
£105,873 (£101,444.99 to £110,485.27;
gamma)
l Generalised linear model with Gaussian
distribution and log-link; explanatory
variable is gestational age group
l See Appendix 9 for more detailsGestational age:
28–32 weeks
£62,255.37 (£54,711.87 to £70,838.93;
gamma)
Scenario 1
Scenario 1 adjusts for gestational age
subgroup and whether or not the baby
survived to 6 months
Gestational age:
23–27 weeks
l Alive: £114,691.36 (£110,174.42 to
£119,393.50; gamma)




l Alive: £63,322.75 (£56,054.96 to
£71,532.85; gamma)
l Dead: £31,007.98 (£22,387.28 to
£42,948.29; gamma)
Scenario 2
Scenario 2 adjusts for gestational age group,
whether or not the baby survived to 6 months




l Alive/no BSI: £112,420.32 (£107,654.68
to £117,396.93; gamma)
l Alive/BSI: £129,832.44 (£112,545.85 to
£149,774.18; gamma)
l Dead/no BSI: £54,393.50 (£42,482.35 to
£69,644.29; gamma)




l Alive/no BSI: £62,943.95 (£55,523.41 to
£71,356.23; gamma)
l Alive/BSI: £72,692.97 (£58,046.05 to
£91,035.79; gamma)
l Dead/no BSI: £31,454.83 (£21,910.47 to
£42,331.21; gamma)
l Dead/BSI: £35,171.80 (£22,905.95 to
£54,005.87; gamma)
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TABLE 71 Maximum acquisition price per AM-PICC effectiveness (gestational age: 23–27 weeks)


















TABLE 72 Maximum acquisition price per AM-PICC effectiveness (gestational age: 28–32 weeks)
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Figures 23 and 24 represent the incremental change of net monetary benefit, with respect to its mean



































FIGURE 22 Maximum acquisition price per AM-PICC effectiveness, gestational age: 28–32 weeks.
–1500 –1000
Incremental change in net monetary benefit, with respect to its mean value
–500 500 10000
RR of infection
p(death 0–6 months, no infection)
OR(death 6 months–2 years, infection)
Baseline p(infection)
p(death 6 months–2 years, no infection)
Cost 0–6 months: alive, no infection
Cost 0–6 months: alive, infection
p(NDI, no infection)
OR(NDI, infection)
Cost 0–6 months: dead, infection
Cost 0–6 months: dead, no infection
Mild NDI (%)
Moderate NDI (%)
RR(death 0–6 months, infection)
Cost 6 months–2 years
FIGURE 23 Univariate sensitivity analyses for gestational age subgroup 23–27 weeks at the £20,000 per QALY
cost-effectiveness threshold. Adapted from Grosso et al.106 © Author(s) (or their employer(s)) 2020. Re-use permitted
under CC BY. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons
Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this
work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether
changes were made. See: https://creativecommons.org/licenses/by/4.0/. Minor formatting changes have been made.
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FIGURE 24 Univariate sensitivity analyses for gestational age subgroup 28–32 weeks at the £20,000 per QALY
cost-effectiveness threshold.
TABLE 73 Incremental net health and monetary benefit by scenario for cost-effectiveness thresholds of £13,000 and
£20,000 per QALY
Sensitivity analysis
Incremental net monetary benefit (£)









Base case –145.07 –69.75 –193.63 –77.98
No effect of infection on NDI –101.25 –59.70 –128.97 –63.16
No effect of infection on death between
6 months and 2 years
–98.83 –63.85 –120.29 –68.67
Apply RR on death from PREVAIL trial –728.45 –99.40 –1,127.72 –124.98
Apply transition probabilities up to
18 years of age
–134.82 –67.12 –187.20 –74.10
Stop backward transitions for babies with
severe NDI
–150.80 –70.98 –202.04 –79.80
Differentiate costs between PICC insertion
and 6 months of age by survival and
gestational age
–134.11 –69.03 –182.65 –77.26
Differentiate costs between PICC
insertion and 6 months by survival,
gestational age and infection status
–259.43 –90.26 –307.97 –98.49
Use 3-year transition probabilities –123.08 –64.44 –161.17 –70.14
Double costs after 18 years of age –145.27 –70.06 –193.83 –78.29
Apply HRQoL age and sex decrement –147.55 –70.10 –197.43 –78.53
Assume NDI does not increase the risk
of death after the age of 2 years
–143.83 –69.43 –191.46 –77.43
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Appendix 12 Additional information on
generalisability study: linkage methods
Parts of this appendix are reproduced from Fraser et al.111 © 2019 Fraser et al. This is an openaccess article distributed under the terms of the Creative Commons Attribution License
(https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original author and source are credited.
We used deterministic and probabilistic linkage to link babies in the NNRD to BSI records from national
infection surveillance. We first performed deterministic linkage using the NHS number. However, not all
babies had a complete NHS number; therefore, we also used probabilistic methods. In both deterministic
and probabilistic linkage, links were restricted to those with a sample date from the surveillance data
between 7 days before admission and 14 days after discharge from the NNU. Further restrictions to BSI
dates were applied depending on the definition of BSI being used (e.g. during PICC time at risk/early
onset/late onset). Each BSI could be linked to only one baby; however one baby could be linked to
multiple BSI records. Therefore, linkage was one to many.
Deterministic linkage
We first used deterministic linkage to link babies in the NNRD with BSI records in the surveillance
data. Records were linked if the same NHS number was recorded in each data set. The NHS number is
a unique 10-digit identifier assigned at birth. NHS number matches were manually reviewed to ensure
that they represented true matches. NHS number links were then used as the training data set for
probabilistic linkage.
Probabilistic linkage
For records that were not linked on NHS number, we used probabilistic linkage based on the remaining
common identifiers in each data set. The available identifiers were date of birth, postcode prefix,
postcode suffix, sex and hospital/laboratory. In probabilistic linkage, match weights are created that
represent the likelihood that two records belong to the same subject, according to the similarity of a
set of identifiers.138 We first used ‘blocking’ to restrict the comparisons to records that agreed on at
least one of date of birth, postcode prefix or postcode suffix.139 This ensured that we compared only
records that had a chance of being a match; otherwise, records could, at most, agree on hospital and
sex, which would not be sufficient to identify a link.
Next, we used the deterministic links as the reference standard for true matches to calculate probabilistic
match weights.112 Match weights were calculated as log2(
m− probability
u− probability)
. We estimated the probability that
records were a true match, given identifiers were in agreement, disagreement or missing in either data set
(m-probabilities). We estimated the probability that records were not a match (i.e. disagreed on NHS
number), given identifier agreement, disagreement or missing in either data set (u-probabilities).
Match weights were totalled across identifiers to produce an overall weight (‘summed weight’) for each
comparison pair, based on the pattern of agreement of identifiers that represents the likelihood that
each pair is a match. A plot of the log frequency of the weights was examined to determine an upper
and lower threshold, above which all pairs are classified as links and below which all pairs are classified
as non-links. The agreement patterns of the weights close to the thresholds were examined and a
second wider set of thresholds was selected to reduce potential missed matches and false matches.
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Comparison pairs with a match weight between these two thresholds were reviewed manually by one
author (CF) following a set of rules agreed by all authors (Table 74). To aid decision-making, any clinical
records indicating BSI in the NNRD were checked as evidence that the baby had an infection. When
date of birth was in disagreement, the difference between the dates was examined. When postcode
prefix or suffix disagreed, the number of letters that matched was recorded (e.g. RG1 and RK1 would
be 2, RG1 and NG2 would be 1).
TABLE 74 The rules followed in manual review
Agreement on identifiersa
(1= agree, 0= disagree, x=missing)
Condition AllocatePrefix Suffix DOB Sex Hospital
Any BSI links to any baby with a match weight above the upper
threshold
Non-link
1 1 1 0 1 BSI does not link to a different baby above the upper threshold Link
1 0 1 1 1 BSI does not link to a different baby with a higher summed weight Link
1 0 x 1 1 BSI does not link to a different baby with a higher summed weight
and baby has a clinical record of BSI with the same sample date
Link
1 0 x 1 1 BSI does not link to a different baby with a higher summed
weight, DOB is recorded in one of the two data sets (missing in
other) and age (in data set with complete DOB) is < 28 days
Link
1 1 0 x 1 BSI does not link to a different baby with a higher summed weight
and DOB disagrees, but is within 7 days
Link
1 x 0 1 1 BSI does not link to a different baby with a higher summed weight
and DOB disagrees, but is same month and year, and age at BSI in
surveillance data is < 28 days
Link
x x 1 1 1 BSI does not link to a different baby with a higher summed weight
and age at BSI in surveillance data is < 28 days
Link
x x 1 1 1 BSI does not link to a different baby with a higher summed weight
and age at BSI in surveillance data is ≥ 28 days old
Missing
x x 1 x x Any given BSI does not link to another baby Missing
x x 1 x 0 Any given BSI does not link to another baby Missing
x x 1 0 x Any given BSI does not link to another baby Missing
x x 1 0 0 Any given BSI does not link to another baby Missing
x x 1 0 1 Any given BSI does not link to another baby Missing
0 x 1 x 0 Any given BSI does not link to another baby Missing
0 x 1 0 x Any given BSI does not link to another baby Missing
0 x 1 1 x Any given BSI does not link to another baby Missing
x x 1 1 x Any given BSI does not link to another baby Missing
x x 1 1 0 Any given BSI does not link to another baby Missing
DOB, date of birth.
a The agreement on identifiers represents how much identifiers agreed for each comparison pair, where 1 indicates
agreement on a given identifier, 0 indicates disagreement, and x indicates that the identifier was missing in one or
both data sets.
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Following probabilistic linkage, we further inspected unlinked records in the NNRD for babies aged
< 28 days with a clinical record of BSI in the NNRD, as we believed that these records should link to
a BSI. For these babies, we searched the surveillance data for any BSI reported to the corresponding
laboratory in the same month and reviewed the potential links. However, few additional links
were identified, suggesting under-reporting of BSI to the surveillance system, or reporting from
unexpected laboratories.
Multiple births
We used the same match weights and rules for manual review of records for babies from multiple
births as for singletons, but manually reviewed the records separately, as babies born on the same day
to the same mother share most of their identifiers. On the few occasions when it was not possible to
determine which baby a BSI should match to, we randomly allocated the BSI to one of the babies to
avoid duplicates. Multiple births were identified in the NNRD using the foetus number, birth order,
date of birth and mother’s NHS number.
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Appendix 13 Additional information
on generalisability study: clearly
pathogenic organisms
BOX 2 List of clearly pathogenic organisms from surveillance data that linked to babies in the NNRD
l E. coli.
l Streptococcus Group B stem.










l Enterobacter other named.
l Streptococcus intermedius group.
l Enterococcus faecium.
l Coliform.
l Candida other named.
l Klebsiella oxytoca.





















l Streptococcus Group G stem.
l Cedecea lapagei.
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l Enterobacter cloacae complex.


























BOX 2 List of clearly pathogenic organisms from surveillance data that linked to babies in the NNRD (continued)
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BOX 3 List of other organisms from surveillance data that linked to babies in the NNRD
l Bacillus sp.
l CoNS.
l Staphylococcus other named.
l Acinetobacter sp.
l Staphylococcus sp.





l Phialophora other named.
l Brevibacterium other named.
l Acinetobacter junii.
l Corynebacterium minutissimum.









l Micrococcus luteus (sarcina).
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l Acinetobacter calcoaceticus (anitratus).
l Burkholderia cepacia.
l Neisseria other named.
l Bifidobacterium breve.
l Moraxella osloensis.































l Aerococcus other named.
l Eikenella corrodens.
l Haematobacter sp.
l Rhodococcus other named.
l Abiotrophia defectiva.
BOX 3 List of other organisms from surveillance data that linked to babies in the NNRD (continued)
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l Streptococcus infantarius ssp. nov.
l Gemella morbillorum.
l Micrococcus other named.
l Kocuria kristinae.





l Aggregatibacter (haemophilus) segnis.
l Pseudomonas oleovorans.
l Pseudoclavibacter sp.
BOX 3 List of other organisms from surveillance data that linked to babies in the NNRD (continued)
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Appendix 14 Additional information on
the generalisability study: changes over
time in national infection surveillance
In England, data on BSIs and other infections are collected through a voluntary surveillance systemoperated by PHE.140 The current voluntary surveillance system, known as the Second Generation
Surveillance System (SGSS), was introduced in 2014 to replace LabBase2, which operated from
2002 to 2014. When LabBase2 ended, data were migrated to SGSS.
In both LabBase2 and SGSS, laboratories are required to provide information on clinically significant
BSIs only. PHE do not produce guidance on what is considered clinically significant; therefore, the type
of BSI submitted varies by laboratory, depending on decision-making of individual staff or on local
procedures. BSIs caused by selected notifiable organisms, for example Streptococcus pneumoniae, were
on a fast-track list in LabBase2 and automatically sent to PHE, but BSIs caused by all other organisms
required authorisation. In contrast, in SGSS, data on all BSIs are automatically uploaded unless a
laboratory requests the ability to manually review a BSI caused by a given organism. It is reported
anecdotally that many laboratories upload data on all BSIs to SGSS without any review of clinical
significance, to reduce burden on staff. This has resulted in SGSS capturing data on BSIs that would
not have been reported to LabBase2, such as positive cultures of skin organisms that have uncertain
clinical significance, for example CoNS.
To understand how case ascertainment changed following the system change, we examined the total
number of BSIs in the surveillance data over time for all BSIs, for BSIs caused by skin organisms and
for BSIs caused by potential pathogens. We used interrupted time series Poisson regression of monthly
BSI rates for all BSIs, BSIs caused by skin organisms and BSIs caused by potential pathogens for infants
aged < 1 year to quantify the change in the number of BSIs reported to the infection surveillance
system.141 SGSS was first implemented in March 2014 and adoption of SGSS was gradual, owing to the
large number of laboratories and their different operating systems; therefore, we examined the time
before introduction (January 2010 to March 2014) and after most laboratories were reporting to SGSS
(December 2015 to July 2017).
The equation used for interrupted time series regression is given in Equation 5, the interrupted time
series Poisson model, where Yt represents the number of BSIs at time t, T represents the months since
January 2001, Xt represents a dummy variable for either pre (0) or post (1) the introduction of SGSS.
β0 represents the baseline level in January 2010, β1 is the pre-system change trend, β2 is the step
change following the introduction of the new system and β3 is the trend change following the
introduction of SGSS:
Y t = β0 + β1T + β2Xt + β3TXt (5)
Following the introduction of SGSS, there was an increase in the number of infections reported.
The largest increase was seen in BSIs caused by skin organisms, which almost doubled [incidence rate
ratio (IRR) 1.96, 95% CI 1.78 to 2.15]. The number of BSIs caused by all organisms increased by 47%
(IRR 1.47, 95% CI 1.39 to 1.56) and potential pathogens increased by 20% (IRR 1.20, 95% CI 1.11 to
1.30) (Table 75). The number of BSIs reported to the infection surveillance system was decreasing by
4% for BSIs caused by potential pathogens before the introduction of SGSS (IRR 0.96, 95% CI 0.95
to 0.98), and the decline continued after the introduction of SGSS (IRR 0.89, 95% CI 0.85 to 0.94).
However, the number of BSIs reported to the infection surveillance system was stable for BSIs
caused by skin organisms before and after the system change.
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TABLE 75 The trend pre and post system change and step change in number of BSIs reported from the interrupted time
series regression of all BSIs, skin organism BSIs only and excluding skin organism BSIs
Component of time series
Monthly rate ratio (95% CI)
Skin organisms Potential pathogens All BSIs
Trend pre system change per year 0.98 (0.96 to 1.00) 0.96 (0.95 to 0.98) 0.97 (0.96 to 0.98)
Step change in number of BSIs reported 1.96 (1.78 to 2.15) 1.20 (1.11 to 1.30) 1.47 (1.39 to 1.56)
Trend post system change per year 1.04 (0.99 to 1.10) 0.89 (0.85 to 0.94) 0.97 (0.94 to 1.01)
System change
implementation
Pre system change Post system change
0



























FIGURE 25 Interrupted time series for the number of BSI episodes reported to the PHE surveillance system over time
for infants aged < 1 year, excluding CoNS (aqua) and only CoNS (coral).
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Appendix 15 Additional information on
the generalisability study: comparison
of included and excluded PREVenting
infection using Antimicrobial-Impregnated
Long lines trial babies
TABLE 76 Distribution of baseline risk factors in babies with S-PICCs in the PREVAIL trial who were included in the
analysis compared with those who were excluded
Risk factors







Total babies (n) 269 154
Gestational age (weeks), n (%)
< 26 59 (22) 38 (25) 0.882
26–28 75 (28) 36 (24)
28–32 114 (42) 67 (44)
32–37 15 (6) 9 (6)
≥ 37 6 (2) 4 (3)
Small for gestational age, n (%) 49 (18) 25 (16) 0.606
Male sex, n (%) 141 (52) 80 (52) 0.926
Babies in NICU that provides surgery, n (%) 144 (54) 48 (31) < 0.001
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Appendix 16 Additional information on
the generalisability study: model-building
for rate per 1000 peripherally inserted
central venous catheter days
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TABLE 77 The IRRs and 95% CIs for risk factors from forward stepwise multilevel Poisson regression of BSI per 1000 PICC days
Model, IRR (95% CI)
1 2 3 4 5 6 7a
Group
PREVAIL babies 1.00 1.00 1.00 1.00 1.00 1.00 1.00
NP babies in
PREVAIL NICUs
1.29 (0.66 to 2.54) 1.55 (0.78 to 3.06) 1.60 (0.81 to 3.17) 1.60 (0.81 to 3.17) 1.59 (0.80 to 3.16) 1.58 (0.80 to 3.14) 1.53 (0.77 to 3.03)
NP NICUs 1.14 (0.57 to 2.26) 1.16 (0.58 to 2.31) 1.20 (0.59 to 2.41) 1.20 (0.60 to 2.42) 1.20 (0.60 to 2.42) 1.20 (0.60 to 2.43) 1.18 (0.59 to 2.37)
LNUs 0.58 (0.27 to 1.24) 0.87 (0.40 to 1.89) 0.93 (0.42 to 2.03) 0.93 (0.43 to 2.04) 0.96 (0.42 to 2.15) 1.42 (0.64 to 3.17) 1.43 (0.64 to 3.20)
NNU variance 0.13 (0.04 to 0.40) 0.13 (0.04 to 0.40) 0.15 (0.06 to 0.43) 0.15 (0.05 to 0.43) 0.82 (0.50 to 1.34) 0.15 (0.05 to 0.45) 0.14 (0.05 to 0.42)
Gestational age (weeks)
< 26 1.00 1.00 1.00 1.00 1.00 1.00
26–28 0.52 (0.37 to 0.74)b 0.53 (0.38 to 0.75)b 0.53 (0.38 to 0.75)b 0.53 (0.38 to 0.75)b 0.62 (0.43 to 0.88)b 0.66 (0.46 to 0.94)b
28–32 0.40 (0.28 to 0.55)b 0.42 (0.30 to 0.58)b 0.41 (0.30 to 0.58)b 0.42 (0.30 to 0.58)b 0.64 (0.44 to 0.93)b 0.63 (0.42 to 0.94)b
32–37 0.27 (0.17 to 0.43)b 0.28 (0.17 to 0.45)b 0.28 (0.17 to 0.45)b 0.28 (0.17 to 0.45)b 0.45 (0.27 to 0.75)b 0.36 (0.21 to 0.62)b
≥ 37 0.32 (0.18 to 0.56)b 0.33 (0.18 to 0.58)b 0.32 (0.18 to 0.58)b 0.32 (0.18 to 0.57)b 0.52 (0.29 to 0.95)b 0.40 (0.21 to 0.74)b
Age (months) at first PICC insertion
0 1.00 1.00 1.00 1.00 1.00
1–2 0.50 (0.31 to 0.79)b 0.50 (0.31 to 0.79)b 0.50 (0.31 to 0.79)b 0.49 (0.31 to 0.78)b 0.49 (0.31 to 0.79)b
3–5 0.62 (0.40 to 0.96)b 0.62 (0.40 to 0.96)b 0.62 (0.40 to 0.96)b 0.59 (0.38 to 0.92)b 0.60 (0.39 to 0.94)b
6–8 0.81 (0.50 to 1.33) 0.82 (0.50 to 1.34) 0.82 (0.50 to 1.34) 0.74 (0.45 to 1.21) 0.72 (0.44 to 1.19)
9–11 0.85 (0.44 to 1.64) 0.85 (0.44 to 1.66) 0.85 (0.44 to 1.65) 0.74 (0.38 to 1.44) 0.73 (0.37 to 1.41)
12–29 0.75 (0.43 to 1.30) 0.75 (0.43 to 1.30) 0.75 (0.43 to 1.30) 0.66 (0.38 to 1.15) 0.65 (0.38 to 1.14)
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Appendix 17 Additional information on
the generalisability study: model-building
for trend per 1000 peripherally inserted
central venous catheter days
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TABLE 78 The IRRs and 95% CIs for risk factors from forward stepwise multilevel Poisson regression of BSI (pathogens) per 1000 PICC days per month
Model, IRR (95% CI)
1 2 3 4 5 6 7
a
Trend
PREVAIL NICUs 1.002 (0.998 to 1.006) 1.002 (0.999 to 1.006) 1.002 (0.999 to 1.006) 1.002 (0.999 to 1.006) 1.002 (0.999 to 1.006) 1.002 (0.999 to 1.006) 1.002 (0.999 to 1.006)
Non-PREVAIL
NICUs
1.002 (0.999 to 1.005) 1.002 (0.999 to 1.005) 1.002 (0.999 to 1.005) 1.002 (0.999 to 1.005) 1.002 (0.999 to 1.005) 1.002 (0.999 to 1.005) 1.002 (0.999 to 1.005)
LNUs 0.996 (0.990 to 1.001) 0.996 (0.991 to 1.002) 0.996 (0.991 to 1.002) 0.997 (0.991 to 1.002) 0.996 (0.991 to 1.002) 0.998 (0.993 to 1.003) 0.998 (0.993 to 1.004)
Group
PREVAIL NICUs 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Non-PREVAIL
NICUs
1.05 (0.05 to 20.85) 1.15 (0.06 to 22.87) 1.14 (0.06 to 22.67) 1.26 (0.06 to 25.03) 1.15 (0.06 to 22.89) 1.02 (0.05 to 20.49) 0.94 (0.05 to 18.89)
LNUs 35.92
(0.55 to 2 to 348.57)
34.63
(0.53 to 2 to 273.80)
36.55
(0.55 to 2 to 409.53)
34.60
(0.53 to 2 to 264.16)
34.31
(0.52 to 2 to 256.43)
16.57
(0.25 to 1 to 100.00)
15.40
(0.23 to 1 to 023.51)
NNU variance 0.24 (0.14 to 0.39) 0.21 (0.12 to 0.34) 0.21 (0.13 to 0.34) 0.19 (0.11 to 0.31) 0.21 (0.12 to 0.34) 0.21 (0.13 to 0.35) 0.22 (0.13 to 0.36)
Gestational age (weeks)
< 26 1.00 1.00 1.00 1.00 1.00 1.00
26–28 0.54 (0.47 to 0.63)b 0.55 (0.48 to 0.64)b 0.54 (0.47 to 0.62)b 0.54 (0.47 to 0.63)b 0.63 (0.54 to 0.73)b 0.66 (0.56 to 0.76)b
28–32 0.40 (0.35 to 0.46)b 0.42 (0.36 to 0.48)b 0.40 (0.35 to 0.46)b 0.40 (0.35 to 0.46)b 0.59 (0.51 to 0.70)b 0.58 (0.49 to 0.68)b
32–37 0.32 (0.27 to 0.39)b 0.33 (0.28 to 0.40)b 0.32 (0.26 to 0.38)b 0.32 (0.27 to 0.39)b 0.52 (0.42 to 0.64)b 0.44 (0.36 to 0.55)b





































Model, IRR (95% CI)
1 2 3 4 5 6 7
a
Age (months) at first PICC insertion
0 1.00
1–2 0.88 (0.71 to 1.10)
3–5 0.91 (0.73 to 1.14)
6–8 1.11 (0.88 to 1.39)
9–11 1.16 (0.87 to 1.54)
12–29 0.98 (0.74 to 1.28)
≥ 30 0.93 (0.71 to 1.22)
Small for gestational age 1.10 (0.96 to 1.26)
Surgery 0.98 (0.72 to 1.32)
Days of invasive ventilation
0 1.00 1.00
1 1.15 (0.86 to 1.53) 1.22 (0.91 to 1.63)
2–4 1.50 (1.20 to 1.87)b 1.60 (1.28 to 2.00)b
5–6 2.27 (1.75 to 2.93)b 2.46 (1.90 to 3.20)b
7–8 2.62 (1.99 to 3.44)b 2.89 (2.19 to 3.80)b
9–12 3.02 (2.37 to 3.85)b 3.32 (2.60 to 4.25)b
13–21 2.74 (2.16 to 3.48)b 3.03 (2.38 to 3.86)b
≥ 22 2.73 (2.17 to 3.43)b 3.08 (2.44 to 3.89)b
Days of non-invasive ventilation
0 1.00
1 0.85 (0.65 to 1.11)
2–5 0.86 (0.71 to 1.06)
6–9 0.79 (0.63 to 0.99)b
10–15 0.78 (0.63 to 0.97)b
16–49 0.68 (0.57 to 0.80)b
≥ 50 0.61 (0.49 to 0.74)b
a Selected model.








































































































































































































































































































































































Appendix 18 Additional information on
the generalisability study: model-building
for trend per 1000 days
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TABLE 79 The IRRs and 95% CIs for risk factors from forward stepwise multilevel Poisson regression of the rate of BSI (pathogens) per 1000 days of intensive and high-dependency
care per month
Model, IRR (95% CI)
1 2 3 4 5 6 7
a
Trend
PREVAIL NICUs 0.998 (0.996 to 1.001) 0.998 (0.996 to 1.000) 0.998 (0.996 to 1.000) 0.998 (0.996 to 1.000) 0.998 (0.996 to 1.001) 0.999 (0.997 to 1.001) 0.999 (0.997 to 1.001)
Non-PREVAIL NICUs 1.001 (1.000 to 1.003) 1.001 (0.999 to 1.003) 1.001 (0.999 to 1.003) 1.001 (0.999 to 1.003) 1.001 (0.999 to 1.003) 1.002 (1.000 to 1.003) 1.002 (1.000 to 1.004)
LNUs 0.996 (0.994 to 0.999)b 0.996 (0.994 to 0.999)b 0.996 (0.994 to 0.999)b 0.996 (0.994 to 0.999)b 0.997 (0.994 to 0.999)b 0.998 (0.995 to < 1.000)b 0.998 (0.995 to < 1.000)b
Group
PREVAIL NICUs 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Non-PREVAIL NICUs 0.13 (0.02 to 0.88) 0.12 (0.02 to 0.79) 0.14 (0.02 to 0.94) 0.14 (0.02 to 0.94) 0.14 (0.02 to 0.92) 0.15 (0.02 to 1.03) 0.13 (0.02 to 0.87)
LNUs 3.70 (0.43 to 31.65) 3.83 (0.45 to 32.78) 3.84 (0.45 to 32.79) 3.78 (0.44 to 32.31) 2.90 (0.34 to 24.83) 2.86 (0.33 to 24.48) 2.84 (0.33 to 24.36)
NNU variance 0.13 (0.09 to 0.19) 0.13 (0.09 to 0.19) 0.11 (0.07 to 0.16) 0.11 (0.07 to 0.16) 0.10 (0.07 to 0.16) 0.11 (0.07 to 0.16) 0.13 (0.09 to 0.19)
Gestational age (weeks)
< 26 1.00 1.00 1.00 1.00 1.00 1.00
26–28 0.66 (0.60 to 0.72)b 0.66 (0.60 to 0.73)b 0.66 (0.60 to 0.73)b 0.68 (0.62 to 0.75)b 0.73 (0.66 to 0.81)b 0.73 (0.66 to 0.80)b
28–32 0.61 (0.56 to 0.67)b 0.62 (0.56 to 0.68)b 0.62 (0.56 to 0.68)b 0.68 (0.62 to 0.76)b 0.58 (0.52 to 0.64)b 0.58 (0.52 to 0.64)b
32–37 0.65 (0.59 to 0.72)b 0.66 (0.59 to 0.73)b 0.66 (0.60 to 0.73)b 0.78 (0.70 to 0.88)b 0.48 (0.43 to 0.55)b 0.48 (0.42 to 0.54)b
≥ 37 1.00 (0.91 to 1.10) 1.00 (0.91 to 1.10) 1.00 (0.91 to 1.10) 1.16 (1.04 to 1.29) 0.65 (0.58 to 0.74)b 0.65 (0.58 to 0.73)b
Small for gestational age 0.91 (0.83 to 0.99)b 0.91 (0.83 to 0.99)b 0.91 (0.83 to 0.99)b 0.93 (0.85 to 1.02)
Surgery 0.97 (0.78 to 1.19)
Days of invasive ventilation
0 1.00 1.00 1.00
1 1.28 (1.12 to 1.45)b 1.37 (1.20 to 1.55)b 1.37 (1.21 to 1.56)b
2–4 1.36 (1.22 to 1.50)b 1.47 (1.33 to 1.63)b 1.48 (1.33 to 1.64)b
5–6 1.51 (1.32 to 1.74)b 1.71 (1.49 to 1.97)b 1.72 (1.49 to 1.97)b
7–8 1.81 (1.56 to 2.11)b 2.11 (1.82 to 2.46)b 2.11 (1.82 to 2.46)b
9–12 1.73 (1.51 to 1.99)b 2.05 (1.78 to 2.36)b 2.06 (1.79 to 2.36)b
13–21 1.68 (1.47 to 1.92)b 2.04 (1.78 to 2.33)b 2.04 (1.78 to 2.33)b
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Appendix 19 Additional information on
the generalisability study: model-building
for rate per 100 admissions
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TABLE 80 The IRRs and 95% CIs for risk factors from forward stepwise multilevel Poisson regression of the rate of total late-onset BSIs (pathogens) per 100 admissions per month
Model, IRR (95% CI)
1 2 3 4 5 6a
Trend
PREVAIL NICUs 0.996 (0.994 to 0.998)b 0.997 (0.995 to 0.999)b 0.997 (0.995 to 0.999)b 0.998 (0.995 to < 1.000)b 0.998 (0.995 to < 1.000)b 0.998 (0.995 to < 1.000)b
Non-PREVAIL NICUs 0.999 (0.998 to 1.001) 1.001 (0.999 to 1.003) 1.001 (0.999 to 1.003) 1.001 (0.999 to 1.003) 1.001 (0.999 to 1.003) 1.001 (0.999 to 1.003)
LNUs 0.994 (0.991 to 0.996)b 0.995 (0.993 to 0.998)b 0.995 (0.993 to 0.998) 0.997 (0.995 to < 1.000)b 0.997 (0.995 to < 1.000)b 0.997 (0.995 to < 1.000)b
Group
PREVAIL NICUs 1.00 1.00 1.00 1.00 1.00 1.00
Non-PREVAIL NICUs 0.09 (0.01 to 0.62) 0.08 (0.01 to 0.55) 0.09 (0.01 to 0.67) 0.10 (0.01 to 0.73) 0.08 (0.01 to 0.61) 0.09 (0.01 to 0.62)
LNUs 1.92 (0.21 to 17.75) 1.90 (0.20 to 17.66) 2.08 (0.22 to 19.28) 1.39 (0.15 to 12.80) 1.38 (0.15 to 12.74) 1.39 (0.15 to 12.83)
NNU variance 0.16 (0.11 to 0.23) 0.15 (0.10 to 0.22) 0.12 (0.08 to 0.17) 0.10 (0.07 to 0.15) 0.13 (0.09 to 0.19) 0.13 (0.08 to 0.19)
Gestational age (weeks)
< 26 1.00 1.00 1.00 1.00 1.00
26–28 0.58 (0.53 to 0.64)b 0.58 (0.53 to 0.64)b 0.83 (0.75 to 0.92)b 0.83 (0.75 to 0.92)b 0.79 (0.71 to 0.87)b
28–32 0.28 (0.25 to 0.31)b 0.28 (0.25 to 0.31)b 0.63 (0.57 to 0.70)b 0.63 (0.57 to 0.70)b 0.66 (0.60 to 0.74)b
32–37 0.12 (0.11 to 0.13)b 0.12 (0.11 to 0.13)b 0.36 (0.31 to 0.40)b 0.36 (0.32 to 0.40)b 0.42 (0.37 to 0.48)b
≥ 37 0.15 (0.14 to 0.17)b 0.15 (0.14 to 0.17)b 0.42 (0.37 to 0.47)b 0.42 (0.37 to 0.47)b 0.49 (0.43 to 0.55)b
Small for gestational age 1.19 (1.08 to 1.31)b 1.07 (0.97 to 1.18)
Surgery 1.20 (0.96 to 1.49)
Days of invasive ventilation
0 1.00 1.00 1.00
1 1.58 (1.39 to 1.80)b 1.58 (1.39 to 1.80)b 1.54 (1.35 to 1.76)b
2–4 2.26 (2.03 to 2.51)b 2.26 (2.03 to 2.51)b 2.17 (1.95 to 2.41)b
5–6 3.75 (3.25 to 4.33)b 3.75 (3.25 to 4.32)b 3.50 (3.03 to 4.05)b
7–8 5.03 (4.29 to 5.91)b 5.04 (4.29 to 5.92)b 4.64 (3.95 to 5.45)b
9–12 5.82 (5.02 to 6.74)b 5.83 (5.03 to 6.76)b 5.28 (4.55 to 6.13)b
13–21 6.67 (5.79 to 7.69)b 6.69 (5.80 to 7.71)b 5.96 (5.16 to 6.89)b
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Appendix 20 Additional information on
the generalisability study: bloodstream
infection definitions
TABLE 81 Definitions of BSI used in this study
BSI term Definition
1. BSI during PICC days at risk BSI that occurs from 1 day after PICC insertion to 2 days after PICC removal
2. Early-onset BSI BSI that occurs in babies aged < 2 days (excluding BSI during PICC days at risk)
3. Late-onset BSI (no PICC) BSI that occurs from 2 days of age to 2 days after discharge (excluding BSI during
PICC days at risk)
4. Total late-onset BSI BSI that occurs during PICC days at risk plus BSIs that are late onset (no PICC)
5. Total BSI All BSI that meet any of the criteria for terms 1–3a
a Terms 1–3 are mutually exclusive, whereby if a BSI occurs during PICC days at risk, it cannot be early onset
(no PICC) or late onset (no PICC).
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Appendix 21 Additional information on
the generalisability study: flow diagram
of included PREVAIL babies
• From a NICU not included in data, n = 4
• For whom we were not able to f ind links, n = 4 
• Babies from September 2015 to February 2016, 
    n = 97
• Poor BSI reporting, n = 24
• Missing discharge dates, n = 2
• Without PICC recorded, n = 31
Babies  with S-PICC in PREVAIL
linked to NNRD-SGSS data
(n = 423)
Babies randomised to receive S-PICC
included in generalisability analysis
(n = 269)
Babies randomised to receive S-PICC
(n = 431)
FIGURE 26 Flow diagram to show babies randomised to receive S-PICCs in PREVAIL who were linked to the NNRD and
included in the generalisability analysis.
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Appendix 22 Additional information on the
generalisability study: causative organisms
TABLE 82 The distribution of causative organisms of the first BSI during PICC days at risk per admission in the PREVAIL





NICUs (n= 28) LNUs (n= 68)
Number of babies 5433 3754 2381
Number of admissions 5958 4061 2485
Number of admissions with a BSI 189 338 92
Clearly pathogenic organisms, n (%)
E. coli 22 (8) 62 (11) 10 (5)
Group B streptococci 8 (3) 20 (4) 11 (5)
Other Gram negative 29 (11) 55 (10) 21 (10)
Other Gram positive 17 (6) 19 (4) 9 (4)
Staphylococcus aureus 20 (8) 45 (8) 14 (7)
Other organisms, n (%)
CoNS 151 (57) 322 (58) 135 (64)
Other 17 (7) 20 (4) 11 (5)




Fungi were excluded from the table as a result of small cell counts.
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Appendix 23 Additional information on the
generalisability study: rates of bloodstream
infection per 1000 peripherally inserted

























































p = 0.225 p = 0.642 p = 0.379
Non-PREVAIL babies
FIGURE 27 Crude and risk-adjusted rates of BSI (pathogens) per 1000 PICC days in babies who received S-PICCs
in NICUs and LNUs according to enrolment in the PREVAIL trial during the PREVAIL trial period (August 2015 to
January 2017). Adjusted for gestational age at birth, age at first PICC and days of invasive and non-invasive ventilation.
p-value for effect of group (PREVAIL babies in NICU, babies in non-PREVAIL trial NICUs, babies in LNUs) on BSI rate in
comparison to babies in the PREVAIL trial. Period for NICUs that participated in the PREVAIL trial depends on NICU
start and end date of recruitment; period for other NICUs and LNUs is August 2015 to January 2017 (whole PREVAIL
trial recruitment period).
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TABLE 83 Crude and risk-adjusted rates of BSI per 1000 PICC days for babies in PREVAIL trial NICUs, non-PREVAIL
trial NICUs and LNUs during the PREVAIL trial period (August 2015 to January 2017)
BSI per 1000 PICC days
NICUs (n= 16) participating in PREVAILa
NICUs (n= 27) and LNUs (n= 67)









Babies (n) 269 1608 3745 2358
Admissions (n) 325 1522 4051 2460
PICC days (n) 3809 18,115 49,902 17,187
All BSIs
Number of BSIs 31 185 379 96
Crude BSI rate (95% CI) 8.1 (5.3 to 11.0) 10.2 (8.7 to 11.7) 7.6 (6.8 to 8.4) 5.6 (4.5 to 6.9)
Adjusted BSI rateb (95% CI) 7.8 (5.0 to 10.6) 9.9 (8.5 to 11.4) 7.4 (6.6 to 8.1) 5.0 (3.9 to 6.0)
p-valuec
BSI due to clearly pathogenic organisms
Number of BSI 10 64 151 27
Crude BSI rate (95% CI) 3.2 (1.4 to 4.9) 3.3 (2.5 to 4.1) 3.2 (2.7 to 3.7) 1.5 (0.9 to 2.1)
Adjusted BSI rateb (95% CI) 2.5 (0.9 to 4.1) 3.4 (2.6 to 4.3) 2.9 (2.4 to 3.4) 1.5 (0.9 to 2.0)
p-valuec 0.225 0.642 0.379
a Admissions to PREVAIL trial NICUs are restricted to NICU-specific trial recruitment period, whereas admissions to
other NICUs and LNUs include the whole recruitment period (August 2015 to January 2017).
b Adjusted for gestational age at birth, age at first PICC and days of invasive and non-invasive ventilation.
c p-value comparing difference in rate compared with PREVAIL babies.
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Appendix 24 Additional information on
the generalisability study: trends in
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≥ 37 weeks
28 to < 32 weeks
26 to < 28 weeks
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Gestation at birth (weeks)





FIGURE 29 The mean number of days of intensive and high-dependency care per baby in NICUs and LNUs by week
of gestational age at birth. (a) Days of stay in NICUs; and (b) days of stay in LNUs. p-value from two-way ANOVA
demonstrating whether or not the mean is significantly different by week of gestation in 2010, compared with 2017.
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FIGURE 30 The mean number of PICC days per baby in NICUs and LNUs by week of gestational age at birth. (a) PICCs
in NICUs; and (b) PICCs in LNUs. p-value from two-way ANOVA demonstrating whether or not the mean is significantly
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FIGURE 31 The mean number of central line days per baby in NICUs and LNUs by week of gestational age at birth.
(a) Central lines in NICUs; and (b) central lines in LNUs. p-value from two-way ANOVA demonstrating whether or not the
mean is significantly different by week of gestation in 2010, compared with 2017.
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FIGURE 32 The mean age at first PICC insertion in NICUs and LNUs by week of gestational age at birth. (a) NICUs; and
(b) LNUs. p-value from two-way ANOVA demonstrating whether or not the mean is significantly different by week of



























































FIGURE 33 The mean number of non-invasive ventilation days per baby in NICUs and LNUs by week of gestational age
at birth. (a) NICUs; and (b) LNUs. p-value from two-way ANOVA demonstrating whether or not the mean is significantly
different by week of gestation in 2010, compared with 2017.
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FIGURE 34 The mean number of invasive ventilation days per baby in NICUs and LNUs by week of gestational age at
birth. (a) NICUs; and (b) LNUs. p-value from two-way ANOVA demonstrating whether or not the mean is significantly
different by week of gestation in 2010, compared with 2017.
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Appendix 25 Additional information on
the generalisability study: flow diagrams
NICUs and LNUs
(n = 112)
8443 admissions involving 7482
babies who received S-PICCs during

























FIGURE 35 The number of admissions and babies receiving S-PICCs according to NNU level and enrolment in the
PREVAIL trial for the PREVAIL trial period (August 2015 to January 2017).
NICUs and LNUs
(n = 112)
55,058 admissions involving 47,669
babies who received S-PICCs from

















FIGURE 36 The number of admissions and babies who received PICCs from March 2010 to June 2017 and who were
included in the analysis of changes over time in BSI during PICC days at risk.
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161,117 admissions involving 140,110
babies who received high-dependency or

















FIGURE 37 The number of admissions and babies who received intensive or high-dependency care from March 2010 to
June 2017 and who were included in the analysis of changes over time in late-onset BSI.
APPENDIX 25








Part of the NIHR Journals Library
www.journalslibrary.nihr.ac.uk
This report presents independent research funded by the National Institute for Health Research (NIHR).  
The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the  
Department of Health and Social Care
Published by the NIHR Journals Library
